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Abstract 
 
Inflammation is a protective response but if dysregulated it can lead to chronic inflammatory 
conditions. Currently, these diseases are treated by inhibiting the factors that drive 
inflammation but such treatments can interfere with the tissue healing processes, e.g. NSAIDs 
or impair antimicrobial immunity, e.g. corticosteroids and biologics. Resolution is the other end 
of inflammatory spectrum and has been demonstrated to be an active process mediated by 
specific cellular events, soluble mediators and their receptors, that provide counter-regulatory 
signals to switch inflammation off. In this regard, specialised pro-resolving lipid mediators 
(SPMs), as effector molecules of resolution have shown promise as a novel therapeutic option 
to treat dysregulated inflammation. However, research supporting beneficial effect of SPMs 
has been largely conducted in murine models and there is a need to translate it for patient 
benefit. A human model of resolution of inflammation can facilitate investigation of the 
pharmacological action of SPM based therapies and their comparison with known anti-
inflammatory agents. To attain this objective, I first performed a detailed characterisation of 
cantharidin skin blister model and learnt that neutrophil clearance, an important sign of 
resolution, can be affected by stromal scaffold around inflammatory contents. Therefore, I 
developed a novel model of self-resolving acute inflammation triggered by intradermal injection 
of UV killed E. coli bacteria (UVkEc), where local inflammatory exudate was acquired into a 
suction blister raised during onset and resolution phases of inflammatory response. UVkEc 
triggered self-resolving dermal inflammation model allowed appreciation of quantifiable indices 
of resolution such as clearance of neutrophils, reduction of inflammatory stimulus, pro-
inflammatory cytokines and lipid mediators as well as vascular hyperaemia. In addition, I 
identified the presence of different classes of SPMs and their receptors at the junction between 
onset and resolution. Using this model, I showed that local therapeutic supplementation of 
SPMs, in physiological dose range, reduced neutrophil numbers during resolution but had 
modest effect on clearance of the inflammatory stimulus, reduction of pro-inflammatory 
cytokines or switch of macrophages to a pro-resolving phenotype. In another approach, I 
demonstrated that an oral, SPM inducing small molecule, JBT-101, a CB2 receptor agonist 
(chemical name: ajulemic acid) inhibited neutrophil numbers at onset coincident with enhanced 
clearance of inflammatory stimulus and reduction in levels of leukotriene B4, prostanoids and 
IL-8. It also increased the levels of the SPMs including lipoxin A4, resolvin D1 and resolvin D3 
during resolution. However, there was lack of correlation between the rise in SPMs and the 
effect of JBT-101 on resolution indices and there was no inverse correlation between levels of 
SPMs and neutrophil numbers during onset or resolution. Using UVkEc triggered self-resolving 
dermal inflammation model as a tool, this thesis demonstrates that in humans, effect of SPMs, 
at physiological doses, may be limited only to enhancing neutrophil clearance. It also shows 
that orally active SPM inducing molecule, JBT-101, at doses currently being employed in 
phase II clinical trials, has a potent anti-inflammatory effect and uncovers that its main 
mechanism is possibly via inhibiting the pro-inflammatory mediators than by inducing SPMs. 
Investigation of effect of pro-resolving therapies on resolution indices in humans can inform 
their future clinical development.	
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Chapter 1  
Introduction  
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Inflammation is a defence response against noxious stimuli like microbes or 
tissue injury. A successful inflammatory response comprises an onset phase, 
during which immune cells migrate to the site and eradicate the offending 
pathogen. Clearance of the inciting stimulus is followed by a resolution phase, 
characterised by immune cell clearance and tissue repair. The process of 
resolution is tightly controlled to minimise bystander tissue damage by 
activated immune cells; however, its dysregulation can contribute to a state of 
persistent inflammation as seen in chronic inflammatory disorders [1]. For a 
long time, it was presumed that resolution is a passive process following 
removal of inflammatory stimulus and catabolism of pro-inflammatory 
mediators. However, in recent years’ investigation of self-resolving 
inflammatory exudates have revealed that resolution is an active process 
mediated by specific cellular processes, receptors and an array of endogenous 
factors [2].  
 
For my introduction, I will first describe the evolution of an inflammatory 
response with emphasis on the key events that mediate the active resolution of 
acute inflammatory response. Secondly, I will discuss the origin, mechanism 
and role of different classes of specialised pro-resolving mediators (SPMs), a 
novel genus of lipid mediators, in mediating resolution processes. Thirdly, I will 
highlight the potential benefits of SPM based therapies over the conventional 
anti-inflammatory agents. Finally, I will describe the need for translating 
research on SPMs in humans to justify my PhD aims.   
 
 
 
 21 
1.1 Onset  
 
1.1.2 Recognition of inflammatory stimulus  
 
At steady state, the tissue comprises resident immune cells are interspersed 
amongst the parenchyma, connective tissue as well as the vascular and 
lymphatic networks of the organ. The resident immune cell compartment is 
comprised of macrophages, dendritic cells, mast cells, memory CD4+ and 
CD8+ T cells and the recently identified innate lymphoid cells [3].  
 
An important function of resident immune cells is immunosurveillance i.e. the 
sensing of microbes or tissue injury associated products. This is facilitated by 
the presence of germline encoded receptors called pattern recognition 
receptors (PRRs) on immune cells. Different PRRs are present on the immune 
cells which either sense the pathogen associated molecular patterns (PAMPs) 
derived from the microbes or damage associated molecular pattern (DAMPs) 
produced during tissue injury. PRRs are classified into multiple families 
including Toll like receptors (TLRs), e.g. TLR4 which binds to bacterial 
lipopolysaccharide (LPS), TLR2 which detects tissue injury derived heat shock 
proteins (HSP) and high mobility group box protein (HMGB), nucleotide 
oligomerization domain like receptors (NLRs), e.g. NOD1 which detects 
bacterial products like muramyl dipeptide (MDP), C-type lectin receptors 
(CLRs), e.g. dectin-1 which detects b- glucan on fungi and retinoic acid-
inducible gene (RIG)-I-like receptors (RLRs), e.g. RIG-1 which detects double 
stranded RNA of viruses [4].  
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 Immunosurveillance is further enhanced by the strategic location of resident 
immune cells at sites of invasion in the tissue, e.g. Langerhans cells and CD8+ 
resident memory T cells are located in the skin epidermis, tissue resident 
macrophages are located in the epithelial lining of serous cavities such as in 
peritoneum, pleural cavity and also occupy perivascular areas. In addition to 
resident immune cells, stromal cells such as fibroblasts and epithelial cells 
have also been shown to be involved in detection of inflammatory stimuli [5]. 
 
Activation of PRRs triggers nuclear translocation of transcription factors such 
as nuclear factor NF-kB, activator protein 1 (AP-1), interferon regulatory 
factors (IRF) which lead to transcription of inflammatory genes encoding for 
pro-inflammatory mediators including histamine, cytokines (TNFa, IL-6, etc.), 
Type 1 interferons and anti-microbial proteins. Together they activate the 
endothelium to facilitate extravasation of immune cells to the site [6].  
 
1.1.3 Activation of the endothelium   
 
Endothelial activation leads to an increase in blood flow, which underlies the 
major clinical signs of inflammation such as redness (rubor), heat (calor) and 
plasma leakage leading to tissue oedema (tumor).  
 
Endothelial activation can be categorised into two types depending on the rate 
of activation. The Type 1 response is rapid and doesn't involve gene 
transcription as it is mediated by the release of pre-formed ligands within the 
endothelium. In contrast, the type 2 response is slower to evolve and requires 
the generation of inflammatory mediators by de novo gene transcription [7]. 
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Type 1 activation is mediated by G-protein coupled receptor (GPCR) ligands 
such as mast cell derived histamine. It is rapid and short lived as signalling via 
the GPCR receptors lasts for 20-30 min before they get desensitised [8]. 
GPCR signalling leads to increase in levels of cytosolic Ca++ levels and 
activation of the myosin light chain kinase (MLCK). Increased Ca++ releases 
cytoplasmic phospholipase A2 (cPLA2) and also activates endothelial nitric 
oxide synthase (eNOS) [9]. cPLA2 releases arachidonic acid (AA) and 
lysophosphatidylcholine (LPC) from membrane phospholipids. AA is first 
oxidised then reduced by constitutionally expressed cyclooxygenase-1 (COX-
1) to generate prostaglandin H2 (PGH2), which is further metabolised by 
prostacyclin synthase to prostacyclin (PGI2). PGI2 together with nitric oxide 
(NO) derived from eNOS act as potent vasodilators [10]. Activated MLCK 
results in contraction of actin that leads to opening of gap junctions between 
the endothelial cells [11]. In addition, MLCK and cytosolic Ca++ in combination 
result in the exocytosis of Weibel Palade bodies containing P-selectin onto the 
endothelial surface [12]. Simultaneously, LPC formed by the action of cPLA2, 
is acetylated in the endothelial cells to form PAF (platelet activating factor). 
Combined expression of P-selectin and PAF provide the first signal for 
adherence of neutrophils to the endothelial surface [13].   
 
Type 2 activation supplements the transient stimulation provided by Type 1 
activation and amplifies the leucocyte infiltration. Type 2 activation is 
classically mediated by TNFa and IL-1 family of cytokines produced by the first 
batch of neutrophil arriving at the site leading to a sustained endothelial 
activation. TNFa and IL-1 activate the NF-kB and AP-1 transcription factors 
that lead to the production of pro-inflammatory proteins, e.g. cyclooxygenase-
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2(COX-2), interleukin (IL)-8 and adhesion molecules, e.g. E-selectin, 
intercellular cell adhesion molecule-1 (ICAM1), vascular cell adhesion 
molecule-1 (VCAM1) [14]. COX-2 increases the production of prostaglandins 
(PGE2, PGI2) causing further vasodilation [15]. IL-8 and E-selectin expression 
further enhance the neutrophil recruitment and adhesion to the endothelial 
surface. Together the above changes lead to increase in blood flow and 
extravascular leakage of plasma proteins, facilitating leucocyte migration into 
the tissues.   
 
1.1.4 Migration of leucocytes  
 
1.1.4.1 Neutrophil migration 
 
Neutrophil migration from the endothelium to tissue comprises multiple steps: 
tethering and rolling, adhesion, crawling, transmigration. P-selectin and E-
selectin on the activated endothelium bind to P-selectin glycoprotein ligand -1 
(PSGL-1) on neutrophils causing them to tether to the endothelial surface [16]. 
Neutrophil L-selectin (also referred as CD62L) plays an additional role in 
tethering and rolling by binding to E- and P-selectin on the endothelium [17]. 
Subsequently, neutrophils start to slow down and adhere to the endothelial 
surface. This arrest of neutrophil rolling is facilitated by binding of endothelial 
ICAM-1 with neutrophil lymphocyte function associated antigen-1 (LFA-1) [18]. 
IL-8, acting via CXC chemokine receptor 2 (CXCR2/IL8RB) on neutrophils, 
also causes firm adhesion [19]. The next step is crawling, which is mediated by 
the interaction between neutrophil CD11b and endothelial ICAM-2 [20]. The 
final step is transmigration of the neutrophils through the endothelium which 
occurs either via a paracellular (between endothelial gap junctions) or 
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transcellular route (through the endothelial cells). This step involves binding of 
neutrophil LFA-1, macrophage antigen-1 (Mac-1), very late antigen- 4 (VLA-4) 
and platelet endothelial cell adhesion molecule (PECAM-1) correspondingly to 
the endothelial ICAM-1, ICAM-2, VCAM, PECAM-1 as well as junctional 
adhesion molecules (JAM) such as JAM-C [21].  
 
Migration of neutrophils in the extravascular space is facilitated by a strong 
chemotactic gradient in tissue created by complement component 5a (C5a), 
and pathogen derived N-formyl-methionyl-leucyl-phenylalanine (fMLP) [22]. 
Once inside the tissue, neutrophils produce its own chemoattractants which 
provide a feedback loop to recruit more neutrophils. These chemoattractants 
include cytokines such as IL-17 [23] and lipid mediators such as leukotriene B4 
(LTB4), formed by the action of 5-lipoxygenase 5-LO on AA [24]. The process 
of rolling and exposure to pro-inflammatory cytokines and growth factors cause 
neutrophil activation and subsequent engagement of their killing mechanisms.  
 
1.1.4.2 Monocyte migration  
 
Monocytes migrate sequentially after the neutrophil infiltration and follow a 
similar cascade of rolling and tethering, adhesion, crawling and transmigration. 
In the case of monocytes, rolling is facilitated by interaction of monocyte 
PSGL-1 with endothelial E-selectin, the adhesion by the interaction of VLA4 
and Mac1 on monocytes with VCAM-1 and ICAM-1 on endothelium and 
transmigration is supported by binding of PECAM1 on monocytes and 
endothelium [25]. 
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Activated neutrophils control sequential monocyte chemotaxis by modifying the 
monocyte chemoattractants and adhesion molecules. For instance, activated 
neutrophils lead to Type 2 endothelial activation causing it to release CC 
chemokine ligand 2 (CCL2), a classical monocyte chemoattractant protein that 
interacts with monocyte CC chemokine receptor 2 (CCR2) [26]. Type 2 
endothelial activation by neutrophils is triggered by IL-6 trans-signalling. 
Neutrophils shed IL6R into the inflammatory milieu, which binds to IL-6 to form 
the IL6-s/IL6R complex. This complex binds to glycoprotein 130 (gp130) on the 
endothelium to initiate IL-6 trans-signalling and upregulate its expression of 
CCL2 and VCAM1 [27]. Neutrophil granule proteins further amplify monocyte 
migration. Azurocidin, derived from the secretory vesicles of neutrophils 
upregulates monocyte adhesion molecules on endothelium and also acts as a 
chemotactic signal to formyl peptide receptors (FPR) on monocytes. Neutrophil 
derived cathelicidin antimicrobial peptides (CAP) and alpha defensins also 
direct monocyte chemotaxis acting via its FPR receptors [28]. The role of 
neutrophil granule proteins in monocyte chemotaxis is also supported by the 
clinical observation where patients lacking CAP-18, a pro-form of cathelicidins 
show decreased monocyte accumulation at the site of infection or injury [29]. 
In addition to inducing the expression of adhesion molecules and acting as a 
chemotactic signal, neutrophil granule proteins have also been shown to 
increase the potency of monocyte chemoattractants. Serine protease causes 
amino-terminal modification of several monocyte chemokines like CCL-6, -19, -
25. This results in a multi-fold increase in the ability of these ligands to bind to 
monocyte CCR1 and induce chemotaxis [30].  
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1.1.4.4 Removal of inflammatory stimulus: Tipping point of resolution  
 
Migration along the endothelium and exposure to pro-inflammatory mediators 
causes activation of neutrophils and monocytes. Activated leucoytes eliminate 
the pathogen either via intracellular or extracellular killing mechanisms. The 
intracellular mechanism involves phagocytosis of the microbe and formation of 
a phagosome, which is exposed to reactive oxygen species (ROS) and anti-
bacterial granules proteins, e.g. defensins, lactoferrin [31]. Extracellular 
mechanisms are mediated via neutrophil extracellular traps (NETs) or direct 
release of anti-bacterial proteins into the extracellular environment. NETs are 
composed of core DNA elements along with histones which trap the pathogen, 
limiting its spread and thus facilitating phagocytosis [32]. Defects in pathways 
regulating microbial killing can cause persistent inflammatory reaction and 
recurrent infections as seen in patients with chronic granulomatous disease 
(CGD) where ROS producing NADPH oxidase (nicotinamide adenine 
dinucleotide phosphate) system is either absent [33]. Another clinical example 
is of neutrophil specific granule deficiency characterised by lack of granule 
proteins such as lactoferrin, gelatinase-B and collagenase and marked 
deficiency of defensins [29]. 
 
1.2 Resolution  
 
 
Eradication of the inflammatory stimulus by neutrophils and monocytes paves 
the way for resolution, characterised by clearance of immune cells from the 
site and tissue repair. Resolution was originally thought to be a passive 
process following catabolism of pro-inflammatory mediators and death of 
immune cells locally. However, it is now widely appreciated that resolution is 
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an active process and it involves distinct signalling and cellular processes 
aimed at inhibiting further recruitment of immune cells and promoting 
clearance of the leucocytes that have migrated to the site [34]. The section 
below describes the different processes involved in the resolution of 
inflammation. 
 
 
 
1.2.1. Inhibition of chemokine signalling 
 
 
Chemokines provide directional cues to leucocytes to migrate to the site of 
inflammation. Thus, to stop the continuous recruitment of neutrophils during 
resolution, it is important that the chemokine signalling networks be 
interrupted. A major mechanism by which body attenuates chemokine 
signalling is through sequestration and degradation of chemokines via decoy 
receptors. Decoy receptors are chemokine receptors that fail to initiate a 
signalling cascade. They are identified by the lack of DRY motif, an important 
component that couples the extracellular receptor loops of GPCR to G 
proteins. Two main members of this family are the D6 and DARC (Duffy 
antigen receptor complex) [35].  
  
D6 receptor is highly expressed on the lymphatic endothelium [36]. It binds 
mainly to the inflammatory agonists of CCR1, CCR2 and CCR5 receptors but 
does not initiate the downstream signalling pathway [37]. It also clears their 
ligands by internalisation and endolysosomal degradation [38]. Compared to 
D6, DARC is expressed on the post capillary venular endothelium and has 
affinity for > 60% of pro-inflammatory cytokines including both CC and CXC 
chemokines, e.g. CCL5, CCL7, CCL2, CXCL8, CXCL5, CXCL11 [39]. By 
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binding to DARC, these inflammatory cytokines become inaccessible to bind to 
the functional chemokine receptors. DARC is also expressed on red blood 
cells, which can create a 'sink' for chemokines such as IL-8. This was 
evidenced by compartmentalization of IL-8 with RBCs when it was added to 
whole blood. IL8 bound to RBC was also unable to stimulate neutrophils [40]. 
The role of both these chemokine scavenger receptors as negative regulators 
of inflammation is further substantiated by receptor knockout studies in 
multiple murine models of inflammation, e.g. in a model of skin inflammation 
triggered by Freund’s complete adjuvant D6-/- mice showed increased 
neutrophil migration and necrosis at site of inflammation along with increased 
cellular infiltrate and levels of CCL2 in the lymph node [41]. Similarly, DARC-/- 
mice showed hyper-inflammatory characterised by increased neutrophil 
infiltration in the liver and lung in response to intraperitoneal endotoxin [42]. 
 
The functional chemokine receptors like CCR5 and CCR2 can also act as 
decoy receptors and contribute to the resolution of inflammation. CCR5 on 
apoptotic neutrophils has been shown to sequester the chemokines CCL3 and 
CCL5. The levels of these chemokines increased in peritoneal exudates of 
CCR5 deficient mice and were scavenged by transfer of apoptotic neutrophils 
[43]. CCR2 receptor usually mediates monocyte trafficking but becomes 
insensitive by uncoupling itself from the G proteins under the simultaneous 
exposure of LPS-interferon-g (IFN-g) and IL-10. Monocytes treated this way 
show reduced migration in response to monocyte chemoattractants such as 
CCL-2, -3, -4 [44].  
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Another mechanism of inhibition of chemokine signalling is through chemokine 
proteolysis, which alters chemokine structure in a way that renders them 
ineffective on its receptor [45], e.g. matrix mettalopeptidase-12 (MMP-12) 
derived from macrophages truncates ELR motif from the CXC chemokines 
including CXCL-1,-2,-3,-5 and -8, which is critical for receptor binding. 
Accordingly, mice lacking MMP12 showed increased infiltration of neutrophils 
compared to wild-type mice in the bronchoalveolar lavage in response to LPS 
stimulation [46]. Another example is of stromal cell-derived gelatinase A which 
cleaves CCL-7, and thus renders it ineffective to signal via CCR-1, -2, -3 
receptors. Moreover, gelatinase cleaved CCL-7 acts as an antagonist of these 
receptors. It was further shown in the murine model of acute zymosan 
peritonitis model, that gelatinase cleaved MCP-3 but not full length, attenuated 
trafficking of monocytes in the peritoneal cavity [47]. 
 
1.2.2 Neutrophil Apoptosis - Desired route of cell death for resolution    
 
Neutrophil cell death at the site of inflammation occurs in many ways including 
autophagy, neutrophil extracellular trap (NET) osis, necrosis, necroptosis, and 
apoptosis [48]. The major mechanism of cell death in neutrophils is governed 
by the pathological state. For instance, autophagy, which involves breaking 
down and recycling of dispensable intracellular constituents occurs mainly in 
the low nutrient environment and during growth factor deprivation. Autophagy 
is a non-apoptotic form of cell death and serves to dampen inflammation by 
removing the endogenous inflammasome agonists like mitochondrial DNA 
(mtDNA) [49]. Another non-apoptotic form of cell death is NETosis which 
involves the release of nuclear chromatin and granule proteins in the 
extracellular environment (NETs) following the rupture of nuclear and plasma 
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membrane rupture [50]. While earlier it was proposed that NETs promote 
phagocytosis of bacteria and limit their spread [32], recent reports have 
cautioned that NETosis can cause exaggerated inflammation due to the 
release of autoantibodies to nuclear components [51][52]. Neutrophil death by 
necrosis can occur as a primary event in response to direct cellular insults 
such as heat shock and osmotic shock or in response to signalling via the TNF 
death receptor, Toll-like receptors, genotoxic stress. It can also occur as an 
event secondary to delayed apoptosis in which case it is referred as secondary 
necrosis such as in response to pathogen encoded caspase inhibitors [53]. A 
common feature of necrotic cell death is permeabilization of lysosomal and 
plasma membrane leading to release of toxic cellular components which can 
result in persistent inflammation [54].      
 
Apoptosis is programmed cell death without loss of cell's membrane integrity 
and ensures safe disposal of neutrophil's toxic contents [55]. In addition, 
clearance of apoptotic cells by macrophages by the process of efferocytosis 
(discussed later) causes inhibition of inflammatory signalling. Neutrophil 
apoptosis is thus central event to mediate resolution. During resolution, 
neutrophil apoptosis is controlled by multiple regulatory mechanisms involving 
extrinsic and intrinsic apoptotic pathways. In an example of extrinsic pathway, 
neutrophils undergo apoptosis in response to ligation of surface death 
receptors to Fas ligand generated from macrophages [56] [57]. Reports have 
also shown that TNF-a at high concentrations can directly induce extrinsic 
apoptosis of neutrophils by increasing the turnover of an anti-apoptotic 
molecule myeloid leukaemia cell differentiation protein 1 (MCL-1) [58]. 
Neutrophils also regulate their own life span, e.g. cathepsin D, a protein 
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released from azurophilic granules of neutrophil causes independent activation 
of the pro-apoptotic caspase 8 pathway [59]. Another mechanism of neutrophil 
apoptosis involves phagocytosis induced cell death pathway. Phagocytosis of 
certain bacteria, e.g. E. coli results in an NADPH oxidase mediated production 
of ROS [60]. ROS thus generated induces apoptosis by a combination of 
extrinsic and intrinsic pathways, which involve direct activation of caspase-3 
and increase in permeabilization of mitochondrial outer membrane leading to 
formation pro-apoptotic molecules of B-cell lymphoma-2 (BCL-2) family 
including Bcl-2 homologous antagonist/killer (BAK) and Bcl-2-associated X 
protein (BAX). The role of ROS in mediating neutrophil apoptosis is further 
substantiated from the clinical observation that neutrophils from CGD patients, 
who have a defective ROS system show delayed apoptosis compared to those 
from healthy donors [61]. 
 
Apoptotic neutrophils can also control other resolution processes through 
multiple mechanisms. Specifically, by secreting Annexin A1, which acts via 
FPR2/ALX, they can limit further recruitment of neutrophil during resolution. 
Annexin A1 also promotes neutrophil apoptosis in a paracrine manner and 
also promotes their clearance via macrophages [62] [63]. Apoptotic neutrophils 
also directly bind to LPS and aid in its removal [64].  
 
 
1.2.3 Efferocytosis 
 
 
 
Efferocytosis is the clearance of the apoptotic cells and is accomplished by 
professional phagocytes like macrophages with support from non-professional 
phagocytes, e.g. fibroblasts [65] and epithelial cells [66]. Although it resembles 
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phagocytosis which is classically defined as macrophage uptake of microbes, 
it involves the distinct family of receptors and downstream signalling pathways 
[67].    
   
The process of efferocytosis can be subdivided into four steps: phagocyte 
attraction, apoptotic cell sensing, uptake and digestion [68]. The first step 
involves secretion of 'find me' signals by apoptotic neutrophils, e.g. nucleotides 
ATP and UTP, CXC3CL1, LPC. These “find-me” signals create a signalling 
gradient for the corresponding receptors on the macrophages namely 
purinergic receptor P2Y2, CX3CR1, G2A which then migrate towards the 
apoptotic neutrophil [69]. The next step is apoptotic cell sensing by 
macrophages, facilitated by surface expression of the 'eat me' signals by 
apoptotic neutrophils, e.g. phosphatidylserine (PS) and calreticulin (CRT). 
These eat me signals on apoptotic neutrophils engage with the phagocyte in 
two ways. They either bind them directly, e.g. PS and CRT binding 
respectively to brain-specific angiogenesis factor-1 (BAI1) and CD91, the 
surface receptors on phagocyte. In another approach, the binding is facilitated 
by bridging molecules, e.g. PS bridges with aVb3 on phagocyte via milk fat 
globule EGF 8 (MFGE8), growth arrest specific gene-6 (Gas6) promotes the 
interaction between PS and TAM (Tyro3-Axl-Mer) receptor family on 
phagocytes [70]. Receptor engagement leads to rearrangement of cytoskeletal 
proteins within the phagocyte leading to engulfment of the apoptotic neutrophil 
in its entirety, a process which resembles macropinocytosis [71]. Engulfment of 
the apoptotic cells leads to the formation of a phagosome, a membrane bound 
compartment containing the apoptotic debris. Phagosome becomes 
increasingly acidic and then fuses with the lysosome to form a 
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phagolysosome, where it is degraded by the lysosomal enzymes like DNase, 
acidic proteases and nucleases into their basic cell materials i.e. amino acids, 
nucleotides, fats [72].      
  
Timely clearance of apoptotic neutrophils avoids their death by secondary 
necrosis, which can lead to spillage of toxic cytoplasmic contents leading to a 
sustain inflammatory reaction or development of autoimmunity [73]. In addition, 
efferocytosis switches the phenotype of macrophage from pro-inflammatory to 
anti-inflammatory phenotype and is associated with the generation of anti-
inflammatory mediators like IL-10, PGE2 and TGF-b [74]. Efferocytosis also 
induces production of growth factors such as vascular endothelial growth 
factor (VEGF) and hepatocyte growth factor (HGF) from macrophages, which 
together with transforming growth factor- b (TGF-b) mediate the regeneration 
of tissue components, e.g. fibroblasts, endothelial and epithelial cells [75][76].  
 
1.2.4 Lymphatic emigration 
 
Lymphatic vessels have also been shown to provide an exit to inflammatory 
cells during resolution. Macrophages migrate via lymphatics to the local lymph 
node during resolution [77], which is in part controlled by efferocytosis induced 
expression of CXCR4 on macrophages [78]. CXCR4-CXCL12 axis is known to 
participate in lymphatic migration of dendritic cells, and it seems a similar 
mechanism is involved in macrophage lymphatic egress. Relatedly, the 
interaction of macrophages with apoptotic cells induces expression of the 
sphingosine-1-phosphate receptor (S1PR1) on macrophages, which primes 
them for lymphatic migration via the S1PR1-S1P axis [79]. Thus, efferocytosis 
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not only controls the clearance of neutrophils but also facilitates egress of 
macrophages from the site of inflammation.  
Neutrophils have also been shown to leave the inflamed site via the 
lymphatics. However, this event is observed primarily in microbe triggered 
inflammation compared to tissue injury induced inflammation. Similar to 
macrophages, neutrophil lymphatic migration is controlled via CXCR4 on their 
surface [80]. CCR7, a chemokine receptor associated with dendritic cells and 
T cell migration to the lymph node also mediates neutrophil lymphatic egress 
[81]. In addition to reducing cellular burden at inflammation site, lymphatic 
migration of neutrophils facilitates shuttling of bacteria to the lymph node and 
modulates antigen presentation [82] [83].  
 
 
1.2.5 Reverse transmigration  
 
 
According to the classical view, neutrophils arrive at the site of inflammation 
via activated endothelium and are cleared at the site by efferocytosis during 
resolution. However, recent reports have identified a novel route for neutrophil 
clearance via the microvasculature called reverse transmigration. Reverse 
transmigration is the re-entry of neutrophils from the interstitial site into the 
vasculature and finally to the circulating compartment [84].  
 
Re-entry of inflamed neutrophils back into circulation via microvasculature was 
first reported by Matthias et al in the zebrafish model of tissue injury using 
green fluorescent protein (GFP) expressing neutrophils [85]. These findings 
were later also confirmed in murine model of ischaemia reperfusion injury 
using real-time confocal imaging. In this murine study, Woodfin et al. identified 
that neutrophils exit across the endothelial sites which express low levels of 
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JAM-C, an adhesion molecule involved in neutrophil transmigration. 
Furthermore, they showed that reduction of JAM-C by pharmacological or 
genetic means enhanced reverse transmigration [86]. This process has also 
been replicated in vitro using primary human neutrophils on endothelial 
monolayer, and a similar phenotype of tissue experienced neutrophils have 
also been found in rheumatoid arthritis patients [87].   
 
1.2.6 Post resolution  
 
Classically, the hallmarks of resolution comprised removal of the inflammatory 
stimulus, reduction in levels of pro-inflammatory cytokines and clearance of 
inflammatory cells to restore tissue homoeostasis. However, recent studies 
have shown that the resolved tissue does not just return to its original state, 
but to a state of 'adapted homeostasis' and homes a diverse population of cells 
including monocyte-derived macrophages, monocyte-derived dendritic cells, 
regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) and 
other lymphocytes including B1, B2, NK and gd T cells [88] [89]. 
 
The cells occupying the site during post resolution serve two important 
functions. First, they maintain immune tolerance at the site by inhibiting 
proliferation of effector T cells. This function is mediated via 
immunosuppressive Tregs and MDSCs, which exert this regulatory function by 
producing cytokines like IL-10 and TGF-b [90,91]. Furthermore, MDSCs also 
suppress the effector T cells directly by producing iNOS and arginase at the 
site by cell-cell contact [92]. Second, the post resolution monocyte-derived 
cells regulate the lymphocyte activation in the lymph node in an iNOS 
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dependent manner leading to the effective generation of memory T and B 
lymphocytes in blood [88].  
 
 
 
 
Figure 1.1 Events during onset and resolution of acute inflammation 
 
 
1.3 Specialised pro-resolving mediators (SPMs) 
 
SPMs are the novel genus of lipid mediators that serve as endogenous 
agonists of resolution of inflammation. Depending on the fatty acid substrate 
from which they are derived, SPMs are classified into multiple subsets. The 
section below describes each subset detailing their biosynthesis, the receptors 
through which they mediate their action and their effect on the resolution 
processes.  
 
 
1.3.1 Lipoxins  
 
 
Lipoxins are derived from arachidonic acid (AA) via two main routes, the 15S-
hydroxyeicosatetranoic acid (15S-HETE) pathway and the leukotriene A4 
(LTA4) pathway. In the 15S-HETE pathway, AA is first converted by 15-
lipoxygenase (15-LO) into 15S-HETE. 15S-HETE is then further converted to 
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5(6)- epoxytetraene by 5-lipoxygenase (5-LO). In the second route, AA is first 
converted by the action of 5-LO into LTA4 which is then further converted by 
12 or 15-LO to 5(6)- epoxytetraene [93]. In both pathways, the 5(6)- 
epoxytetraene undergoes enzymatic hydrolysis to lead to the formation of 
lipoxin A4 (LXA4) and its isomer lipoxin B4 (LXB4) [94] (Figure 1.2).  
The lipoxin family also includes 15-epi-lipoxins, which are derived from AA in 
the presence of aspirin. Biosynthesis of 15-epi-lipoxins involves conversion of 
AA into 15R-HETE by the acetylated cyclooxygenase-2 (COX-2). Here, aspirin 
mediates the acetylation of COX-2. 15R-HETE is converted by 5-LO into 15-
epi-LXA4 or 15-epi-LXB4 [95]. 15-epi-lipoxins can also be produced by the 
cytochrome p450 mediated oxygenation of AA [96] (Figure 1.2).   
 
 
 
LXA4 and 15-epi-LXA4 mediate their function primarily via a specific formyl 
peptide receptor, FPR2 (also called ALX), a member of FPR class of G-protein 
coupled receptor (GPCR) family. The receptor for LXB4 or 15-epi-LXB4 is still 
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Figure 2.2 Biosynthesis lipoxins and 15-epi-lipoxins  
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unknown [97]. In humans, FPR2/ALX has been identified on multiple immune 
cell types including neutrophils, monocytes, T cells as well as endothelial cells 
and epithelial cells [98].  
 
1.3.2 Resolvins, Protectins and Maresins 
 
Resolvins are a family of specialised pro-resolving mediators derived from 
omega-3 fatty acids. Depending on the omega 3 fatty acid, these mediators 
are broadly classified into two series: E-series resolvins, derived from 
eicosapentaenoic acid (EPA) and D-series resolvins, derived from 
docosahexaenoic acid (DHA). DHA gives rise to another family of SPMs called 
protectins and maresins [99].  
 
Biosynthesis of E-series resolvins involves an aspirin dependent pathway and 
aspirin independent pathway. In the aspirin dependent pathway, acetylated 
COX-2 mediates the conversion of EPA to 18R-HEPE, and in the aspirin 
independent pathway, p450 enzymes convert EPA to 18-R-HEPE. Irrespective 
of the route, the 18R-HEPE intermediate is converted by the sequential action 
of leucocyte derived 5-LO into 5S-hydroperoxy-18R-HEPE and then into 
resolvin E1 (RvE1) or resolvin E2 (RvE2) [100]. 18R-HEPE can also be a 
substrate for 12/15-LO which leads to the formation of resolvin E3 (RvE3) 
[101] (Figure 1.3). 
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DHA gives rise to three different types of SPM families: D-series resolvins, 
maresins and protectins. D- series resolvins involve the conversion of DHA by 
15-LOX into 17S-hydroperoxy-DHA (17S-HDHA), which is then catalysed by 
the 5-LO to generate positional isomers including RvD1, RvD2, RvD3, RvD4, 
RvD5 and RvD6. The action of acetylated COX-2 on DHA yields 17R-
hydroperoxy-DHA (17-R-HDHA), which is converted by 5-LO into aspirin-
triggered D- resolvins including AT-RvD1, AT-RvD2, AT-RvD3, AT-RvD4. 
Similar to other aspirin-triggered SPMs, cytochrome P450 can also form 
aspirin-triggered D- resolvins [102]. 17-S-HDHA and 17-R-HDHA also give rise 
to protectin D1 and aspirin triggered-protectin D1 after undergoing enzymatic 
epoxidation and enzymatic hydrolysis [103]. Maresin synthesis involves the 
conversion of DHA by macrophage 12-LO into 14S-hydroperoxy-DHA in 
macrophages, followed by oxygenation [104] (Figure 1.4). 
 
 
Eicosopentaenoic
acid	(EPA)
18-HEPE
RvE1	and	RvE2RvE3
Figure 1.3 Biosynthesis of E-series Resolvins 
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RvE1 mediates its actions via two GPCR receptors: ChemR23 and BLT1[105]. 
RvE1 is a full agonist of ChemR23, which is primarily expressed on the 
monocytes, dendritic cells and also on the epithelial and endothelial cells [106] 
[107]. It also acts as a partial agonist on the BLT1 receptor. BLT1 is expressed 
on the granulocytes, monocytes and dendritic cells [108]. Receptors for RvE2 
and RvE3 are not yet identified. Amongst the D-series resolvins, receptors 
have been determined for RvD1, RvD2, RvD3 and RvD5. RvD1 and its aspirin-
triggered epimer AT-RvD1 activate two GPCR receptors, FPR2/ALX and 
GPR32 [109]. FPR2/ALX is primarily the LXA4 receptor but is also activated by 
RvD1 at higher concentrations. GPR32 is also activated by RvD2 and RvD5, 
which are structurally similar to RvD1. GPR32 is primarily expressed on 
neutrophils, monocytes and monocyte-derived macrophages [109]. Resolvin 
D2 triggers GPR18, which is mainly expressed on neutrophils, monocytes 
[110].  
 
 
Docosahexaenoic	
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5-LOX	 5-LOX	
Aspirin	triggered	
D-Resolvins
Figure 1.4 Biosynthesis of D-series Resolvins 
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1.3.4 Role of SPMs in promoting resolution processes  
 
Through concerted action on different cell types, SPMs control the severity of 
inflammation and promote multiple resolution processes. SPMs inhibit 
neutrophil trafficking, e.g. LXA4 and ATL-LXA4 have been shown to exert their 
negative effects on neutrophil trafficking by preserving CD62L and 
downregulating CD11b on neutrophils, causing reduced adhesion on 
endothelium [111]. LXB4 also inhibits neutrophil adhesion by downregulating 
expression of P-selectin on the endothelium [112]. RvE1 acts as a partial 
agonist of BLT1 receptor and interrupts the signalling via potent neutrophil 
chemoattractant LTB4 [113]. Similar to lipoxins, RvD1 and AT-RvD1 also show 
inhibitory effect on neutrophil trafficking via FPR2/ALX [114][115].  
 
In addition to inhibiting neutrophil migration, SPMs also promote neutrophil 
apoptosis and enhance their clearance by efferocytosis. RvE1 and 15-epi-
LXA4 increase neutrophil apoptosis by attenuating myeloperoxidase (MPO) 
induced expression of anti-apoptotic molecule MCL-1 [116][117]. LXA4 and 
LXB4 induce selective migration of monocytes and also reprogram these 
monocytes to increase efferocytosis [118][119]. In fact, the interaction between 
macrophages and apoptotic cells have been shown to enhance formation of 
SPMs like RvD1, RvE1 and PD1. Thus, efferocytosis and SPMs maintain a 
positive feedback loop to ensure resolution [120].  
 
SPMs also downregulate the production of pro-inflammatory cytokines. One 
mechanism through which they mediate this action is by inhibiting the 
transcription of cytokines, e.g. LXA4 reduces IL-8 transcription by activating the 
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repressors of the NF-kB [121][122]. RvD1 upregulates expression of mi-RNA 
146b, which targets NF-kB signalling and reduces transcription of pro-
inflammatory cytokines IL-8 and IL-1b [123]. In another mechanism, SPMs 
reduce the levels of chemokines by promoting their scavenging, e.g. LXA4 
increases the expression of CCR5 on apoptotic neutrophils, which scavenge 
the chemokines CCL3 and CCL5 [124]. 
 
In addition to their effect on immune cells, SPMs exert an effect on the stromal 
tissue to promote resolution. Lipoxins inhibit the fibroblast-derived 
metalloproteinases production. For instance, exposure of LXA4 to human 
synovial expressing FPR2/ALX reduced their production of matrix 
metalloproteinase MMP-3, which otherwise can cause tissue destruction [125]. 
In another example, RvD2 was shown to promote revascularization in a model 
of ischaemic injury. Here it was shown that RvD2 enhances endothelial cell 
migration which promotes arteriogenesis and myocyte regeneration [126]. 
SPMs have also been shown to maintain epithelial barrier integrity. In a mouse 
model of dry eye, RvE1 not only decreased inflammation but also increased 
the density of corneal epithelial cells and improved tear production [127]. The 
effect on epithelial function was also seen in the model of colitis where RvE1 
increased the expression of intestinal alkaline phosphatase and reduced the 
loss of epithelial barrier [128].     
 
Another important characteristic of SPMs is their effect on promoting the 
clearance of microbes. In the cystic fibrosis model, LXA4 administration directly 
reduced the lung burden of P. aeruginosa [129]. Likewise, RvE1 enhanced the 
clearance of E. coli in addition to decreasing neutrophil accumulation in an 
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acute lung injury model [130]. SPMs have also been shown to enhance the 
effects of antibiotics, e.g. 15-epi-LXA4 in combination with the antibiotic 
ceftazidime reduced the bacterial load in a sepsis model triggered by E. coli 
induced peritonitis [131]. A similar effect has been shown in combination with 
ciprofloxacin for RvD1 and PD1. SPMs (RvD1, RvD5 and PD1) also enhance 
antibiotic effects of vancomycin in mouse model skin infection caused by S. 
aureus [132].  
 
1.4 SPMs: A novel approach to treat inflammatory disorders 
 
 
The current strategy to treat chronic inflammatory disorders is largely based on 
the 'anti-inflammatory' approach i.e. inhibiting the factors that drive 
inflammation. The anti-inflammatory tool kit comprises of three main classes. 
The most commonly used are NSAIDs, which function by inhibiting COX to 
reduce the levels of pro-inflammatory prostaglandins [133]. Second, 
corticosteroids, which act on multiple pathways including inhibition of NF-kB 
transcription, inhibition of phospholipase A2, downregulation of cell adhesion 
molecules, induction of anti-inflammatory proteins such as lipocortin, secretory 
leucocyte protease inhibitor (SLPI) [134]. And third, the disease modifying anti-
rheumatic drugs (DMARDs) which can be further sub-classified into non-
biologics for, e.g. methotrexate and biologics which are monoclonal antibodies 
against the cytokines or their receptors, e.g. anti-TNF and anti- IL1 [135].  
 
While NSAIDs and corticosteroids are effective at relieving symptoms, they are 
associated with side effects in multiple organ systems including the immune 
system. NSAIDs can cause gastric ulcers, increase the risk myocardial 
infarction and stroke, and renal failure in patients with kidney disease 
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[136][137]. Furthermore, they directly interfere with the resolution processes 
and tissue repair [138][139]. The side effect profile of corticosteroids is more 
severe. They can predispose to diabetes mellitus, affect the nervous system 
and can cause mood disturbances and sleep disorders. Steroids also interfere 
with skin wound healing and have side effects on the skeletal system and can 
cause osteoporosis. Furthermore, they reactivate latent infections, e.g. 
cytomegalovirus (CMV) and tuberculosis (TB) and increase the risk of 
infections, e.g. candida infection [136]. Biologics, like corticosteroids, can also 
weaken the antimicrobial host defence of the body [140].  
 
In recent years, evidence has accumulated that pathogenesis of chronic 
inflammatory disorders can in part be due to defects in the pro-resolution 
pathways [141], e.g. In a rat model of carrageenan-induced pleurisy, it was 
observed that decreased in the production of cyclopentenone prostaglandin 
15d-PGJ2, by COX-2 inhibition can lead to sustained inflammation [138]. In 
another example, mice deficient of 12/15 LO, a key enzyme involved in the 
generation of SPMs, showed exaggerated inflammation in a model of 
experimental arthritis [142]. These observations are also supported by clinical 
scenarios, e.g. levels of LXA4 in the exhaled breath condensates and activated 
blood of asthmatic patients inversely correlated with disease severity [143].  
 
Mounting evidence that 'failure to resolve' could contribute to the pathogenesis 
of chronic inflammatory disorders have given momentum to the novel 'pro-
resolving approach, which involves enhancing the levels of endogenous 
mediators of resolution to correct the resolution deficit. While a diverse range 
of compounds such as lipid mediators, e.g. cyclopentenone prostaglandins 
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(15d-PGJ2) [144], epoxy-oxylipins [145], gasses, e.g. hydrogen sulphide [146], 
purine nucleoside, e.g. adenosine [147], peptides, e.g. annexin A1, 
melanocortin and chemerin-derived peptides [148–150] have been shown to 
ameliorate inflammation, SPMs have been at the forefront of the pro-resolving 
approach. 
 
The beneficial effect of SPMs has been proven in multiple models of chronic 
inflammatory disorders including arthritis [151], asthma [152], inflammatory 
bowel disease [153] and also in acute inflammatory conditions, e.g. sepsis 
[154]. In addition, SPMs actively promote tissue repair and in concert with 
antibiotics enhance the immune defence against microbial response [132] 
[155]. Furthermore, they have direct analgesic by modulating the central pain 
pathways and reducing pain hypersensitivity [156].  
 
The promising results in animal models supported by correlation studies in 
patient populations make SPM based therapy an ideal candidate for drug 
development. Carefully designed human studies with validated biomarkers to 
confirm efficacy and support patient stratification will ensure they reach clinical 
practice in a timely manner.    
 
1.5 Rationale for using human models of inflammation   
 
Animal models have been indispensable for understanding disease 
mechanisms. By allowing genetic or pharmacologic manipulation, in vivo 
imaging and cell tracking, they have not only elucidated novel drug targets but 
have also allowed to investigate the pharmacology of novel compounds on 
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disease progression [157]. Despite the high quality of evidence from animal 
studies, the predictability of animal models to inform the success of clinical 
trials in humans has come into question [158]. The problem is worse in the 
case of inflammatory disorders exemplified by the failure of more than 100 
clinical trials in sepsis [159].  
 
An important factor that contributes to this problem could be differences within 
the immune systems of rodents and humans, e.g. in humans, the dominant 
immune cell type in circulating blood is neutrophils (50 - 70%), while in mice it 
is lymphocytes (75-90%) [160]. In addition to the quantitative differences, the 
immune cell types differ qualitatively. For instance, human neutrophils are rich 
in defensins, an antimicrobial peptide but it is absent in mouse neutrophils 
[161]. Another controversial example is a lack of inducible nitric oxide 
expression in human macrophages, which is otherwise clearly expressed by 
mouse macrophages in response to LPS and IFN-g [162]. The differences are 
also evident in the adaptive immune components. For e.g. Fc receptors (FcR) 
which mediate the binding of antigen-antibody complexes are differently 
expressed between the two species. Mice lack the expression of FCaRI which 
is otherwise expressed in humans. Furthermore, there are species differences 
in the chemokines which partake in the movement of immune cells during the 
inflammatory response. The chemokines CXCL8, CXCL7, CCL13 are absent 
in mice, while CCL-6, -9 and -12 are absent in humans [163]. The non-immune 
cell components, like endothelial cells, are also different between two species. 
For instance, P-selectin, an integrin present on the endothelial cell to mediate 
trafficking of leucocytes is upregulated in response to LPS in mice but not in 
humans [164].  
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The variation in inflammatory response between mice and humans have also 
been highlighted at the systems level. Seok et al. showed that the genomic 
responses to different inflammatory stimuli including trauma, burns and 
endotoxin in humans poorly correlated with mice. Furthermore, they 
demonstrated that human model of intravenous endotoxin administration 
correlated highly with patients than any of the murine models of inflammation. 
In addition, they found that for same stimuli, the recovery time i.e. the time 
required for upregulated gene to decrease to half its maximum value, was 
significantly lower in murine models compared to the humans. This 
observation emphasises that the resolution of inflammatory signalling is 
variable in human and mice [165]. Humans are also 100,000-fold more 
responsive to intravenous LPS than mice, an effect which is in part due to 
differences in serum proteins between two species [166]. These differences 
are important to consider as LPS is one of the commonly used inflammatory 
stimulus in mice to model human inflammatory response [167].  
 
Utilising human models is thus an important step towards understanding the 
pathogenesis of inflammatory diseases, particularly in cases where animal 
models fail to capture the characteristics of the disease in patients. Even 
though they lack the mechanistic rigour of animal models, humans can serve 
as a platform to validate the findings described in mice and understand their 
relevance and representativeness to human immunology [168]. They can also 
be used as proof of concept platform to validate mechanism of novel immune 
therapeutics and obtain data on their early clinical efficacy. Such proof of 
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concept studies also allows to discover new biomarkers or confirm the utility of 
existing ones for late stage clinical trials [169].  
 
1.6 Human models of acute inflammation  
 
 
Human models of acute inflammation are broadly classified into two groups, 
systemic and local. Systemic models, e.g. intravenous endotoxin mimic early 
sepsis [170]. In local models, inflammation is triggered in the tissue, either lung 
or skin to facilitate investigation of leucocyte migration and soluble mediators 
of inflammation [171]. Lung models of acute inflammation include endotoxin 
inhalation, ozone challenge and rhinovirus challenge models [169]. Skin is a 
preferred site as it allows the use of minimally invasive techniques, 
investigation of multiple sites and provides easy access to inflammatory 
contents. In the context of this thesis, I have described below the different 
types of skin inflammation models.  
 
1.6.1 Cantharidin skin blister  
 
Cantharidin is a blistering agent produced as a defence mechanism by a 
species of beetle collectively referred as Spanish fly or blister beetle [172]. On 
contact with skin, cantharidin causes the release of serine proteases within the 
epidermis, resulting in loss of cohesion between keratinocytes, a process 
called acantholysis [173]. Acantholysis induced tissue injury leads to sterile 
inflammation which gives rise to a skin blister. This blistering property of 
cantharidin is also exploited clinically for the treatment of plantar warts [174]. 
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Cantharidin induced skin blister was first demonstrated by Day et al. to be a 
suitable in vivo model to investigate leucocyte migration and cytokines during 
onset phase of acute inflammation [175]. Their technique involved the 
application of cantharidin solution on a filter paper disc placed on the skin and 
then covering it using an adhesive dressing for 24h. After 24h, a skin blister is 
formed which can be aspirated to obtain the inflammatory exudate, which 
contains cells and soluble mediators. Morris et al. extended the use of 
cantharidin skin blister to study resolution biology in humans. In their study, 
two blisters were raised on the forearm of healthy volunteers; one was 
aspirated at 24h to study the onset of acute inflammation and the other one at 
72h, to explore the resolution phase [176].  
 
Cantharidin skin blister has been employed for multiple uses. For instance, 
Dinh et al. validated its use to study the effect of anti-inflammatory drugs, e.g. 
Anti-TNFa and corticosteroids on neutrophil migration at onset [177]. In 
another example, it was employed in patients undergoing cardiopulmonary 
bypass surgery, to understand dysfunction of leucocytes trafficking post-
surgery [178].  
 
1.6.2 Skin chamber technique 
 
Skin chamber technique involves two steps. In the first step, a skin blister is 
generated by application of negative pressure on the skin followed by removal 
of the blister roof to form a denuded skin surface. In the second step, the 
denuded skin area is covered using a plastic collection chamber filled with 
autologous serum and kept for 4-24h. During this interval, the leucocytes and 
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soluble mediators accumulate in collection chamber fluid which can be 
sampled to investigate the different phases of inflammation.  
 
Skin chamber technique has been primarily used to investigate defects in 
neutrophil migration in patient populations, e.g. cirrhosis patients [179] and 
renal failure[180].  
 
1.6.3 Skin abrasion models  
   
Skin abrasion models involve the creation of lesion on the superficial layer of 
skin with the use of either high-speed drill [181], tape stripping[182] or 
sandpaper [183]. The lesion provides a skin window for exudation of 
inflammatory contents on to the skin. The contents are either directly 
aspirated, or they are collected on a filter paper disc overlaid over the lesion. In 
the latter case, the cells are extracted by layering the filter paper disc on a 
glass slide which is then fixed and stained. The soluble mediators in the filter 
paper disc are eluted by incubating it in normal saline followed by 
centrifugation [183]. Skin abrasion models have also been employed to 
investigate defect in innate immune response in patients, e.g. Crohn's disease.   
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1.7 PhD aims and objectives  
 
Studies demonstrating beneficial effects of SPMs in inflammatory diseases 
have been primarily conducted in animal models, and there is a need to 
investigate the SPM physiology and pharmacology in human models of 
inflammation that can lend themselves to delineating pro-resolution pathways 
and that are amenable to therapeutic intervention.  
 
Keeping this aim mind, my PhD objectives were:  
 
 
- To characterise an in vivo model of resolution of acute inflammation in 
healthy humans.  
 
- To investigate SPM generation, SPM receptor expression and effect of SPMs 
on resolution indices using an in vivo model of resolution of acute inflammation 
in healthy humans.    
  
- To investigate the effect of an SPM based drug on resolution indices and 
compare it to the conventional anti-inflammatory agent using an in vivo model 
of resolution of acute inflammation in healthy humans.  
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Chapter 2  
METHODS 
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2.1 Cantharidin skin blister model   
 
2.1.1 Ethics statement  
Cantharidin skin blister study was approved by UCL Institutional Ethics 
Committee (Project ID: 2907/002). The procedures performed were in 
accordance with the ethical standards of the UCL Institutional Committee and 
Declaration of Helsinki. Written informed consent was obtained from all 
volunteers.    
 
2.1.2 Volunteer recruitment 
Healthy, young, non-smoking males (18-50 years) were recruited for this 
study. Volunteers were excluded if they had a history of any chronic 
inflammatory condition or allergies, recent history (< 1 month) of an acute 
inflammatory condition, immunisation in last three months, were taking regular 
medications or had taken any medication in the week before proposed study 
start date. Volunteers were advised to refrain from heavy exercise and alcohol 
for two days before study start date, during the study period and two days after 
the study period.   
 
2.1.3 Application of cantharidin skin blister 
 
Overall, the procedure involved three visits:  
2.1.4.1 Visit 1: Blister induction 
 
After obtaining written consent, two sites were marked over a forearm, 10-15 
cm away from the elbow crease. The marked sites were cleaned using 70% 
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isopropyl alcohol and then dry shaved. Two filter paper discs (10mm diameter, 
Whatman grade 1) were placed over the marked sites, and 12.5 μl of 0.1% 
cantharidin solution (0.7% Cantharone, Dormer Laboratories Inc., Canada 
diluted 1:7 in acetone) was pipetted on to each of the filter paper disc (Figure 
2.1A). Each filter paper disc was then covered by laboratory film (16mm 
diameter; Parafilm) and further overlaid by two foam pads (30mm diameter, 
Activheal non-adhesive foam pad) (Figure 2.1 B, C and D). The two sites 
were then secured by application of an adhesive dressing (Mepore, 10 x 14 
cm) (Figure 2.1 E, F). Participants were advised to keep the dressing dry and 
return the next day at the same time. A 5 ml sample of peripheral blood was 
also collected from the contralateral forearm before the application of 
cantharidin blister.   
 
2.1.4.2 Visit 2: Dressing change and 24h blister exudate aspiration  
 
At the 24h time point, the dressings were carefully removed. After ensuring 
that a patent blister has formed over both the sites, one of the blisters was 
pierced using a 26.5-gauge needle. The roof of the pierced blister was then 
gently squeezed using a sterile 1 ml syringe to push out the blister exudate,  
which was aspirated using a sterile pipette (Figure 2.2 A, B). The blister 
exudate was mixed with 50 μl of 3% sodium citrate in a sterile 1.5 ml micro-
centrifuge tube to prevent coagulation. The tube was then centrifuged at 1000 
x g for 5 min at 40 C, and the resulting cell pellet was suspended in 1 ml of 
FACS buffer (PBS with 5% FCS + 0.1% sodium azide). Leucocytes were first 
enumerated as described in section 2.3 and then processed for flow cytometry 
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as described in section 2.6. The supernatant was aliquoted and stored at -80 
0C.  
 
The aspirated blister was cleaned using an aseptic solution (0.1 % Cetrimide, 
Savlon) and was covered with a protective dressing pad (9 x 10 cm, Mepore). 
The unaspirated blister was protected for another 48h using a cap dressing 
(Figure 2.2 C, D). The cap dressing involved fitting a concentrically cut ulcer 
dressing (Comfeel Plus, Ulcer Dressing 10 x10cm) around the blister and then 
securing a blister cap over it. The blister cap was prepared by coating a plastic 
cap [the cap of a 50 ml specimen tube (Sterilin)] with an ulcer dressing along 
the rim. The blister cap and ulcer dressing were further secured by support 
bandage. The volunteer was asked to return after two days for 72h blister 
aspiration. 
Figure 2.4 Study procedures involved in the UVkEc triggered self resolving dermal
inflammation
Acute inflammation was triggered in the ventral aspect of the forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100ul of sterile saline (A).
After a certain interval, depending on phase of acute inflammation being investigated, the injected
site was scanned by a laser Doppler imager to quantify local blood flow (B). Subsequently, a
suction chamber connected to a negative pressure instrument was placed over the injection site to
raise a 10mm blister to acquire the inflammatory exudate present at the site (C). Immediately after
formation of the the blister, its roof was pierced using a sterile needle and the inflammatory exudate
were aspirated by a pipette (D).
Figure 2.3 Graphic showing the technique of intradermal injection of UV
killed E. coli (A) and acquisition of inflammatory exudate using suction
blister (B)
Figure 2.2 Aspiration of cantharidin blister exudate and application of cap dressing for 72hr
time-point
Blister roof is pierced along the lateral border using a needle and fluid is rolled out using a 1 ml
syringe which is then collected by a pipette (A and B). 72hr cantharidin blister is secured using a
cap dressing made of hard plastic cap and ulcer dressing (C and D). (Image reproduced from
Jenner WJ, G. D. (2012). Assessment of leukocyte trafficking in humans using the cantharidin
blister model. J R Soc Med Cardio, 1 no. 1 4)
Figure 2.1 Application of cantharidin skin blister
0.1 % Cantharidin is pipetted over a filter paper disc (A). Filter paper disc is then covered by a
parafilm and a foam pad (B, C and D). Foam pads are covered by an adhesive dressing (E and F).
(Image reproduced from Jenner WJ, G. D. (2012). Assessment of leukocyte trafficking in humans
using the cantharidin blister model. J R Soc Med Cardio, 1 no. 1 4)
A B C
D E F
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2.1.4.3 Visit 3: 72h blister exudate aspiration  
 
At this visit, the blister cap dressing was carefully removed, and the blister fluid 
was aspirated and processed in the manner described above for the 24h time 
point. The aspirated blister area was cleaned using an aseptic solution and 
covered with a protective dressing (Mepore). Volunteers were asked to keep 
the site dry until a visible scab formed over both the aspirated blister sites. 
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Figure 2.4 Study procedures involved in the UVkEc triggered self resolving dermal
inflammation
Acute inflammation was triggered in the ventral aspect of the forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100ul of sterile saline (A).
After a certain interval, depending on phase of acute inflammation being investigated, the injected
site was scanned by a laser Doppler imager to quantify local blood flow (B). Subsequently, a
suction chamber connected to a negative pressure instrument was placed over the injection site to
raise a 10mm blister to acquire the inflammatory exudate present at the site (C). Immediately after
formation of the the blister, its roof was pierced using a sterile needle and the inflammatory exudate
were aspirated by a pipette (D).
Figure 2.3 Graphic showing the technique of intradermal injection of UV
killed E. coli (A) and acquisition of inflammatory exudate using suction
blister (B)
Figure 2.2 Aspiration of cantharidin blister exudate and application of cap dressing for 72hr
time-point
Blister roof is pierced along the lateral border using a needle and fluid is rolled out using a 1 ml
syringe which is then collected by a pipette (A and B). 72hr cantharidin blister is secured using a
cap dressing made of hard plastic cap and ulcer dressing (C and D). (Image reproduced from
Jenner WJ, G. D. (2012). Assessment of leukocyte trafficking in humans using the cantharidin
blister model. J R Soc Med Cardio, 1 no. 1 4)
Figure 2.1 Application of cantharidin skin blister
0.1 % Cantharidin is pipetted over a filter paper disc (A). Filter paper disc is then covered by a
parafilm and a foam pad (B, C and D). Foam pads are covered by an adhesive dressing (E and F).
(Image reproduced from Jenner WJ, G. D. (2012). Assessment of leukocyte trafficking in humans
using the cantharidin blister model. J R Soc Med Cardio, 1 no. 1 4)
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2.2 UV killed E. coli (UVkEc) triggered self-resolving dermal 
inflammation model 
 
2.2.1 Ethics statement  
 
The study characterising the UVkEc triggered self-resolving dermal 
inflammation model was approved by UCL Institutional Ethics Committee 
(Project ID: 5051/001). All procedures performed were in accordance with the 
ethical standards of the UCL Institutional Committee and Declaration of 
Helsinki. Written informed consent was obtained from all volunteers.  
 
2.2.2 Volunteer recruitment 
 
Healthy, young, non-smoking males (18-50 years) were recruited in this study. 
Volunteer exclusion criteria included: a history of any chronic inflammatory 
condition or allergies, recent history (< 1 month) of an acute inflammatory 
condition, immunisation in last three months, were taking regular medications 
or had taken any medication in the week before proposed study start date. 
Volunteers were advised to refrain from heavy exercise and alcohol for two 
days prior to study start date, during the study period and two days after the 
study period. Volunteers were also asked to refrain from high concentration 
tasks, e.g. driving for the first 24h after UVkEc injection. 
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2.2.3 Preparation and injection UV-killed E. coli (UVkEc) 
 
E. coli bacteria (Strain: NCTC 10418, Source: Public Health England, UK) 
were a kind gift from Dr Andrew Smith (UCL Division of Medicine). Using a 
wire loop, an aliquot of bacteria was transferred into Luria- Bertani broth (LB 
broth) (LB broth was prepared by mixing LB broth powder (Sigma) at 20 gm/L 
in distilled water followed by autoclaving). E. coli bacteria were incubated 
overnight at 370 C in LB broth. Next morning the LB broth was centrifuged 
(2500 x g, 20 min, 40 C) to pellet the bacteria. The bacterial pellet was washed 
twice (2500 x g, 5 min, 40 C) using sterile PBS and was then suspended in 
sterile saline (Braun). Bacteria in saline were transferred to a petri dish and 
were killed by exposure to ultraviolet light (UV) source (302 nm, ChemiDoc, 
trans-UV mode) for 60 min. The UV exposed bacteria were washed again 
using sterile saline. The non-viability of bacteria was confirmed by the testing 
absence of culture on the LB agar plate. Bacterial count was estimated using a 
spectrophotometer using the formula: OD600 = 0.365 equates to 108E. coli/ml 
(derived by Dr Andrew Smith, Division of Medicine). The final aliquots were 
prepared in sterile saline to contain 1.5 x 108 bacteria per ml of saline and 
were stored at -80 0 C. The non-viability of frozen sample was again confirmed 
by UCLH (University College London Hospitals, UK) Microbiology department. 
 
On the day of the study, the aliquot of frozen UVkEc in saline was thawed 30 
min before volunteer arrival. The thawed tube was vortexed, and the bacteria 
were aspirated in 1 ml syringe. The skin on the volar aspect of forearm not 
overlying the subcutaneous veins was marked. The marked site was 
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disinfected and dry shaved and 1.5 x 107 UVkEc in 100 μl of sterile saline were 
injected intradermally where the site was marked (Figure 2.4 A).     
 
2.2.4 Laser Doppler Imaging.  
 
Laser Doppler Imager (moor LDI-HIR, Moor Instruments Ltd, Axminster, 
Devon, UK) was used to quantify the vascular hyperaemia (blood flow) at the 
site of inflammation. It is based on the principle of Doppler shift. The frequency 
of a monochromatic light source is broadened (shifted) after it is scattered by 
moving red blood cells (RBCs) [184].     
 
To assess vascular hyperaemia, the inflamed site on the forearm was placed 
under the scanner at a fixed distance. The laser beam emitted by the scanner 
head of the imager is scattered by RBCs in the inflamed area. The reflected 
light rays with broadened frequency are then detected by a photo detector of 
the imager. The scatter (Doppler frequency shift) is proportional to velocity and 
number of red blood cells at the site and is measured as a photocurrent signal. 
The strength of this signal from different parts of the inflamed site is 
represented by an image. This image called a flux image is composed of a 
colour spectrum, where each colour indicates the degree of vascular 
hyperaemia. The flux images were analysed by moorLDI software (Version 
5.2) and the vascular hyperaemia (measured in perfusion units) was obtained 
by multiplying the number of valid pixels in the flux image above the 
background signal (Cut-off = 300 perfusion units) with the mean signal over 
the valid pixels [182, 183] (Figure 2.4 B) 
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2.2.5 Suction Blister Technique 
 
Suction blister was raised directly above the UVkEc triggered site to obtain the 
inflammatory exudate from the site (Figure 2.3). This procedure is modified 
version of the procedure described previously [187]. To raise a suction blister, 
a suction chamber was placed over the marked injection site and then 
strapped on the forearm. The chamber was made of three parts: an aluminium 
plate with 10 mm aperture, a nylon cup, and a transparent glass lid, all secured 
by a detachable air-tight seal. The suction chamber was connected to negative 
pressure instrument (NP-4, Electronic diversities Ltd., MD, USA). After 
ensuring the position of the suction chamber to the forearm, the negative 
pressure was applied gradually at a rate of 1 inch of mercury (in of Hg) every 5 
min until a bleb was observed. At this point, the pressure was kept constant 
until a uniloculated blister covering the surface area within the aperture was 
formed. After a complete blister had been formed, the pressure was lowered 
gradually at the rate of 1 in of Hg per min. The suction chamber was 
unstrapped carefully without disturbing the formed blister. The duration of 
suction blister induction process varied from 1.5-2h depending on the 
volunteer and phase of inflammation (Figure 2.4 C).  
 
Suction blister was aspirated immediately after formation. Firstly, the blister 
roof was pierced along its lateral border using a 26.5 gauge needle. The blister 
exudate was then gently pushed out on the skin by rolling a 1 ml syringe over 
the blister surface and was simultaneously aspirated using a 200 µl pipette. 
(Figure 2.4 D) The aspirated blister site was cleaned using an aseptic solution 
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(0.1% Cetrimide), and the site was covered with a protective dressing. 
Volunteers were asked to keep the site dry until a scab formed. 
 
The fluid was collected into a 96 well plate containing 50 μl of 3% sodium 
citrate. The plate was then centrifuged at 1000 x g for 5 min at 40 C to 
separate the cells from the supernatant. After centrifugation, the resulting cell 
pellet obtained was suspended in 200 µl of RBC lysis buffer (Lonza) to lyse the 
RBCs. RBC deplete cell pellet was suspended in 100 µl of FACS buffer and 
processed for cell counting as described in section 2.5 and for flow cytometry 
as described in section 2.6. The supernatant was aliquoted and stored at -80 
0C.    
 
 
Figure 2.3 Graphic showing the technique of intradermal injection of UV
killed E. coli (A) and acquisition of inflammatory exudate using suction
blister (B)
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2.2.6 Volunteer feedback on the tolerability of UVkEc triggered self- 
resolving dermal inflammation model.  
 
Volunteer feedback on the discomfort associated acute inflammation 
symptoms and due to research procedures employed in UVkEc triggered self- 
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D
Figure 2.4 Study procedures involved in the UVkEc triggered self resolving dermal
inflammation
Acute inflammation was triggered in the ventral aspect of the forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100ul of sterile saline (A).
After a certain interval, depending on phase of acute inflammation being investigated, the injected
site was scanned by a laser Doppler imager to quantify local blood flow (B). Subsequently, a
suction chamber connected to a negative pressure instrument was placed over the injection site to
raise a 10mm blister to acquire the inflammatory exudate present at the site (C). Immediately after
formation of the the blister, its roof was pierced using a sterile needle and the inflammatory exudate
were aspirated by a pipette (D).
Figure 2.3 Graphic showing the technique of intradermal injection of UV
killed E. coli (A) and acquisition of inflammatory exudate using suction
blister (B)
Figure 2.2 Aspiration of cantharidin blister exudate and application of cap dressing for 72hr
time-point
Blister roof is pierced along the lateral border using a needle and fluid is rolled out using a 1 ml
syringe which is then collected by a pipette (A and B). 72hr cantharidin blister is secured using a
cap dressing made of hard plastic cap and ulcer dressing (C and D). (Image reproduced from
Jenner WJ, G. D. (2012). Assessment of leukocyte trafficking in humans using the cantharidin
blister model. J R Soc Med Cardio, 1 no. 1 4)
Figure 2.1 Application of cantharidin skin blister
0.1 % Cantharidin is pipetted over a filter paper disc (A). Filter paper disc is then covered by a
parafilm and a foam pad (B, C and D). Foam pads are covered by an adhesive dressing (E and F).
(Image reproduced from Jenner WJ, G. D. (2012). Assessment of leukocyte trafficking in humans
using the cantharidin blister model. J R Soc Med Cardio, 1 no. 1 4)
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resolving dermal inflammation model was obtained using an online 
questionnaire. The online questionnaire was prepared on the 
https://www.surveymonkey.com, and the link to the feedback form was sent to 
volunteers. Responses from the volunteers were anonymised.     
 
2.3 Cell counting 
 
 
Blister exudate was centrifuged to separate cells from the supernatant. Cells 
were suspended in FACS buffer and supernatant was transferred to a 1.5 ml 
microcentrifuge tube (Eppendorf) tube. Cell count was obtained using a 
manual haemocytometer. 10 μl of this cell suspension was mixed 1:1 with 
0.4% trypan blue and 10 μl of this mixture was loaded on to the 
haemocytometer (C-chip, Digital-Bio Ltd.) and placed on a light microscope 
(Olympus). Total cell count, blister fluid volume and cell count/ml were 
obtained as below:  
-Total cell count = Cell count in 1mm2 square (average numbers of cells in four 
corner squares of haemocytometer) x 104 x 2 x cell suspension volume (ml).  
 
-Blister fluid volume = (Weight of microcentrifuge tube with blister supernatant) 
- (weight of microcentrifuge tube). 
 
-Cell count/ml = Total cell count/ blister fluid volume   
The leucocyte count in inflammatory exudate obtained in Chapter 6, was 
obtained using an automatic cell counter (ADAM MC 2000, Nanoetek).    
 
2.4 Flow cytometry  
 
 
Immune cell subsets in the blister fluid were phenotyped by multicolour flow 
cytometry. For cell surface marker staining, blister cells in 100 μl of FACS 
buffer were incubated for 30 min with an antibody cocktail (Flow cytometry 
antibodies specific for each study are described in Table 2.1, Table 2.2 and 
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Table 2.3 below). Stained samples were washed twice with wash buffer (1% 
FCS in PBS + 2 mM EDTA) at 1000 x g for 5 min, 40 C. The washed cell pellet 
was then suspended in 150μl of wash buffer followed by 150μl of 1% 
formaldehyde (Thermo Fischer) to fix the cells, and the mixture was 
transferred to 1 ml FACS tubes. Fixed samples were stored in the dark at 40 C 
and analysed within 24h on BD LSR Fortessa flow cytometer. Spectral overlap 
between fluorochromes was corrected by running single fluorochrome stained 
compensation beads (BD) before main samples. For apoptotic cell staining, 
cells were incubated with AnnexinV-FITC and 7AAD (BD apoptosis detection 
kit) and were acquired on flow cytometer without fixation and within 15 min. 
Flow cytometry data was analysed using FlowJo 7.6.1. The dilution of antibody 
used here was obtained after titration on peripheral blood leucocytes. Here, 
the positive events were identified by using fluorescent minus one (FMO) 
control, which contains all antibodies except the one of interest. The gating 
strategy to identify leucocyte subpopulations was first characterised on 
peripheral blood leucocytes (described in Chapter 3, Figure 3.1 and 3.2).  
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Table 2.1 Flow cytometry antibodies used for identification of 
leukocytes in the study characterising cantharidin skin blister model  
(Chapter 3)
Serial 
no.
Cell 
surface 
marker
Antibody
clone
Fluorescent
conjugate Dilution Manufacturer
1 CD3 UCHT1 APC 1:10 BD Biosciecnes
2 CD14 M5E2 AF400 1:40 BD Biosciecnes
3 CD16 3G8 FITC 1:5 BD Biosciecnes
4 CD19 SJ25C1 PE-Cy7 1:40 BD Biosciecnes
5 CD56 B159 PerCP-Cy5.5 1:40 BD Biosciecnes
6 Siglec-8 7C9 PE 1:20 Biolegend
7 HLA-DR L243 V450 1:40 BD Biosciecnes
8 CD163 GHI/61 PE 1:20 BD Biosciecnes
 67 
 
 
Table 2.2 Flow cytometry antibodies used for identification of 
leukocytes in the study characterising UVkEc triggered self resolving 
dermal inflammation model and in the study  investigating effects of 
SPMs using this model.
(Chapter 4 and Chapter 5)
Serial no. 
Cell 
surface 
marker
Antibody
clone
Fluorescent
conjugate Dilution Manufacturer
1 CD3 HIT3a FITC 1:80 Biolegend
2 CD4 RPA-T4 AF400 1:80 Biolegend
3 CD8 RPA-T8 BV510 1:80 Biolegend
4 CD14 M5E2 BV605 1:80 Biolegend
5 CD16 3G8 APC 1:100 Biolegend
6 CD45 HI30 BV785 1:80 Biolegend
7 CD19 HIB19 FITC 1:80 Biolegend
8 CD56 HCD56 PerCP-Cy5.5 1:80 Biolegend
9 HLA-DR G46-6 APC-H7 1:40 BD Pharmingen
10 CD62L MEL-14 PE-Cy7 1:80 Biolegend
11 CD1c L161 BV421 1:80 Biolegend
12 CD163 M80 PE 1:100 Biolegend
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2.5 Peripheral blood analysis 
 
Peripheral blood was obtained from the volunteer's antecubital vein using a 
21-gauge butterfly needle (BD). Depending on the downstream application, 
blood was drawn into different anticoagulant vacutainers.  
 
For flow cytometry on peripheral blood leucocytes, blood was drawn into 
ethylenediaminetetraacetic acid (EDTA) vacutainer. For this application, red 
blood cells (RBC) in the blood were first lysed by incubating EDTA 
anticoagulated blood 1:10 in RBC lysis buffer (Lonza) for 5-10 min until the 
solution turned translucent. The solution was then centrifuged at 300 x g for 5 
Table 2.3 Flow cytometry antibodies used for identification of 
leukocytes in the study investigating pro-resolving effect of JBT-101 in	
UVkEc triggered self resolving dermal inflammation model 
(Chapter 6)
Serial no. Cell surface marker
Antibody
clone
Fluorescent
conjugate Dilution Manufacturer
1 CD3 HIT3a FITC 1:80 Biolegend
2 CD14 M5E2 BV605 1:80 Biolegend
3 CD16 3G8 APC 1:100 Biolegend
4 CD19 HIB19 FITC 1:80 Biolegend
5 CD45 HI30 BV785 1:80 Biolegend
6 CD56 HCD56 FITC 1:80 Biolegend
7 CD62L MEL-14 PE-Cy7 1:80 Biolegend
8 CD86 IT2.2 PerCP-Cy5.5 1:50 Biolegend
9 HLA-DR L243 BV510 1:50 Biolegend
10 CD163 M80 BV421 1:80 Biolegend
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min at room temperature. The supernatant containing plasma and lysed RBCs 
was discarded, and the leucocyte pellet was washed using 5 ml of wash buffer. 
Washed pellet was suspended in 1 ml of FACS buffer and processed for flow 
cytometry.        
 
For peripheral blood differential count analysis, the vacutainer containing 
EDTA anticoagulated blood was sent to TDL (The Doctor's Laboratory, UK) 
pathology lab.   
 
For measurement of systemic CRP, a serum sample was sent to TDL 
pathology lab. To prepare serum sample, blood was collected in BD 
Vacutainer SST tubes and first allowed to clot for 30 min. After 30 min, the 
tubes were centrifuged at 1300 x g for 10 min at RT.   
 
For systemic cytokine response, multiplex ELISA was performed on the 
plasma sample. To prepare plasma, blood was collected in lithium heparin 
vacutainer (BD) and centrifuged immediately at 2500 x g, 10 min at RT. 
Separated plasma was aliquoted and stored at -800 C until analysed. 
 
2.6 Skin biopsy and immunohistochemistry 
 
Skin biopsy procedure was performed by the clinicians in the Gilroy Laboratory 
(Dr Julia Flint, Dr Marc George, Dr Daniel Marks). Acu-Punch 3 mm kit 
(Schuco) kit, containing the 3mm punch biopsy needle was used. Skin was 
cleaned using alcohol and povidone-iodine. It was then anaesthetized using 
1% lignocaine. After ensuring that the site is numb, a 3mm skin punch biopsy 
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needle was inserted, and the biopsy was collected using disposable forceps. 
The skin biopsy was irrigated with saline and then transferred in neutral 
buffered formalin. The biopsied site was compressed using sterile gauze and 
then protected using a water proof dressing. Aseptic technique was followed 
throughout all steps. Volunteers were advised to keep the site dry and 
maintain the dressing for at least 72h. 
 
Formalin-fixed biopsies were transferred to UCL Institute of Neurology for 
immunohistochemistry. The antibodies used for immunohistochemistry are as 
follows: rabbit anti-human FPR2 (Novus Biologicals), rabbit anti-human 
ChemR23 (Thermo Scientific), rabbit anti-human GPR32 (Thermo Scientific), 
rabbit anti-human GPR18 (Lifespan Biosciences). Negative controls were 
stained for a corresponding isotype control. The digital images of the stained 
slides were obtained on a Nanozoomer (Hamamatsu) at UCL Rayne Institute.   
 
2.7 Cytology 
 
The cell populations of interest were first sorted on BD FACS Aria. For cell 
sorting, blister cells were suspended in 500 µl of FACS buffer in FACS tubes 
(BD). Cells were sorted in FACS buffer and after a wash step (1000 x g for 5 
min, 40 C) they were suspended in 150 µl of PBS.  
 
Cells in PBS were centrifuged on poly-lysine glass slides (Thermo Scientific) 
using a cytospin (Thermo Shandon) at 800 RPM (revolutions per minute), 8 
min. Cell smear on the slide was allowed to air dry for 10 min and followed by 
fixation in methanol. After methanol fixation, the slides were stained by 
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Modified Wright-Giemsa staining (Kwik-Diff Method, Thermo Shandon). The 
staining procedure involved incubation of slides for 10 seconds in eosin 
solution followed by 5 seconds on methylene blue solution at room 
temperature. Stained slides were washed in distilled water and then air dried. 
Immediately after drying, the slides were dipped in xylene solution for 5 min. 
Xylene coated slides were mounted using a DPX mounting media (Sigma 
Aldrich) followed by placement of a cover slip on the smear area. Images were 
obtained using Optimus BX41 microscope and processed using Image Pro 
6.3.  
 
2.8 Lipid mediator profiling  
 
Lipid mediator analysis by liquid chromatography- mass spectrophotometry 
(LC-MS) on the inflammatory exudate was performed by external 
collaborators. Prof. Anna Nicolaou (University of Bradford) performed 
lipidomics of cantharidin blister exudate. Prof Charles Serhan (Harvard 
University) performed lipidomics of UVkEc triggered inflammatory exudate. 
Data was analysed at UCL.  
 
2.9 Preparation of SPM cocktail for injection  
 
SPM cocktail (comprising LXB4, RvE1, RvD2 and AT-RVD1) was prepared in 
sterile saline and validated for purity by Dr Jesmond Dalli, Queen Mary 
University of London (QMUL). Dr Dalli also ensured that the purity was >98% 
and the endotoxin content was below detection limits (< 0.1 EU/ml). The final 
concentration of each SPM in the cocktail was as follows: LXB4 (570 pM = 200 
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pg/ml), RvE1 (115 pM = 40 pg/ml), RvD2 (450 pM = 170 pg/ml), AT-RvD1 (3.2 
nM = 1200 pg/ml).100 µl of this cocktail solution was used for intradermal 
injection. The cocktail was prepared fresh by Dr Dalli and collected from QMUL 
University on the morning of the day of the injection.  
 
2.10 Multiplex ELISA  
 
Cytokines in the blister fluid were measured by V-PLEX Proinflammatory 
multiplex ELISA kit (Meso Scale Discovery, USA).  
 
MSD multiplex ELISA is based on an electro-chemiluminescence principle. 
Each well in the 96-well plate had ten spots, each spot specific for a cytokine 
and coated with a cytokine specific capture antibody. After addition of test 
sample, the capture antibody binds to the analyte in the sample. The bound 
analyte is then sandwiched by the addition of a cytokine specific detection 
antibody. The detection antibody is tagged to an electro-chemiluminescent 
label (MSD SULFO-TAG™). The plate is read on an MSD reader that 
quantifies the intensity of light emitted from each spot in the well and the 
intensity is directly proportional to the amount of analyte present in the sample 
[188]. 
 
The ELISA protocol consisted four main steps  
 
1) Preparation of standards  
2) In-well dilution addition of cell free blister exudate sample 
3) Addition of detection antibody 
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4) Signal acquisition on MSD reader 
 
The highest concentration standard was prepared by adding 1000 µl of dilution 
reagent 2 in multi-analyte lyophilized calibrator vial (both supplied by MSD). 
The highest standard was diluted down 1:4, six times to generate seven tubes 
representing seven standard points for the standard curve. A final eight 
standard point consisted of the tube containing diluent 2 only. 50µl volume 
from each standard point tube was added to the standard curve column of the 
plate in duplicate.  
 
The blister fluid sample was diluted 1:10 with diluent 2 directly in the plate to 
get a final volume of 50 µl. The 96-well plate containing standards and 
samples was sealed using an adhesive film and incubated at room 
temperature on a shaker at 1000 RPM for 2h. After the incubation period, the 
plate was washed 3 times with 150 µl of ELISA wash buffer (0.05 % Tween 20 
in PBS) to remove the unbound analyte.   
 
After the final wash above, 25 µl of detection antibody mix was added to each 
well of the plate. Detection antibody mix contained detection antibody for each 
cytokine or chemokine in dilution reagent 3 (both supplied by MSD). The plate 
was sealed again incubated at room temperature on a shaker at 1000 RPM for 
2h. After the incubation period, the plate was washed three times with 150 µl of 
ELISA wash buffer (0.05 % Tween 20 in PBS) to remove unbound detection 
antibody. 
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After the final wash in above step, 50 µl of read buffer (diluted 1:2 in PBS) was 
added to each well of the plate. The plate was read immediately on the MSD 
Sector Imager 6000 to acquire the analytical signal. The data file was analysed 
on MSD Discovery Workbench software.  
 
2.11 Kinetic turbidimetric Limulus amebocyte lysate (LAL) 
assay for measuring endotoxin    
Endotoxin in the blister exudate was measured using the Pyrogent-5000 
endotoxin measurement kit (Lonza). The test is based on the principle that 
gram-negative endotoxin causes the formation of a clot upon contact with 
lysate from the amebocytes of horse shoe crab (Limulus polyphemus). The 
turbidity of clot is directly proportional to levels of endotoxin in the sample. By 
comparing a fixed level of clot turbidity between test samples and endotoxin 
standards, the levels of endotoxin in the samples can be obtained [189]. The 
above method of measuring endotoxin is termed as kinetic turbidimetric LAL 
(Limulus amebocyte lysate) assay.  
For use with this kit, the cell-free blister exudate was first treated to denature 
proteins by diluting 1:20 in 0.1% tween 80 buffer (Sigma) to a final volume of 
100 µl, followed by heating at 700 C for 15 min as recommended previously for 
human biological matrices [190]. Endotoxin standards were prepared by 
diluting the stock endotoxin solution 1:10, five times in 0.1% tween 80 buffer to 
a final volume of 100 µl. 50 µl of treated samples was plated on a 96 well flat 
bottom cell culture plate (COSTAR) along with the endotoxin standards. After 
this step, the plate was incubated for 10 min at 370 C. Following the 
incubation, 50 µl of LAL reagent was added to each well, and then the plate 
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was immediately transferred to the microplate reader (OmegaStar, Biorad). As 
per manufacturer's instructions, clot turbidity was measured by assessing the 
optical density at 340nm every 60 seconds for 2 h and increase in absorbance 
by 0.03 was set as the threshold for turbidity. The values relative to the 
endotoxin standard are reported here.  
 
2.12 Statistical analysis  
 
 
GraphPad Prism software (Version 7) was used for generating figures and for 
statistical analysis. Data are presented as individual values with the mean ± 
standard deviation (SD) on a linear scale, but in the case of skewed data sets, 
the data are presented on a logarithmic scale. 
 
For statistical testing, data were first assessed for normal distribution using the 
normality tests recommended by the software. For normally distributed data, 
differences between two groups were tested for statistical significance by 
paired t test (if paired data) or unpaired t test (if unpaired data). For more than 
two groups, differences were detected by Ordinary one-way ANOVA (for 
unpaired data) followed by Bonferroni's test to correct for multiple 
comparisons. 
 
For non-normally distributed data, differences between two groups were tested 
for statistical significance by Wilcoxon matched pairs signed rank test (if paired 
data) or Mann-Whitney test (if unpaired data). For more than two groups, 
differences were detected by Kruskal-Wallis test (for unpaired data) followed 
by Dunn's test to correct for multiple comparisons. 
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A p value < 0.05 was taken as threshold for significance. The p values are 
indicated as follows: < 0.05 = ' * ', <0.01 = ' ** ', <0.001 = ' *** '.  
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Chapter 3 
Characterisation of onset and resolution phase 
in cantharidin induced skin blister model of 
acute inflammation  
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3.1 INTRODUCTION 
 
Cantharidin induced skin blister model lends itself to investigate both the onset 
and the resolution phase of acute inflammation. For instance, it has been 
utilised to show that anti-TNFa antibody and corticosteroids inhibit neutrophil 
migration at onset [177] and has also been to demonstrate the effect of low 
dose aspirin on the formation of 15-epi-lipoxins and neutrophil clearance 
during resolution [176]. However, a detailed characterisation of leucocytes, 
cytokines and lipid mediators during onset as well as resolution in this model is 
lacking. In this chapter, I investigated the above three parameters and 
highlighted the uses and limitations of the cantharidin skin blister model for 
studying resolution in humans. This study was done in collaboration with Dr 
William Jenner.  
  
3.2 STUDY DESIGN  
 
Each volunteer was asked to the make three visits to the laboratory. On the 
first visit, cantharidin was applied on two sites on one of the forearms, and a   
5 ml sample of peripheral blood was collected from the contralateral forearm. 
The second visit was 24h later, during which one of the blisters was aspirated 
to investigate the onset phase and the other blister was covered with a 
protective dressing. The third visit was 72h after cantharidin application, and at 
this time the remaining blister was aspirated to investigate the resolution 
phase. The technique is described in detail in methods section 2.1 (Figure 2.1 
and Figure 2.2).  
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3.3 RESULTS  
 
 
3.3.1 Flow cytometric characterisation of peripheral blood leucocytes 
 
The flow cytometric gating strategy was first validated on peripheral blood 
leucocytes. After exclusion of cell debris and doublets (Figure 3.1 A), the 
remaining total leucocyte population was firstly gated for CD3+ T cells and 
CD19+ B cells (Figure 3.1 C). Resulting CD3-/CD19- cells were then gated on 
CD56 to identify CD56+ NK cells (Figure 3.1D). The remaining leucocytes 
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Figure 3.1 Polychromatic flow cytometric characterisation of peripheral blood
leukocytes – I
Leucocytes from the peripheral blood of healthy volunteers were incubated with an antibody
cocktail and phenotyped by flow cytometry. The FSC (size) vs SSC (granularity) plot of total
leucocytes (A) and the modified Wright-Geimsa stained cytospin of total leucocytes (B) is
shown. The FSC vs SSC plot was probed to first identify lymphocytes including CD3+ T cells,
CD19+ B cells (C) and CD56+ NK cells (D). Remaining cells were divided into HLA-DR+ and
HLA-DR- cells (E) and characterised further in Figure 3.2. Representative gating plots are
shown here
Figure 3.2 Polychromatic flow cytometric characterisation of peripheral blood
leukocytes- II
HLA-DR+ and HLA-DR- cells identified in Figure 3.1E were further analysed (A). HLA-DR+
cells were characterised into classical monocytes (CD14++/CD16-), intermediate monocytes
(CD14++i/ CD16+) , non classical monocytes (CD14+/CD16+ monocytes) and dendritic cells
(CD14-/CD16-) (B). The expression of CD163 on classical monocytes (C), intermediate
monocytes (D) and non classical monocytes (E) is also shown. On extended characterisation,
HLA-DR+/CD14-/CD16- dendritic cells comprised subpopulations of CD141+ and CD11c+
dendritic cells (E). HLA-DR- cells comprised neutrophils (CD16hi, CD66+) (H) and a CD16lo
population which mainly comprised Siglec-8+ eosinophils (I, J). Representative gating plots are
shown here.
Figure 3.3 Polychromatic flow cytometric characterisation of leucocytes in cantharidin
skin blister at 24hr (onset) – I
24hr after application of cantharidin, the blister was aspirated and the exudate was collected in
3% sodium citrate. Leukocytes in the blister were incubated with an antibody cocktail and
phenotyped by flow cytometry. The FSC (size) vs SSC (granularity) plot of total leucocytes (A)
and the modified Wright-Geimsa stained cytospin of total leucocytes (B) is shown here. Based
on the gating strategy for peripheral blood described in Figure 3.1, CD3+ T cells (C) and
CD56+ NK cells (D) were first identified and the remaining cells were divided into HLA-DR+
and HLA-DR- cells (E). Representative gating plots are shown here
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were then differentiated by HLA-DR expression (Figure 3.1 E). This allowed 
for separate classification of HLA-DR+ mononuclear and HLA-DR- granulocytic 
populations, as has been previously described [191].  
 
Analysis of HLA-DR+ gate (Figure 3.2 A) revealed the expected distribution of 
classical CD14++/CD16-, intermediate CD14++/CD16+, and non-classical 
CD14+/CD16+ monocytes (Figure 3.2 B) possessing varying degrees of the 
scavenger receptor marker, CD163 (Figure 3.2 C, D, F) [192]. Within this 
HLA-DR+ population we also identified CD14- CD16- dendritic cells, which upon 
extended characterisation were identified to be a mixture of CD141+ and 
CD11c+ dendritic cells (Figure 3.2 E).  
 
The HLA-DR- gate (Figure 3.2 A) comprised two sub-populations with varying 
degree of expression for CD16, labelled here as CD16hi and CD16lo (Figure 
3.2 G). CD16hi population was identified as neutrophils, confirmed by 
expression of CD66b (Figure 3.2 H). On extended characterisation, the CD16lo 
cells in blood were identified as Siglec-8+ eosinophils (Figure 3.2 I, J). 
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cells were characterised into classical monocytes (CD14++/CD16-), intermediate monocytes
(CD14++i/ CD16+) , non classical monocytes (CD14+/CD16+ monocytes) and dendritic cells
(CD14-/CD16-) (B). The expression of CD163 on classical monocytes (C), intermediate
monocytes (D) and non classical monocytes (E) is also shown. On extended characterisation,
HLA-DR+/CD14-/CD16- dendritic cells comprised subpopulations of CD141+ and CD11c+
dendritic cells (E). HLA-DR- cells comprised neutrophils (CD16hi, CD66+) (H) and a CD16lo
population which mainly comprised Siglec-8+ eosinophils (I, J). Representative gating plots are
shown here.
Figure 3.3 Polychromatic flow cytometric characterisation of leucocytes in cantharidin
skin blister at 24hr (onset) – I
24hr after application of cantharidin, the blister was aspirated and the exudate was collected in
3% sodium citrate. Leukocytes in the blister were incubated with an antibody cocktail and
phenotyped by flow cytometry. The FSC (size) vs SSC (granularity) plot of total leucocytes (A)
and the modified Wright-Geimsa stained cytospin of total leucocytes (B) is shown here. Based
on the gating strategy for peripheral blood described in Figure 3.1, CD3+ T cells (C) and
CD56+ NK cells (D) were first identified and the remaining cells were divided into HLA-DR+
and HLA-DR- cells (E). Representative gating plots are shown here
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3.3.2 Flow cytometric characterisation of leucocytes in cantharidin skin 
blister at 24h and 72h 
 
Skin blister aspirated 24h following cantharidin application showed a robust 
inflammatory cell infiltrate, also evident by cytology (Figure 3.3 B). By utilising 
the gating strategy developed for peripheral blood leucocytes, 24h blister 
exudate revealed mainly CD3+ T and CD56+ NK cells (Figure 3.3 C, D). The 
remaining population was then probed for HLA-DR expression as for 
circulating leucocytes, and separated into the HLA-DR+ and HLA-DR- cells 
(Figure 3.3 E).  
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The HLA-DR+ population (Figure 3.4 A) comprised CD14+/CD16- 
monocytes/macrophages expressing CD163 (Figure 3.4 B, C), and a CD14- 
CD16- dendritic cell population, which upon extended characterisation, 
constituted three dendritic cell subpopulations: CD11c+, CD141+, and 
CD11c+/CD141+ (Figure 3.4 D). 
 
The HLA-DR- population, included CD16hi and CD16lo cell populations (Figure 
3.4 E). CD16hi population labelled positive for CD66b and was identified as 
neutrophils (Figure 3.4 F). The CD16lo cells comprised two different 
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Figure 3.1 Polychromatic flow cytometric characterisation of peripheral blood
leukocytes – I
Leucocytes from the peripheral blood of healthy volunteers were incubated with an antibody
cocktail and phenotyped by flow cytometry. The FSC (size) vs SSC (granularity) plot of total
leucocytes (A) and the modified Wright-Geimsa stained cytospin of total leucocytes (B) is
shown. The FSC vs SSC plot was probed to first identify lymphocytes including CD3+ T cells,
CD19+ B cells (C) and CD56+ NK cells (D). Remaining cells were divided into HLA-DR+ and
HLA-DR- cells (E) and characterised further in Figure 3.2. Representative gating plots are
shown here
Figure 3.2 Polychromatic flow cytometric characterisation of peripheral blood
leukocytes- II
HLA-DR+ and HLA-DR- cells identified in Figure 3.1E were further analysed (A). HLA-DR+
cells were characterised into classical monocytes (CD14++/CD16-), intermediate monocytes
(CD14++i/ CD16+) , non classical monocytes (CD14+/CD16+ monocytes) and dendritic cells
(CD14-/CD16-) (B). The expression of CD163 on classical monocytes (C), intermediate
monocytes (D) and non classical monocytes (E) is also shown. On extended characterisation,
HLA-DR+/CD14-/CD16- dendritic cells comprised subpopulations of CD141+ and CD11c+
dendritic cells (E). HLA-DR- cells comprised neutrophils (CD16hi, CD66+) (H) and a CD16lo
population which mainly comprised Siglec-8+ eosinophils (I, J). Representative gating plots are
shown here.
Figure 3.3 Polychromatic flow cytometric characterisation of leucocytes in cantharidin
skin blister at 24hr (onset) – I
24hr after application of cantharidin, the blister was aspirated and the exudate was collected in
3% sodium citrate. Leukocytes in the blister were incubated with an antibody cocktail and
phenotyped by flow cytometry. The FSC (size) vs SSC (granularity) plot of total leucocytes (A)
and the modified Wright-Geimsa stained cytospin of total leucocytes (B) is shown here. Based
on the gating strategy for peripheral blood described in Figure 3.1, CD3+ T cells (C) and
CD56+ NK cells (D) were first identified and the remaining cells were divided into HLA-DR+
and HLA-DR- cells (E). Representative gating plots are shown here
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populations with varying autofluorescence and side scatter. The 
autofluorescent CD16loSSChi were identified as Siglec-8+ eosinophils (Figure 
3.4 H), whereas CD16loSSClo population stained positive for apoptotic cell 
marker, Annexin-V/7AAD and were characterised as apoptotic neutrophils, as 
reported previously (Figure 3.4 G) [193].  
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Figure 3.4 Polychromatic flow cytometric characterisation of leucocytes in
cantharidin skin blister at 24hr (onset) – II
24hr after application of cantharidin, the blister was aspirated and the exudate was collected
in 3% sodium citrate. HLA-DR+ and HLA-DR- cells identified in Figure 3.3E were further
analysed (A). HLA-DR+ cells mainly comprised of CD14+/CD16lo monocytes/macrophages
and HLA-DR+/CD14-/CD16- dendritic cells (B). The expression of CD163 on CD14+/CD16-
monocytes/macrophages (C) is also shown. On extended characterisation, HLA-DR+/CD14-
/CD16- dendritic cells comprised subpopulations of CD141+ and CD11c+ dendritic cells (D).
HLA-DR- cells comprised neutrophils (CD16hi, CD66b+) (E,F) and a population of CD16lo
cells which comprised of Siglec-8+ eosinophils (H, I) and AnnexinV/7AAD+ apoptotic/dead
neutrophils (G). Representative gating plots are shown here.
Figure 3.5 Polychromatic flow cytometric characterisation of leucocytes in
cantharidin skin blister at 72hr (resolution) – I
72hr after application of cantharidin, the blister was aspirated and the exudate was collected
in 3% sodium citrate. Leukocytes in the blister were incubated with an antibody cocktail and
phenotyped by flow cytometry. The FSC (size) vs SSC (granularity) plot of total leucocytes
(A) and the modified Wright-Geimsa stained cytospin of total leucocytes (B) is shown here.
Based on the gating strategy for peripheral blood described in Figure 3.1, CD3+ T cells (C)
and CD56+ NK cells (D) were first identified and the remaining cells were divided into HLA-
DR+ and HLA-DR- cells (E). Representative gating plots are shown here.
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Flow cytometric characterisation of the 72h blister is outlined in Figure 3.5 and 
Figure 3.6. The gating strategy employed here is similar to one carried out for 
the 24h time point. In addition, the major 72h leucocyte subsets were sorted 
using flow cytometer and assessed for their morphological appearance to 
confirm the phenotype. HLA-DR-CD16++ neutrophils revealed the classical 
polymorphonuclear appearance (Figure 3.6 E), whilst HLA-DR+ CD14+ 
monocytes/macrophages were large mononuclear cells with a kidney shaped 
nucleus and vacuoles in the cytoplasm (Figure 3.6 D). Siglec 8+ cells 
displayed a characteristic eosinophil morphology, namely a typical bi-lobed 
nucleus along with red cytoplasm (Figure 3.6 I). CD16lo AnnexinV/PI+ cells 
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Figure 3.4 Polychromatic flow cytometric characterisation of leucocytes in
cantharidin skin blister at 24hr (onset) – II
24hr after application of cantharidin, the blister was aspirated and the exudate was collected
in 3% sodium citrate. HLA-DR+ and HLA-DR- cells identified in Figure 3.3E were further
analysed (A). HLA-DR+ cells mainly comprised of CD14+/CD16lo monocytes/macrophages
and HLA-DR+/ D14-/CD16- dendritic cells (B). The expression of CD163 on CD14+/CD16-
monocytes/macrophages (C) is also shown. On extended characterisation, HLA-DR+/CD14-
/CD16- dendritic cells comprised subpopulations of CD141+ and CD11c+ dendritic cells (D).
HLA-DR- cells comprised neutrophils (CD16hi, CD66b+) (E,F) and a population of CD16lo
cells which comprised of Siglec-8+ eosinophils (H, I) and AnnexinV/7AAD+ apoptotic/dead
neutrophils (G). Representative gating plots are shown here.
Figure 3.5 Polychromatic flow cytometric characterisation of leucocytes in
cantharidin skin blister at 72hr (resolution) – I
72hr after application of cantharidin, the blister was aspirated and the exudate was collected
in 3% sodium citrate. Leukocytes in the blister were incubated with an antibody cocktail and
phenotyped by flow cytometry. The FSC (size) vs SSC (granularity) plot of total leucocytes
(A) and the modified Wright-Geimsa stained cytospin of total leucocytes (B) is shown here.
Based on the gating strategy for peripheral blood described in Figure 3.1, CD3+ T cells (C)
and CD56+ NK cells (D) were first identified and the remaining cells were divided into HLA-
DR+ and HLA-DR- cells (E). Representative gating plots are shown here.
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appeared either as degranulated cells or cells with condensed nuclei (Figure 
3.6 G) [194]. 
 88 
 
A
B
C
D
F
H
G
H
LA
-D
R
CD16
C
D
16
CD14
C
D
14
1
CD11c
Siglec-8
SS
C
-A
C
D
16
CD14
Siglec-8
7A
AD
Annexin V
CD66b
CD163
E
Figure 3.6 Polychromatic flow cytometric characterisation of  leucocytes in cantharidin 
skin blister at 72hr (resolution) – II
72hr after application of cantharidin, the blister was aspirated and the exudate was collected in
3% sodium citrate. HLA-DR+ and HLA-DR- cells identified in Figure 3.3E were further analysed
(A). HLA-DR+ cells mainly comprised of CD14+/CD16lo monocytes/macrophages and HLA-
DR+/CD14-/CD16- dendritic cells (B). The expression of CD163 on CD14++/CD16+
monocytes/macrophages (C) is also shown. On extended characterisation, HLA-DR+/CD14-
/CD16- dendritic cells comprised subpopulations of CD141+ and CD11c+ dendritic cells (D).
HLA-DR- cells comprised of neutrophils (CD16hi, CD66b+) (E,F) and a population of CD16lo
cells which comprised Siglec-8+ eosinophils (H, I) and AnnexinV/7AAD+ apoptotic/dead
neutrophils (G). Representative dot plots are shown here (n=17).
Figure 3.7 Profile of lymphocytes in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red blood
cells were lysed and the remaining leukocytes counted by haemocytometer. Leukocytes were
incubated with an antibody cocktail and processed for flow cytometry. For 24hr and 72hr time
point, proportion of CD3+ T cells of total leukocytes (A), total numbers of CD3+ T cells (B),
proportion CD56+ NK cells of total leukocytes (C) and total numbers of CD56+ NK cells (D) are
shown here. Data expressed as individual values with mean SD (n=17).
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3.3.3 Temporal profile of leucocytes in cantharidin skin blister  
 
The lymphocytes subsets identified in this model did not show significant 
differences in proportion or total count between 24h and 72h. CD3+ T cells 
comprised 3.4 ± 1.75% and 4.3 ± 2.2% of total leucocytes at 24h and 72h 
respectively (Figure 3.7 A). The total numbers of CD3+ T cells at 24h and 72h 
are shown in Figure 3.7 B. The origin of these CD3+ T cells in the blister is 
currently not known. They could either have trafficked from the peripheral 
blood or could represent a population of skin resident T cells. Further 
characterisation using CD69 and CLA, the resident T cell markers can 
elucidate their origin. The numbers of CD56+ NK cell numbers were lower than 
CD3+ T cells at both the time points. The proportion of CD56+ NK cells was 
0.13 ± 0.1% and 0.22 ± 0.19% at 24h and 72h respectively (Figure 3.7 C). The 
total numbers of CD56+ NK cells at 24h and 72h are shown in Figure 3.7 D. 
CD19+ B cells were present in < 0.01% at both the time points (not shown 
here). 
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Figure 3.6 Polychromatic flow cytometric characterisation of  leucocytes in cantharidin 
skin blister at 72hr (resolution) – II
72hr after application of cantharidin, the blister was aspirated and the exudate was collected in
3% sodium citrate. HLA-DR+ and HLA-DR- cells identified in Figure 3.3E were further analysed
(A). HLA-DR+ cells mainly comprised of CD14+/CD16lo monocytes/macrophages and HLA-
DR+/CD14-/CD16- dendritic cells (B). The expression of CD163 on CD14+/CD16lo
monocytes/macrophages (C) is also shown. On extended characterisation, HLA-DR+/CD14-
/CD16- dendritic cells comprised subpopulations of CD141+ and CD11c+ dendritic cells (D).
HLA-DR- cells comprised of neutrophils (CD16hi, CD66b+) (E,F) and a population of CD16lo
cells which comprised Siglec-8+ eosinophils (H, I) and AnnexinV/7AAD+ apoptotic/dead
neutrophils (G). Representative dot plots are shown here (n=17).
Figure 3.7 Profile of lymphocytes in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red blood
cells were lysed and the remaining leukocytes counted by haemocytometer. Leukocytes were
incubated with an antibody cocktail and processed for flow cytometry. For 24hr and 72hr time
point, proportion of CD3+ T cells of total leukocytes (A), total numbers of CD3+ T cells (B),
proportion CD56+ NK cells of total leukocytes (C) and total numbers of CD56+ NK cells (D) are
shown here. Data expressed as individual values with mean SD (n=17).
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Neutrophils were the dominant cell type at 24h comprising 57.97 ±18.57% of 
total leucocytes at 24h. By 72h the neutrophil proportion reduced significantly 
to 19.34 ± 8.54% (Figure 3.8 A). The total numbers of neutrophils at 24h and 
72h are shown in Figure 3.8 B. Conversely, the numbers of CD16lo apoptotic 
neutrophils increased significantly from 24h to 72h (Figure 3.8 D). CD16lo cells 
increased from 4.94 ± 2.34% of the total leucocytes at 24h to 34.7 ± 12.06 % 
at 72h (Figure 3.8 C). The total numbers of apoptotic neutrophils at 24h and 
72h are shown in Figure 3.8 D. The difference in the proportion of eosinophils 
between 24h and 72h was insignificant. Eosinophils constituted 2.10 ± 2.96 % 
and 3.55 ± 4.59 % of total leucocytes at 24h and 72h (Figure 3.8 E). However, 
the cell count of eosinophils increased significantly from 3,749 ± 4,243 at 24h 
to 11,208 ± 17,428 at 72h (Figure 3.8 F).  
 
The proportion of monocytes/macrophages did not change from 24h to 72h, 
but their numbers decreased significantly. Monocytes/macrophages 
constituted 18.41 ± 9.54% and 13.29 ± 6.26% of total leucocytes at 24h and at 
72h, respectively (Figure 3.8 G). The numbers of these cells decreased from 
60,044 ± 51,001 at 24h to 34,363 ± 20,709 at 72h (Figure 3.8 H). 
Furthermore, the expression of CD163 did not change from 24h to 72h (Figure 
3.8 I).  
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Figure 3.8 Profile of myeloid cells in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red
blood cells were lysed and the remaining leukocytes were counted by haemocytometer.
Leukocytes were then incubated with an antibody cocktail and processed for flow
cytometry. For 24hr and 72hr time point, proportion of CD16hi neutrophils of total leukocytes
(A), total count of CD16hi neutrophils (B), proportion of CD16lo apoptotic neutrophils of total
leukocytes (C), total count of CD16lo apoptotic neutrophils (D), proportion of Siglec-8+
eosinophils total leukocytes (E) and total numbers of Siglec-8+ eosinophils (F), proportion
of monocytes/macrophages of total leukocytes (G) and total numbers of
monocytes/macrophages (H) and CD163 expression on monocytes/macrophages (I) are
shown here. Data expressed as individual values with mean SD (n=17). p values are
denoted as < 0.05 = ' * ', <0.01 = ' ** ', <0.001 = ' *** '.
Figure 3.9 The correlation between neutrophils at onset (24hr) and neutrophil
clearance (72hr-24hr neutrophil)
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red
blood cells were lysed and the remaining leukocytes were counted by haemocytometer.
Leukocytes were then incubated with an antibody cocktail and processed for flow
cytometry. The correlation between neutrophil numbers at onset (24hr) and neutrophil
clearance (defined as 72hr – 24hr neutrophils) is shown here (n=17).
Figure 3.10 Cytokine/chemokine profile in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. The cell
free exudate was analysed for cytokines by multiplex ELISA. The change in concentration
of cytokines/chemokines from 24hr to 72hr is shown here (A-G). Data expressed as
individual values with mean SD (n=17). p values are denoted as < 0.05 = ' * ', <0.01 = ' **
', <0.001 = ' *** '.
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At 24h, a noticeable spread was observed in numbers of neutrophils (Figure 
3.8 A, B). Subsequent comparison of 24h neutrophils with neutrophil clearance 
(calculated here as 72h neutrophils - 24h neutrophils) revealed that volunteers 
with the highest infiltration of neutrophils at onset showed highest neutrophil 
clearance at resolution (Figure 3.9).  
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p = 0.0001Figure 3.8 Profile of myeloid cells in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red
blood cells were lysed and the remaining leukocytes were counted by haemocytometer.
Leukocytes were then incubated with an antibody cocktail and processed for flow
cytometry. For 24hr and 72hr time point, proportion of CD16hi neutrophils of total leukocytes
(A), total count of CD16hi neutrophils (B), proportion of CD16lo apoptotic neutrophils of total
leukocytes (C), total count of CD16lo apoptotic neutrophils (D), proportion of Siglec-8+
eosinophils total leukocytes (E) and total numbers of Siglec-8+ eosinophils (F), proportion
of monocytes/macrophages of total leukocytes (G) and total numbers of
monocytes/macrophages (H) and CD163 expression on monocytes/macrophages (I) are
shown here. Data expressed as individual values with mean SD (n=17). p values are
denoted as < 0.05 = ' * ', <0.01 = ' ** ', <0.001 = ' *** '.
Figure 3.9 The correlation between neutrophils at onset (24hr) and neutrophil
clearance (72hr-24hr neutrophil)
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red
blood cells were lysed and the remaining leukocytes were counted by haemocytometer.
Leukocytes were then incubated with an antibody cocktail and processed for flow
cytometry. The correlation between neutrophil numbers at onset (24hr) and neutrophil
clearance (defined as 72hr – 24hr neutrophils) is shown here (n=17).
Figure 3.10 Cytokine/chemokine profile in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. The cell
free exudate was analysed for cytokines by multiplex ELISA. The change in concentration
of cytokines/chemokines from 24hr to 72hr is shown here (A-G). Data expressed as
individual values with mean SD (n=17). p values are denoted as < 0.05 = ' * ', <0.01 = ' **
', <0.001 = ' *** '.
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3.3.4 Temporal profile of cytokines and lipid mediators in cantharidin 
skin blister  
 
From 24h to 72h, the levels of pro-inflammatory cytokines TNF-a, IL-6 and IL-
12p70 decreased significantly. At 24h, the concentration of TNF-a in the blister 
was 77.31 ± 41.61 pg/ml, and it declined to 31.32 ± 23.14 pg/ml (Figure 3.10 
A). The levels of IL-6 and IL-12p70 decreased from 665.7 ± 519.3 pg/ml and 
12.21 ± 9.107 pg/ml at 24h to 309.3 ± 344.2 pg/ml and 10.73 ± 18.04 pg/ml at 
72h respectively (Figure 3.10 B, C). The difference in concentrations of other 
pro-inflammatory cytokines IL-1b and IL-8 between 24h and 72h were not 
found to be significant (Figure 3.10 D, E). In contrast, the levels of IFN-g 
showed an increasing trend from 24h to 72h (Figure 3.10 F). Similarly, the 
levels of anti-inflammatory cytokine IL-10 showed an increasing trend from 24h 
to 72h (Figure 3.10 G).  
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Figure 3.8 Profile of myeloid cells in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red
blood cells were lysed and the remaining leukocytes were counted by haemocytometer.
Leukocytes were then incubated with an antibody cocktail and processed for flow
cytometry. For 24hr and 72hr time point, proportion of CD16hi neutrophils of total leukocytes
(A), total count of CD16hi neutrophils (B), proportion of CD16lo apoptotic neutrophils of total
leukocytes (C), total count of CD16lo apoptotic neutrophils (D), proportion of Siglec-8+
eosinophils total leukocytes (E) and total numbers of Siglec-8+ eosinophils (F), proportion
of monocytes/macrophages of total leukocytes (G) and total numbers of
monocytes/macrophages (H) and CD163 expression on monocytes/macrophages (I) are
shown here. Data expressed as individual values with mean SD (n=17). p values are
denoted as < 0.05 = ' * ', <0.01 = ' ** ', <0.001 = ' *** '.
Figure 3.9 The correlation between neutrophils at onset (24hr) and neutrophil
clearance (72hr-24hr neutrophil)
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Red
blood cells were lysed and the remaining leukocytes were counted by haemocytometer.
Leukocytes were then incubated with an antibody cocktail and processed for flow
cytometry. The correlation between neutrophil numbers at onset (24hr) and neutrophil
clearance (defined as 72hr – 24hr neutrophils) is shown here (n=17).
Figure 3.10 Cytokine/chemokine profile in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. The cell
free exudate was analysed for cytokines by multiplex ELISA. The change in concentration
of cytokines/chemokines from 24hr to 72hr is shown here (A-G). Data expressed as
individual values with mean SD (n=17). p values are denoted as < 0.05 = ' * ', <0.01 = ' **
', <0.001 = ' *** '.
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The levels of lipid mediators also decreased significantly from onset to 
resolution. At 24h, the level of PGE2 in the blister was 4,752 ± 3,014 pg/ml, 
and it declined to 1,843 ± 1,090 pg/ml at 72h (Figure 3.11A). The levels of 
TXB2 declined from 6,377 ± 5,015 pg/ml at 24h to 6,377 ± 5,015 pg/ml at 72h 
while the levels of PGF2a declined from 8,674 ± 14,008 pg/ml at 24h to 5,416 ± 
7,907 pg/ml at 72h. (Figure 3.11 B, C). Relative to other prostaglandins 
measured here, the levels of PGD2 were lower at both time points but it 
declined significantly from 24h to 72h. At 24h, the concentration of PGD2 in the 
blister fluid was 906 ± 550 pg/ml, and it declined to 544 ± 401 pg/ml at 72h 
(Figure 3.11 D). The additional lipid mediators measured in this study are 
shown in the appendix (Figure 8.1).         
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Figure 3.11 Prostanoid profile in cantharidin skin blister at 24hr and 72hr
The exudate from 24hr and 72hr cantharidin blister was centrifuged to pellet cells. Cell free
exudate was subject to lipid mediator analysis by mass spectrophotometry by Dr A. Nicolaou
at University of Bedford. The change in concentration of prostanoids from 24hr to 72hr is
shown here. Data expressed as individual values with mean± SD (n=15). p values are denoted
as < 0.05 = ' * ', <0.01 = ' ** ', <0.001 = ' *** '.
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3.4 DISCUSSION 
 
The current study presents an in-depth flow cytometric characterisation of 
leucocytes as well as cytokines and lipid mediators during the onset and 
resolution phases of cantharidin skin blister. The antibody panel and the gating 
strategy were first optimised to identify the major populations of peripheral 
blood leucocytes, and it was then employed to characterise the cantharidin 
skin blister leucocytes, which were further confirmed by cytology. The gating 
strategy serves as a template for future research to utilise the cantharidin 
blister model as a relatively non-invasive tool to quantify the human innate 
immune response in vivo. 
 
One of the key observations from this model in terms of advancing our 
understanding of resolution in humans was that despite some volunteers 
generating strikingly greater numbers of neutrophils in their blisters at 24h than 
others; all volunteers had an approximately similar number of neutrophils 
remaining at resolution. This implies that despite the varying intensity of 
inflammatory response at onset, the resolution processes tune themselves to 
generate a consistent resolution phenotype.  
 
Coincident with a significant decrease in neutrophil numbers from 24h to 72h, 
we saw the accumulation of apoptotic neutrophils at 72h. One explanation for 
this could be due to the absence of stromal scaffold in the blister. From 24h 
onwards the cells that have migrated in the blister are floating in a fluid sac, 
which is atypical when compared to the inflammatory responses in the tissue 
where a stromal scaffold is present. The absence of stromal support could 
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reduce cell-cell interaction and thus impede efficient efferocytosis of apoptotic 
cells by macrophages. In fact, monocytes/macrophages in this blister model 
did not upregulate the expression of CD163, a marker associated with 
efferocytosis [195]. As neutrophil clearance is one of the hallmarks of 
resolution, these data suggest that the 72h time point does not represent 
complete resolution. 
 
Resolution of inflammation is associated with clearance of pro-inflammatory 
cytokines/chemokines and lipid mediators. The production of cytokines and 
chemokines is suppressed, and they are cleared either by scavenging by 
decoy receptors such as D6 leading to lysosomal degradation or proteolysis by 
metalloproteinases such as MMP-12 [196][38][46]. Prostaglandins which are 
involved in oedema, vasodilation and pain are degraded by 15-
hyrdroxyprostaglandin dehydrogenase (15-PGDH), whereby they are first 
oxidised into their corresponding 15-keto compounds, then reduction by Δ13-15 -
ketoprostaglandin reductase and finally followed by their b-oxidation [197]. 
Correspondingly, we observed here that the concentration of pro-inflammatory 
cytokines, e.g. TNF-a, IL-6 and IL-12p70 decreased from 24h to 72h. In 
addition, the prostaglandins including PGE2, PGF2a, TXB2 and PGD2 decreased 
significantly from 24h to 72h. Taken together, these data highlight that the 
cantharidin blister could be utilised to study to clearance of pro-inflammatory 
mediators, an important resolution biomarker, in humans.  
 
Characterisation of eosinophils in this study by flow cytometry proved 
challenging due to the inherent auto-fluorescent nature of these cells. This was 
because of non-specific binding of fluorescein isothiocyanate (FITC) 
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fluorochrome to eosinophils. Eosinophils do not express CD16, but because 
they have an alkaline cytoplasm, they would have bound to FITC, an acidic 
dye. As a result, we got an erroneous impression that eosinophils express 
some CD16. Such non-specific interaction of eosinophils with acidic dyes has 
also been described previously [198]. Future studies should bear this in mind 
when trying to identify eosinophils within mixed cell populations using FITC-
labelled antibodies. Use of Siglec-8 antibody to identify bona fide eosinophils 
can avoid such errors [199]. 
 
Increase in eosinophil numbers during resolution in this model is reminiscent of 
observations made in murine studies, e.g. it was shown in the model of acute 
zymosan-induced peritonitis, that eosinophils accumulate in the abdominal 
cavity during resolution. Furthermore, these animal studies attributed a pro-
resolving function to eosinophils as they expressed high levels of 15-
lipoxygenase and mediated formation of specialised pro-resolving mediator 
protectin D1 [200]. This is in contrast to the vast literature describing 
eosinophils as being pathogenic in allergic inflammatory diseases, e.g. 
asthma, dermatitis where eosinophil granule proteins exert cytotoxic effects on 
epithelial lining [201] [202]. It is unclear at this stage whether an increase in 
eosinophils during resolution in the cantharidin blister model is potentially 
pathogenic or pro-resolving.   
 
The advantages of cantharidin blister model are that it is non-invasive, quick 
and easy to apply without the need of any special equipment. In addition, the 
materials required to induce a blister are inexpensive. Furthermore, the 
localised nature of blister allows induction of multiple blisters at the on the 
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same forearm that allows facilitates investigation of multiple time points of 
inflammation. Cantharidin blister is also devoid of side effects observed in skin 
abrasion models, e.g. bleeding [203]. Also, the skin roof of cantharidin blister 
provides a natural chamber for collection of leucocytes. In other skin abrasion 
models, an artificial collecting chamber has to be placed over the skin to 
facilitate leucocyte collection. These artificial chambers are difficult to maintain 
over skin and can leak if kept for the longer duration [204].   
 
In conclusion, cantharidin skin blister is a model of tissue injury that allows 
investigation of multiple cell types of the innate immune system together with 
cytokines and lipid mediators during the onset and resolution of acute 
inflammation in healthy individuals. A major limitation is that the resolution time 
point in this model does not show complete clearance of apoptotic neutrophils. 
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Chapter 4  
A novel human model of acute self-resolving 
dermal inflammation triggered by                        
ultraviolet light killed E. coli (UVkEc) 
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4.1 INTRODUCTION 
 
An ideal model of resolution of acute inflammation should allow investigation of 
biomarkers of resolution: neutrophil clearance, reduction of pro-inflammatory 
mediators and clearance of the inflammatory stimulus. It should be triggered 
by a uniform dose of inflammatory stimulus to ensure a consistent 
inflammatory response and should facilitate minimally invasive sampling of 
inflamed tissue. Furthermore, it will be advantageous if the model enables 
monitoring of the clinical signs of acute inflammation.  
Acknowledging the above characteristics, I developed a novel model of 
resolution of acute inflammation in healthy humans by adapting two 
techniques. In the first step, acute inflammation was triggered by intradermal 
injection of ultraviolet light killed Escherichia coli bacteria (UVkEc) into the 
forearm. This technique was first employed by Smith et al. to study neutrophil 
trafficking in inflammatory bowel disease patients. In their study, patients were 
transfused with autologous radiolabelled neutrophils before the UvKEc 
injection, and neutrophil migration to the inflamed site was quantified by 
counting the radioactivity directly over the site [205]. While this method 
facilitated investigation of neutrophil kinetics and the inflammation-induced 
vascular hyperaemia, it did not provide information on other immune cell types 
or the soluble mediators of inflammation.  
To investigate multiple immune cell subsets and local mediators, I induced a 
suction blister over the site of UvKEc injection to acquire the inflammatory 
exudate from the site. Immune cells in the exudate can be phenotyped by 
multicolour flow cytometry to characterise multiple immune cell populations 
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while the cell-free exudate can be used to measure the soluble mediators. The 
suction blister technique employed here is based on the approach adopted by 
Vukmanovic et al. who used it to assess the local T cell memory response to a 
vaccine antigen [206].  
In this chapter, I characterised this novel UVkEc induced self-resolving dermal 
inflammation model encompassing the vascular hyperaemia, immune cell 
subsets and cytokines and chemokines at the inflamed site during the onset 
and resolution phases. In addition, I assessed the associated systemic 
immune response. Finally, I have described the tolerability of this approach 
amongst the study volunteers.   
 
4.2 STUDY DESIGN 
 
 
To characterise the different phases of inflammation, the UVkEc injected site 
was allowed to progress until one of the following time-points: 4h, 8h, 14h, 
24h, 48h, 72h, and then a suction blister was raised over the injection site. 
Once the suction blister was formed, it was aspirated immediately. To assess 
vascular hyperaemia over the area of inflammation, the inflamed site on the 
forearm was scanned using laser Doppler imager. For the baseline time point, 
the blister was raised on the naive skin. In summary, each volunteer had two 
injection sites (one on each forearm) and contributed to two time points. Study 
time-points were discussed with the volunteer during recruitment and 
confirmed again before the consent procedure. The technique is described in 
detail in methods section 2.3 (Figure 2.3 and Figure 2.4).   
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4.3 RESULTS  
 
 
4.3.1 Vascular hyperaemia at the site of UVkEc triggered self-resolving 
dermal inflammation. 
 
UVkEc triggered acute inflammation became clinically apparent by 4h as a 
localised area of redness referred here as flare (Figure 4.1 A). At 4h, the flare 
area was 12.18 ± 4.48 cm2. It increased between 4h and 24h and reached its 
maximum size at 24h. At this time point, it was 23.42 ± 8.42 cm2 in size. From 
24h to 48h, the flare reduced significantly, and it disappeared by 72h. (Figure 
4.1 C).  
 
Vascular hyperaemia underlying the inflammation-induced redness was 
assessed by laser Doppler imager. The representative laser Doppler images at 
different phases of inflammation are shown in Figure 4.1 B. The laser Doppler 
images allows objective quantification of the inflammation induced redness in 
perfusion units. At 4h, the hyperaemia at the site was 1.72 x 106 ± 0.6 x 106 
perfusion units. Similar to flare area, the hyperaemia increased between 4h 
and 24h and reached its peak at 24h to 3.19 x 106 ± 1.2 x 106 perfusion units. 
From 24h to 48h it declined significantly. At 48h, it was 0.74 x 106 ± 0.93 x 106 
perfusion units. At 72h, the vascular hyperaemia over injection site was similar 
to baseline skin (Figure 4.1 D).  
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Figure 4.1 Vascular hyperaemia at the site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. Vascular hyperaemia at the site was assessed by laser Doppler imager.
Representative camera images (A) and Doppler flux images (B) at baseline, 4hr, 24hr, 48hr
and 72hr are shown here. Doppler flux images were analysed by moorLDI software to quantify
the area of redness (flare area) (C) and the vascular hyperaemia (D). Data expressed as
individual values with mean ± SD; n=6 at each time point.
Figure 4.2 Characteristics of inflammatory exudate obtained from the site of UV killed
E. coli triggered self resolving dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
total leucocyte count (A), the volume of supernatant representing the blister exudate volume
(B) and the total cell count adjusted per ml of exudate (C) is shown here. Data expressed as
individual values with mean± SD; n=6 at each time point.
Figure 4.3 Polychromatic flow cytometric characterisation of leukocytes in the
inflammatory exudate obtained from the site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site to collect the inflammatory exudate.
Exudate was centrifuged to separate cells from the supernatant. The immune cell subsets
were identified by polychromatic flow cytometry. The gating strategy employed to identify
neutrophils (blue gate) , monocytes/macrophages (red gate), CD4+ and CD8+ T lymphocytes,
CD56+ NK cells and CD1c+ dendritic cells is illustrated here. Representative gating plots from
the 14hr time point are shown here.
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4.3.2 Characteristics of the inflammatory exudate at site of UVkEc 
triggered resolving dermal inflammation 
 
To acquire the inflammatory exudate, the suction blister was raised over the 
injection site. It was immediately centrifuged to separate cells from soluble 
mediators. Total leucocyte count was enumerated using haemocytometer. The 
total leucocyte numbers peaked at 4h to 85,896 ± 55,508 cells. From 4h 
onwards, it declined and was significantly lower at 48h compared to 4h. At 
48h, the total leucocyte count was 10,083 ± 4,521. The total leucocyte count of 
the suction blister exudate at different time points is shown in Figure 4.2 A. 
The suction blister volume, representing the volume of inflammatory exudate, 
is shown in Figure 4.2 B. The total leucocyte count/ml which represents the 
total leucocyte count adjusted for suction blister volume is shown in Figure 4.2 
C. 
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Figure 4.1 Vascular hyperaemia at the site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. Vascular hyperaemia at the site was assessed by laser Doppler imager.
Representative camera images (A) and Doppler flux images (B) at baseline, 4hr, 24hr, 48hr
and 72hr are shown here. Doppler flux images were analysed by moorLDI software to quantify
the area of redness (flare area) (C) and the vascular hyperaemia (D). Data expressed as
individual values with mean ± SD; n=6 at each time point.
Figure 4.2 Characteristics of inflammatory exudate obtained from the site of UV killed
E. coli triggered self resolving dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
total leucocyte count (A), the volume of supernatant representing the blister exudate volume
(B) and the total cell count adjusted per ml of exudate (C) is shown here. Data expressed as
individual values with mean± SD; n=6 at each time point.
Figure 4.3 Polychromatic flow cytometric characterisation of leukocytes in the
inflammatory exudate obtained from the site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site to collect the inflammatory exudate.
Exudate was centrifuged to separate cells from the supernatant. The immune cell subsets
were identified by polychromatic flow cytometry. The gating strategy employed to identify
neutrophils (blue gate) , monocytes/macrophages (red gate), CD4+ and CD8+ T lymphocytes,
CD56+ NK cells and CD1c+ dendritic cells is illustrated here. Representative gating plots from
the 14hr time point are shown here.
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Total leucocytes were phenotyped by multicolour flow cytometry to 
characterise the immune cell subsets. The flow cytometry gating strategy was 
based on the strategy developed for cantharidin blister, described in Chapter 3 
with some modifications. Briefly, after excluding cell debris (Figure 4.3 A), total 
cells were plotted on CD45+ to identify cells of haematopoietic origin (Figure 
4.3 B). CD45+ cells were plotted on forward scatter height and width plots 
(FSC-H vs. FSC-W) to exclude the doublets (Figure 4.3 C). CD45+ single cell 
events were plotted against CD3/CD19 (Figure 4.3 D). CD3+/CD19+ were 
further probed to identify CD4+ and CD8+ T cells (Figure 4.3 D and F). The 
CD3- /CD19- compartment was interrogated further to identify CD56+ NK cells 
(Figure 4.3 E). After exclusion of major lymphocytes, the CD3-/CD19-/CD56- 
myeloid cell population was separated into mononuclear cells and 
granulocytes by HLA-DR (Figure 4.3 G). The HLA-DR+ population was plotted 
on CD14 and CD16, to identify a distinct population of HLA-DR+/CD14+ 
monocytes/macrophages (red gate) and HLA-DR+/CD14-/CD16- dendritic cells 
(Figure 4.3 H), of which a major subset was CD1c+ dendritic cells (Figure 4.3 
I). The HLA-DR- gate comprised mainly CD16++ neutrophils (blue gate) and at 
some time points it also contained the CD16lo apoptotic neutrophils (green 
gate) (Figure 4.3 G).  
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Figure 4.1 Vascular hyperaemia at the site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. Vascular hyperaemia at the site was assessed by laser Doppler imager.
Representative camera images (A) and Doppler flux images (B) at baseline, 4hr, 24hr, 48hr
and 72hr are shown here. Doppler flux images were analysed by moorLDI software to quantify
the area of redness (flare area) (C) and the vascular hyperaemia (D). Data expressed as
individual values with mean ± SD; n=6 at each time point.
Figure 4.2 Characteristics of inflammatory exudate obtained from the site of UV killed
E. coli triggered self resolving dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
total leucocyte count (A), the volume of supernatant representing the blister exudate volume
(B) and the total cell count adjusted per ml of exudate (C) is shown here. Data expressed as
individual values with mean± SD; n=6 at each time point.
Figure 4.3 Polychromatic flow cytometric characterisation of leukocytes in the
inflammatory exudate obtained from the site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site to collect the inflammatory exudate.
Exudate was centrifuged to separate cells from the supernatant. The immune cell subsets
were identified by polychromatic flow cytometry. The gating strategy employed to identify
neutrophils (blue gate) , monocytes/macrophages (red gate), CD4+ and CD8+ T lymphocytes,
CD56+ NK cells and CD1c+ dendritic cells is illustrated here. Representative gating plots from
the 14hr time point are shown here.
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4.3.3 Cellular profile at the site of UVkEc triggered self-resolving dermal 
inflammation 
 
At 4h, neutrophils were the dominant cell type comprising 79.8 ± 15.17 % of 
total leucocytes. From 4h onwards the neutrophil numbers declined, and at 
48h they formed only 4.4 ± 5.2 % of total leucocytes. The neutrophil proportion 
and numbers at different points of inflammation are shown in Figure 4.4 A and 
Figure 4.4 B respectively. Consistent with reports shedding of CD62L during 
neutrophil activation [204], 4h neutrophils had a lower CD62L expression in 
this model. However, the CD62L expression on neutrophils increased 
gradually at later time points (Figure 4.4 C).  
 
Monocytes/macrophages kinetics revealed two peaks. The first peak was 
observed at 8h when they comprised 23.38 ± 8.62 % of total leucocytes. Their 
proportion declined to 11.51 ± 5.72 % at 14h but rose again to 24.79 ± 8.62 % 
at 24h. However, From 24h onwards their numbers declined to form 8.45 ± 
5.35 % of total leucocytes by 72h (Figure 4.4 D). The total numbers of 
monocytes/macrophages during different phases of inflammation is shown in 
Figure 4.4 E. Further characterisation of these cells revealed that at 24h they 
had a higher expression of CD163 and CD16 compared to 
monocytes/macrophages population at 8h. The expression of CD163 and 
CD16 at different time points of inflammation is shown in Figure 4.4 F and 
Figure 4.4 G respectively.  
 
Unlike neutrophils and monocytes/macrophages, CD1c+ dendritic cells were 
present at baseline time point. These cells peaked at 24h and constituted 6.79 
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± 1.83 % of total leucocytes. From 24h to 48h their numbers declined and at 
48h these cells comprised 1.1 ± 0.39 % of total leucocytes. The proportion and 
total numbers of CD1c+ dendritic cells are shown in Figure 4.4 H and Figure 
4.4 I, respectively. 
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Figure 4.4 Profile of myeloid cells at site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
immune cell subsets were identified by polychromatic flow cytometry. Proportion of neutrophils
of total leukocytes (A), total count/ml of neutrophils (B), neutrophil CD62L expression (C),
proportion of monocytes/macrophages of total leukocytes (D), total count/ml of
monocytes/macrophages (E), expression of CD163 (F) and CD16 (G) on
monocytes/macrophages, proportion of CD1c+ dendritic cells of total leukocytes (H) and total
count/ml of CD1c+ dendritic cells (I) are shown here. Data expressed as individual values with
mean ± SD; n=6 at each time point. n=3 for CD62L MFI and CD163 MFI. ND= not detectable.
Figure 4.5 Profile of CD16lo cells at site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site, at the specified interval, to collect
the inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant.
The immune cell subsets were identified by polychromatic flow cytometry. Representative dot
plots of CD16lo apoptotic neutrophils (green gate) at 4hr, 24hr, 48hr and 72hr time point
relative to CD16hi neutrophils (blue gate) and HLA-DR+ CD14+ monocytes/macrophages (red
gate) are shown here (A). The proportion of CD16lo apoptotic neutrophils of total leukocytes at
specified intervals is also shown (B). Data expressed as individual values with mean ± SD;
n=6 at each time point.
Figure 4.6 Profile of lymphoid cells at the site of UV killed E. coli triggered self 
resolving dermal inflammation. 
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
immune cell subsets were identified by polychromatic flow cytometry. Proportion of CD4+ T
cells of total leukocytes (A), total count/ml of CD4+ T cells (B) , proportion of CD8+ T cells of
total leukocytes (C), total count/ml of CD8+ T cells (D), proportion of CD56+ NK cells of total
leukocytes (E) and total count/ml (F) is shown here. Data expressed as individual values with
mean ± SD ; n=6 at each time point. ND= not detectable.
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To examine the effectiveness of neutrophil clearance in this model, I 
investigated CD16lo cells which were identified as a population of apoptotic 
neutrophils in cantharidin skin blister model. At 4h, CD16lo cells (green gate) 
comprised 5.4 ± 8.1 % of total leucocytes and increased up to 10.28 ± 12.46 % 
at 14h. From 14h to 72h they cleared, and by 72h their proportion was < 1% of 
total leucocytes. Thus, CD16lo cells were completely cleared from this model. 
The flow cytometric characterisation of these cells at different time points of 
inflammation is shown in Figure 4.5 A, and their temporal profile as a 
proportion of total leucocytes is shown in Figure 4.5 B. 
Figure 4.4 Profile of myeloid cells at site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
immune cell subsets were identified by polychromatic flow cytometry. Proportion of neutrophils
of total leukocytes (A), total count/ml of neutrophils (B), neutrophil CD62L expression (C),
proportion of monocytes/macrophages of total leukocytes (D), total count/ml of
monocytes/macrophages (E), expression of CD163 (F) and CD16 (G) on
monocytes/macrophages, proportion of CD1c+ dendritic cells of total leukocytes (H) and total
count/ml of CD1c+ dendritic cells (I) are shown here. Data expressed as individual values with
mean ± SD; n=6 at each time point. n=3 for CD62L MFI and CD163 MFI. ND= not detectable.
Figure 4.5 Profile of CD16lo cells at site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site, at the specified interval, to collect
the inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant.
The immune cell subsets were identified by polychromatic flow cytometry. Representative dot
plots of CD16lo apoptotic neutrophils (green gate) at 4hr, 24hr, 48hr and 72hr time point
relative to CD16hi neutrophils (blue gate) and HLA-DR+ CD14+ monocytes/macrophages (red
gate) are shown here (A). The proportion of CD16lo apoptotic neutrophils of total leukocytes at
specified intervals is also shown (B). Data expressed as individual values with mean ± SD;
n=6 at each time point.
Figure 4.6 Profile of lymphoid cells at the site of UV killed E. coli triggered self 
resolving dermal inflammation. 
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
immune cell subsets were identified by polychromatic flow cytometry. Proportion of CD4+ T
cells of total leukocytes (A), total count/ml of CD4+ T cells (B) , proportion of CD8+ T cells of
total leukocytes (C), total count/ml of CD8+ T cells (D), proportion of CD56+ NK cells of total
leukocytes (E) and total count/ml (F) is shown here. Data expressed as individual values with
mean ± SD ; n=6 at each time point. ND= not detectable.
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Lymphocytes (CD4+ and CD8+ T cells) were the predominant cells types at the 
baseline time point. After UVkEc injection the proportion of CD4+ T cells 
increased between 4hr and 14hr followed by a trend towards decline at 24hr. 
At 72hr, CD4+ T cells were 16.02 ± 10.86 % of total leucocytes. The proportion 
and total numbers of CD4+ T cells is shown in Figure 4.6 A and Figure 4.6 B, 
respectively. Proportion of CD8+ T cells and CD56+ NK cells also increased 
from 4hr to 72hr. At 72hr, CD8+ T cells and CD56+ T cells comprised 25.87 ± 
13.37 % and 13.13 ± 8.50 % of total leucocytes respectively. The proportion 
and total numbers of CD8+ cells at the inflamed site is shown in Figure 4.6 C 
and Figure 4.6 D respectively. The proportion and total numbers of CD56+ 
cells is shown is shown in Figure 4.6 E and Figure 4.6 F respectively. Thus, 
lymphocytes were the dominant cell type also at the 48hr and 72hr time points. 
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Figure 4.4 Profile of myeloid cells at site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
immune cell subsets were identified by polychromatic flow cytometry. Proportion of neutrophils
of total leukocytes (A), total count/ml of neutrophils (B), neutrophil CD62L expression (C),
proportion of monocytes/macrophages of total leukocytes (D), total count/ml of
monocytes/macrophages (E), expression of CD163 (F) and CD16 (G) on
monocytes/macrophages, proportion of CD1c+ dendritic cells of total leukocytes (H) and total
count/ml of CD1c+ dendritic cells (I) are shown here. Data expressed as individual values with
mean ± SD; n=6 at each time point. n=3 for CD62L MFI and CD163 MFI. ND= not detectable.
Figure 4.5 Profile of CD16lo cells at site of UV killed E. coli triggered self resolving
dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site, at the specified interval, to collect
the inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant.
The immune cell subsets were identified by polychromatic flow cytometry. Representative dot
plots of CD16lo apoptotic neutrophils (green gate) at 4hr, 24hr, 48hr and 72hr time point
relative to CD16hi neutrophils (blue gate) and HLA-DR+ CD14+ monocytes/macrophages (red
gate) are shown here (A). The proportion of CD16lo apoptotic neutrophils of total leukocytes at
specified intervals is also shown (B). Data expressed as individual values with mean ± SD;
n=6 at each time point.
Figure 4.6 Profile of lymphoid cells at the site of UV killed E. coli triggered self 
resolving dermal inflammation. 
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant. The
cell pellet was suspended in FACS buffer and the cells were counted by haemocytometer. The
immune cell subsets were identified by polychromatic flow cytometry. Proportion of CD4+ T
cells of total leukocytes (A), total count/ml of CD4+ T cells (B) , proportion of CD8+ T cells of
total leukocytes (C), total count/ml of CD8+ T cells (D), proportion of CD56+ NK cells of total
leukocytes (E) and total count/ml (F) is shown here. Data expressed as individual values with
mean ± SD ; n=6 at each time point. ND= not detectable.
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4.3.4 Cytokine and chemokine profile at the site of UVkEc triggered self-
resolving dermal inflammation  
 
Cell-free inflammatory exudate was investigated by multiplex ELISA to 
measure the levels of soluble mediators. At 4h, when the numbers of 
neutrophils peaked at the inflamed site the levels of pro-inflammatory 
cytokines TNF-α, IL-1β and IL-8 were maximum (Figure 4.7 A, B, C). At 4h, 
the levels of TNF-α were 1,568 ± 732 pg/ml, the levels of IL-1β were 509 ± 296 
pg/ml and the levels of IL-8 were 3,556 ± 2232 pg/ml. Co-incidentally, the 
levels of anti-inflammatory cytokines IL-4, IL-10 and IL-13 also peaked (Figure 
4.7 D, E, F). IFN-g, a macrophage activating cytokine peaked at 8h, coinciding 
with the peak of CD163lo pro-inflammatory macrophages (Figure 4.7 G). The 
levels of IL-6 remained consistently high from 4h until 24h (Figure 4.7 H). By 
72h, concurrent with vascular and cellular resolution, the levels of these 
cytokines declined to be close to baseline levels. Additional cytokines and 
chemokines measured in this model are shown in the appendix (Figure 8.2 
and Figure 8.3).  
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Figure 4.7 Profile of cytokines and chemokines at site of UV killed E. coli triggered self
resolving dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Inflammatory exudate was centrifuged to separate cells from the
supernatant containing soluble mediators. Cytokines and chemokines in the cell free exudate
were measured using multiplex ELISA and their concentrations in the exudate obtained at the
specified intervals are shown here. Data expressed as individual values with mean± SD; n=6 at
each time point.
Figure 4.8 Profile of peripheral blood neutrophil and monocyte numbers in UV killed E.
coli triggered self resolving dermal inflammation model.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
Peripheral blood was obtained by venepuncture at specified intervals and the anticoagulated
blood was sent to The Doctor’s Laboratory, Whitfield Street, London, UK for estimation of full
blood count. Peripheral blood neutrophil count (A) and monocyte count (B) are shown here.
Data expressed as individual values with mean ± SD; n=6 at baseline, 4hr and 24hr, n=4 at
48hr and n=3 at 72hr.
Figure 4.9 Profile of plasma cytokines and chemokines in the UV killed E. coli triggered
self resolving dermal inflammation model.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
Peripheral blood was obtained by venepuncture at specified intervals and plasma was
separated by centrifugation. The pro-inflammatory cytokines and chemokines in the plasma
were analysed by multiplex ELISA and their concentration at specified intervals is shown here.
Data expressed as individual values with mean ± SD; n=5 at baseline, 48hr and 72hr, n=4 at 8hr
and 14hr, n=6 at 4hr and 24hr.
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4.3.5 Systemic immune response to the UVkEc intradermal injection  
 
Neutrophil and monocyte count in circulating blood and cytokine levels in 
plasma were measured to estimate the systemic immune response. Neutrophil 
numbers increased from 3.52 x 106 ± 1.49 x 106 cells/ml at baseline to 8.66 ± 
0.64 x 106 cells/ml at 4h (Figure 4.8 A). Peripheral blood monocytes showed a 
single peak at 4h compared to the biphasic monocyte kinetics seen at the site 
of inflammation. Their numbers increased from 0.39 x 106 ± 0.12 x 106 cells/ml 
at baseline to 0.69 x 106 ± 0.15 x 106 cells/ml at 4h (Figure 4.8 B). From 4h 
onwards, neutrophil and monocyte numbers declined gradually and reached 
baseline levels by 72h. 
A B
Ba
se
lin
e
4h
r
24
hr
48
hr
72
hr
0
2
4
6
8
10
B
lo
od
 n
eu
tr
op
hi
ls
 
(1
06
/m
l)
Ba
se
lin
e
4h
r
24
hr
48
hr
72
hr
0.0
0.2
0.4
0.6
0.8
1.0
B
lo
od
 m
on
oc
yt
es
 
(1
06
/m
l)Figure 4.7 Profile of cytokines and chemokines at site of UV killed E. coli triggered self
resolving dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Inflammatory exudate was centrifuged to separate cells from the
supernatant containing soluble mediators. Cytokines and chemokines in the cell free exudate
were measured using multiplex ELISA and their concentrations in the exudate obtained at the
specified intervals are shown here. Data expressed as individual values with mean± SD; n=6 at
each time point.
Figure 4.8 Profile of peripheral blood neutrophil and monocyte numbers in UV killed E.
coli triggered self resolving dermal inflammation model.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
Peripheral blood was obtained by venepuncture at specified intervals and the anticoagulated
blood was sent to The Doctor’s Laboratory, Whitfield Street, London, UK for estimation of full
blood count. Peripheral blood neutrophil count (A) and monocyte count (B) are shown here.
Data expressed as individual values with mean ± SD; n=6 at baseline, 4hr and 24hr, n=4 at
48hr and n=3 at 72hr.
Figure 4.9 Profile of plasma cytokines and chemokines in the UV killed E. coli triggered
self resolving dermal inflammation model.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
Peripheral blood was obtained by venepuncture at specified intervals and plasma was
separated by centrifugation. The pro-inflammatory cytokines and chemokines in the plasma
were analysed by multiplex ELISA and their concentration at specified intervals is shown here.
Data expressed as individual values with mean ± SD; n=5 at baseline, 48hr and 72hr, n=4 at 8hr
and 14hr, n=6 at 4hr and 24hr.
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Plasma cytokines and chemokines did not show a temporal profile as 
observed in the local inflammatory exudate. From baseline to 4h, the plasma 
TNF-a levels unlike the blister exudate TNF-a levels did not rise significantly. 
At baseline, the levels of plasma TNF-a were 1.92 ± 0.94 pg/ml and increased 
to 2.933 ± 0.44 pg/ml at 4h (Figure 4.9 A). Similarly, the plasma concentration 
of IL-8 did not rise at 4h or at the later time points of inflammation. Levels of IL-
1b were undetectable (Figure 4.9 B, C). Plasma IFN-g increased above the 
baseline at 4h and peaked at 8h, coinciding with time point showing peak    
IFN- g levels in the blister exudate. From 8h, its concentration declined and 
reached baseline levels at 72h (Figure 4.9 D). Plasma concentration of IL-6 
was consistently higher at 4h compared to baseline for the all the volunteers. 
Before UVkEc injection, it was 1.86 ± 1.13 pg/ml and increased to 18.6 ± 16.3 
pg/ml at 4h (Figure 4.9 E). By 48h, the concentration of plasma IL-6 returned 
to steady state levels.  
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Figure 4.7 Profile of cytokines and chemokines at site of UV killed E. coli triggered self
resolving dermal inflammation.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
A suction blister was raised over the inflamed site at the specified interval to collect the
inflammatory exudate. Inflammatory exudate was centrifuged to separate cells from the
super atant containing soluble mediators. Cytokines and c emokines in t e cell free exudate
were measured using multiplex ELISA and their concentrations in the exudate obtained at the
specified intervals are shown here. Data expressed as individual values with mean± SD; n=6 at
each time point.
Figure 4.8 Profile of peripheral blood neutrophil and monocyte numbers in UV killed E.
coli triggered self resolving dermal inflammation model.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
Peripheral blood was obtained by venepuncture at specified intervals and the anticoagulated
blood was sent to The Doctor’s Laboratory, Whitfield Street, London, UK for estimation of full
blood count. Peripheral blood neutrophil count (A) and monocyte count (B) are shown here.
Data expressed as individual values with mean ± SD; n=6 at baseline, 4hr and 24hr, n=4 at
48hr and n=3 at 72hr.
Figure 4.9 Profile of plasma cytokines and chemokines in the UV killed E. coli triggered
self resolving dermal inflammation model.
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile saline.
Peripheral blood was obtained by venepuncture at specified intervals and plasma was
separated by centrifugation. The pro-inflammatory cytokines and chemokines in the plasma
were analysed by multiplex ELISA and their concentration at specified intervals is shown here.
Data expressed as individual values with mean ± SD; n=5 at baseline, 48hr and 72hr, n=4 at 8hr
and 14hr, n=6 at 4hr and 24hr.
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4.3.6 Tolerability of the UVkEc triggered self-resolving dermal 
inflammation model  
 
To evaluate the tolerability of symptoms associated with UVkEc triggered 
acute inflammation and the study procedures, a post hoc survey was 
conducted for the volunteers who participated in the study. This survey was 
conducted in collaboration with Dr Julia Flint.   
 
An anonymous online survey was emailed to volunteers asking them to report 
their experience. 13 out of the 24 volunteers who participated in this study 
responded to the survey. Results of the survey revealed that intradermal 
injection of UVkEc caused mild discomfort to 6 out of 13 volunteers. Laser 
Doppler Imaging was found to be very well tolerated. The blister induction 
process was reported to cause only mild discomfort by 9 out of 13 volunteers 
(Figure 4.10 A). Amongst the inflammation associated local symptoms, mild 
pain at the injection site was a most common symptom and was reported by all 
the 13 volunteers. The second most common symptom was mild discomfort in 
the armpit region which was expected due to transient localised lymph node 
congestion and was reported by 6 volunteers. Three volunteers also reported 
arm heaviness which was expected due to localised oedema (Figure 4.10 B).   
 
Systemic symptoms including headache, body ache, malaise and fever were 
less common than the local symptoms. Two volunteers reported headache, 5 
reported body ache and 4 volunteers responded that they had a general 
feeling of illness (malaise). Fever was only reported by one volunteer (Figure 
4.10 B). The survey results also revealed that 4 out of 13 volunteers did not 
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experience any symptoms and that by 48h all the symptoms had subsided 
(Figure 4.10 C). None of the volunteers withdrew from the study due to 
discomfort caused by study procedures or due to the acute inflammation 
associated symptoms.  
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Figure 4.10 Tolerability of UV killed E. coli triggered self resolving dermal inflammation
model
To assess tolerability of acute inflammation associated symptoms and study procedures,
volunteers were invited to take part in an online post hoc survey. Responses from the
volunteers about the discomfort associated with study procedures (A), symptoms of acute
inflammation (B) and the duration for which of these symptom(s) lasted (C) are shown here. 24
volunteers were invited and 13 responded. Data from n=13.
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4.4 DISCUSSION 
 
This study describes a novel in vivo approach quantifying the vascular, cellular 
and soluble mediators elicited in response to UVkEc injection in healthy 
volunteers encompassing both the onset as well as the resolution phases of 
the inflammatory response. 
 
The onset phase evident at 4h was characterised by an increase in blood 
blow, a maximal number of immune cells comprising mainly neutrophils, and 
the highest concentrations of classical pro-inflammatory cytokines. While the 
vascular response plateaued between 4h and 24h and started to resolve 
thereafter, the cellular resolution, classically defined by a reduction of 
neutrophil numbers [207], ensued gradually from 4h with > 90% of neutrophils 
cleared by 48h. During resolution, the expression of CD62L on neutrophils 
increased. These CD62L expressing tissue neutrophils may resemble a 
regulatory neutrophil phenotype that has been previously observed by Pillay et 
al during the resolution of systemic inflammation after intravenous LPS 
challenge in humans [208]. Regulatory neutrophils actively suppress CD4+ T 
cell proliferation and could contribute to tolerance to self-antigens at the 
inflamed site [209]. Neutrophil clearance was also associated with 
monocytes/macrophages switching to a pro-resolution phenotype as evident 
from increase in CD163. CD163 is haemoglobin scavenger receptor which is 
upregulated on macrophages after efferocytosis [178]. 
Monocytes/macrophages also showed increased CD16 expression during 
resolution in this model, similar to the observations made in the cantharidin 
skin blister. The decline in neutrophils and monocytes/macrophages was 
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associated with an increase in lymphocytes, consistent with the results 
observed during resolution of acute peritonitis in the mice [88]. Taken together, 
the findings in this model are in agreement with our existing knowledge of the 
acute inflammatory response seen in patients and are also reminiscent of 
events characterising cellular resolution in mouse models, thus further 
validating the use of this model for investigating resolution processes and 
effect of pro-resolving therapies on resolution indices in humans.  
 
Neutrophil clearance is one of the important hallmarks of resolution of acute 
inflammation. An important feature of a translational model of resolution should 
therefore be to allow investigation and quantification of the extent of neutrophil 
clearance. The UVkEc triggered dermal model of inflammation shows a clear 
temporal profile of neutrophils which were cleared completely from the 
inflamed site, indicating successful resolution. I speculate that complete 
neutrophil clearance is achieved in this model because of a stromal scaffold 
formed around the inflammation site by dermal components including 
fibroblasts, micro-capillaries and lymphatics. The stromal scaffold could 
increase macrophage-neutrophil interactions and enhance macrophage 
efferocytosis, a key process for neutrophil clearance [210]. Fibroblasts would 
further contribute to this process as they have been shown to directly 
phagocytose apoptotic cells [211]. In addition, the microvasculature and 
lymphatics would also facilitate neutrophil clearance by reverse migration and 
lymphatic emigration respectively [212][213]. This inflamed site of UVkEc 
induced dermal inflammation is in contrast to the fluid sac like structure of the 
cantharidin blister at resolution time point where the accumulation of apoptotic 
neutrophils is observed. Taken together, the UVkEc triggered model of dermal 
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inflammation allows investigation of neutrophil clearance, a key resolution 
index that can be used to validate and compare the effect of novel pro-
resolving therapies in humans.  
 
Peripheral blood monocytes are classified into three main subsets namely 
classical monocytes (CD14++ CD16-), intermediate monocytes (CD14++ CD16+) 
and non-classical monocytes (CD14+ CD16+) [214]. In this model, the 
monocytes/macrophages at 4h and 8h time point were mainly of the classical 
phenotype and at 24h and 48h, they had higher expression of CD16 
resembling an intermediate monocyte phenotype. The origin of these CD14+ 
CD16+ monocytes/macrophages, during resolution, in this model is uncertain 
as they could be newly influxed intermediate monocytes from blood or 
classical monocytes at the site that gained CD16 expression or they could be a 
population derived from skin resident macrophages. Each monocyte subset 
has been attributed a specific function. For instance, classical monocytes are 
better at phagocytosis and production of reactive oxygen species compared to 
the intermediate monocytes. [215]. Resident macrophages also have a 
specialised function and are involved in clearance of apoptotic cells [216]. 
Understanding the origin of these monocytes can provide clues to how to 
modulate their numbers in vivo and thereby investigate their effect on the 
resolution indices. Conducting this model together with peripheral blood 
monocyte labelling and tracking techniques in humans, e.g. autologous 
transfusion of ex vivo technetium-99m radiolabelled monocytes [217] may help 
to investigate the origin of these CD14+ CD16+ monocytes/macrophages 
during resolution phase in this model. 
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The suction blister technique offers multiple advantages compared to skin 
biopsy technique for sampling of the inflamed tissue. Firstly, the suction blister 
technique is minimally invasive compared to skin biopsy. Unlike the acquisition 
of skin biopsy, induction of suction blister does not require local anaesthesia 
and has lower risk of bleeding. Secondly, the technique of negative pressure 
induced suction blister provides an inflammatory exudate which can be easily 
processed to obtain cell suspension for polychromatic flow cytometry and a 
cell-free supernatant that can be analysed for soluble mediators by multiplex 
ELISA. Comparatively, the inflamed skin biopsy tissue requires a time 
consuming process of ex vivo digestion to prepare cell suspensions for flow 
cytometry. Finally, compared to the skin biopsy, suction blister wound site 
heals quicker and does not leave a permanent scar. Taken together, suction 
blister is a safer and more productive sampling technique compared to skin 
biopsy. Also, according to the tolerability survey, the process of suction blister 
was reported to be only mild discomforting. One minor limitation is that it 
requires special negative pressure equipment and the process takes around 1-
1.5 h.         
 
Compared to other models of acute inflammation such as cantharidin blister or 
skin window technique, a unique feature of the UVkEc triggered self-resolving 
dermal inflammation model is that it allows monitoring of the clinical signs of 
inflammation. Vascular hyperaemia was investigated in this model, but pain 
could also be assessed by measuring pain threshold using algometer (a 
sensitive pressure application and measuring device) [218]. In addition, heat at 
the site could be measured using an infrared thermometer. Demonstration of 
both these techniques is shown in the appendix (Figure 8.4). By allowing 
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investigation of clinical signs of inflammation and established indices of 
resolution i.e. neutrophil clearance, pro-inflammatory cytokine reduction, pro-
inflammatory to pro-resolving switch in macrophage phenotype, the UVkEc 
triggered self-resolving dermal inflammation model could serve as a robust, 
standardized platform to validate the mechanism and compare the efficacy of 
novel pro-resolving drugs and anti-inflammatory drugs in healthy humans. 
Furthermore, the model can also be employed chronic inflammatory disease 
patients to investigate whether defects in pro-resolution pathways contribute to 
their disease progression. In fact, studies are already ongoing in our laboratory 
to investigate resolution processes in patients with inflammatory bowel disease 
(by Dr Daniel Marks) and rheumatoid arthritis (by Dr Julia Flint) using this 
model.  
 
The major limitations of this model are due to the local and systemic side 
effects caused by the acute inflammation associated symptoms and the study 
procedures. The most common symptoms were pain at the inflamed site on 
the forearm, headache and mild discomfort experienced during induction of 
suction blister. To assess the severity of these side effects a post hoc survey 
was conducted amongst the study volunteers. While the survey revealed that 
the acute inflammation associated symptoms were minimal and did not last 
longer than 24h in the majority of volunteers, it is advised to exercise extra 
caution during screening for volunteers. Specifically, volunteers should be 
screened for history of skin allergies to avoid the risk of a hyper-inflammatory 
response to UVkEc. During the screening, potential volunteers should also be 
counselled in detail about the expected side effects and to minimise these side 
effects they should be asked to refrain from strenuous physical activity and 
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high concentration tasks, e.g. driving during the study period The aspirated 
blister site also poses a risk of secondary infection and to minimise this 
volunteer should also be advised to keep the site covered and dry until a scab 
is formed. The volunteers should also be informed that a hyperpigmentation 
mark persists for 4-6 weeks at the aspirated blister site and that it can remain 
longer in darker skin types.  
 
In conclusion, UVKEc induced self-resolving dermal inflammation model allows 
investigation of quantifiable indices of onset and resolution phases of acute 
inflammation in a minimally invasive way. It can serve as novel proof of 
concept platform to test the efficacy and investigate the mechanism of novel 
anti-inflammatory and pro-resolving drugs in healthy humans. 
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Chapter 5 
 
Effect of SPMs on resolution indices in a human 
model of UVkEc triggered self-resolving dermal 
inflammation  
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5.1 INTRODUCTION 
 
The beneficial effect of SPMs including lipoxins, maresins and protectins have 
been shown in multiple murine models of inflammation. However, evidence 
showing the direct pro-resolution effect of SPMs in humans is lacking.  
 
The UVkEc induced self-resolving dermal inflammation is a novel human 
model that allows detailed investigation of cells and soluble mediators that 
drive the onset and resolution phases of inflammation. More importantly, the 
accessible nature of dermal inflammation lends itself to the local administration 
of immune modulatory agents at a desired time point.   
 
In this chapter, using this novel model, I investigated the temporal profile of 
SPMs and prostanoids during onset and resolution phases of inflammation. In 
addition, I investigated the SPM receptors that transduce their pro-resolution 
effects on the microvascular endothelium and infiltrating leucocytes. Finally, I 
injected SPMs at the tipping point of resolution to investigate their effect on 
resolution biomarkers i.e. reduction of neutrophil numbers, the decline in levels 
of pro-inflammatory cytokines/chemokines and enhanced clearance of the 
inflammatory stimulus. 
 
5.2 STUDY DESIGN 
The temporal profile of SPMs and prostanoids was measured in the 
inflammatory exudate generated at baseline, 4h, 8h, 14h, 24h, 48h and at 72h 
during characterisation of UVkEc triggered dermal inflammation model. This 
was performed in collaboration with Prof Charles Serhan (Harvard University, 
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USA). SPM receptors including FPR2/ALX, ChemR23, GPR18 and GPR32 
were investigated in the skin biopsy collected at baseline and 4h after injection 
of UVkEc. This was performed in collaboration with histologists at UCL 
Institute of Neurology.  
I first validated the anti-inflammatory effect of naproxen, a dual COX-1/COX-2 
inhibitor, in UVkEc triggered dermal inflammation model. For this, volunteers 
received 500mg naproxen twice daily for four days. On the morning of the 
fourth day, immediately after the naproxen administration, UVkEc were 
injected in the forearm, and after 4h, the suction blister was induced to study 
onset. Naproxen used in this study was bought over the counter from a local 
pharmacy.  
 
To test the pro-resolution effect of SPMs, a SPM cocktail comprising LXB4 
(570 pM = 200 pg/ml), RvE1 (115 pM = 40 pg/ml), RvD2 (450 pM = 170 pg/ml), 
AT-RvD1 (3.2 nM = 1200 pg/ml) in 100 µl saline was injected in one of the 
forearm 4h after UvKEc injection and its effect on resolution biomarkers was 
investigated by raising a suction blister over the injection site at 10h. The 
doses of SPMs selected for intradermal injection reflect the highest 
concentration of these SPMs found at the inflamed site in this model. To serve 
as a control, an inflamed site on the contralateral forearm was injected at 4h 
time point with 100 µl saline only. SPM cocktail used in this study was 
prepared and validated by Dr Jesmond Dalli (The William Harvey Research 
Institute, Queen Mary University of London, UK).   
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5.3 RESULTS  
 
5.3.1 Anti-inflammatory effect of naproxen in the UVkEc induced dermal 
inflammation model.  
 
 
Naproxen significantly suppressed vascular hyperaemia at 4h compared to the 
control group. The mean blood flow in control group was 1.72 x 106 ± 0.61 x 
106 perfusion units and it was decreased by naproxen to 0.6 x 106 ± 0.41 x 106 
perfusion units (Figure 5.1 A). The representative laser Doppler images of the 
control and naproxen treated arm are shown in Figure 5.1 B.  
 
In addition to suppressing vascular hyperaemia, naproxen significantly 
inhibited the migration of neutrophils and monocytes/macrophages in the 
inflamed site at 4h compared to the control group. Naproxen treatment 
Figure 5.1 Effect of Naproxen on vascular hyperaemia during onset phase of UV killed
E. coli triggered self resolving dermal inflammation
Healthy volunteers received Naproxen 500mg, twice daily for four days. On morning of fourth
day, acute inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in
100μl of saline. Vascular hyperaemia was assessed 4hr after bacterial injection using a Laser
Doppler Imager. Vascular hyperaemia over the injection site at 4hr time point in the control
arm vs naproxen arm (A) and the representative Doppler flux are shown here. Data
expressed as individual values, mean ± SD. n= 6 for 4hr Control arm and n=3 for the 4hr
naproxen arm. * p< 0.05.
Figure 5.2 Effect of Naproxen on neutrophil and macrophage numbers during onset
phase of UV killed E. coli triggered self resolving dermal inflammation
Healthy volunteers received Naproxen 500mg, twice daily for four days. On morning of fourth
day, acute inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in
100μl of saline. Suction blister was raised over the inflamed site 4hr after UVkEc injection to
acquire inflammatory exudate. The immune cell subsets in cells in the exudate were identified
by multi color flow cytometry. Neutrophil count/ml (A), proportion of neutrophils of total
leukocytes (B), monocytes/macrophages count/ml (C) and proportion of
monocytes/macrophages of total leukocytes (D) are shown here. Data expressed as
individual values with mean ± SD. n= 6 for 4hr control arm and n=3 for the 4hr naproxen arm.
* p< 0.05.
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reduced neutrophil count at 4h from 573,455 ± 284,242/ml in control group to 
206,835 ± 159,500/ml (Figure 5.2 A). The proportion of neutrophils in 
naproxen vs. control group is highlighted in Figure 5.2 B. 
Monocyte/macrophage numbers decreased from 27,199 ± 43,129/ml in the 
control group to 990 ± 262 /ml following naproxen (Figure 5.2 C). The 
proportion of monocytes/macrophages in naproxen vs. control group is 
highlighted in Figure 5.2 D.    
Figure 5.1 Effect of Naproxen on vascular hyperaemia during onset phase of UV killed
E. coli triggered self resolving dermal inflammation
Healthy volunteers received Naproxen 500mg, twice daily for four days. On morning of fourth
day, acute inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in
100μl of saline. Vascular hyperaemia was assessed 4hr after bacterial injection using a Laser
Doppler Imager. Vascular hyperaemia over the injection site at 4hr time point in the control
arm vs naproxen arm (A) and the representative Doppler flux are shown here. Data
expressed as individual values, mean ± SD. n= 6 for 4hr Control arm and n=3 for the 4hr
naproxen arm. * p< 0.05.
Figure 5.2 Effect of Naproxen on neutrophil and macrophage numbers during onset
phase of UV killed E. coli triggered self resolving dermal inflammation
Healthy volunteers received Naproxen 500mg, twice daily for four days. On morning of fourth
day, acute inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in
100μl of saline. Suction blister was raised over the inflamed site 4hr after UVkEc injection to
acquire inflammatory exudate. The immune cell subsets in cells in the exudate were identified
by multi color flow cytometry. Neutrophil count/ml (A), proportion of neutrophils of total
leukocytes (B), monocytes/macrophages count/ml (C) and proportion of
monocytes/macrophages of total leukocytes (D) are shown here. Data expressed as
individual values with mean ± SD. n= 6 for 4hr control arm and n=3 for the 4hr naproxen arm.
* p< 0.05.
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Unlike the reduction of vascular hyperaemia and neutrophil count, naproxen 
increased levels of pro-inflammatory cytokines TNF-a and IL-8 at 4h compared 
to the control group. TNF-a levels in placebo group were 1,568 pg/ml ± 732.5 
and in naproxen group they were 7,608 ± 6,624 pg/ml (Figure 5.3 A). Levels 
of IL-8 in the control group were 3,556 ± 2,232 pg/ml, and in the naproxen 
group, they were 9,601 ± 4,788 pg/ml (Figure 5.3 B). Naproxen had on effect 
on other pro-inflammatory cytokines and chemokines including IL-1b (Figure 
5.3 C), IFN-g (Figure 5.3 D), IL-6 (Figure 5.3 E) or IL-12p70 (Figure 5.3 F).  
 
 
Figure 5.3 Effect of Naproxen on cytokine and chemokine profile during onset phase of
UV killed E. coli triggered self resolving dermal inflammation
Healthy volunteers received Naproxen 500mg, twice daily for four days. On morning of fourth
day, acute inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in
100μl of saline. Suction blister was raised over the inflamed site 4hr after UVkEc injection to
acquire inflammatory exudate. Cytokines and chemokines in the cell free exudate were
measured by multiplex ELISA and their concentrations at 4hr time point in control vs
naproxen arm are shown here. Data expressed as individual values with mean ± SD. n= 6 for
4hr Control arm and n=3 for the 4hr Naproxen arm. * p< 0.05.
Figure 5.4 Profile of prostanoids at the site of UV killed E. coli triggered self resolving
dermal inflammation model
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of PGE2 (A), PGF2a (B), TXB2 (C) and PGD2 (D) in the inflammatory
exudate at specified intervals are shown here. Data is expressed as individual values with
mean ± SD. n=6 for each time point.
Figure 5.5 Profile of lipoxins and aspirin triggered-lipoxins at the site of UV killed E.
coli triggered self resolving dermal inflammation model
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of LXA4 (A), LXB4 (B), AT-LXA4 (C), AT-LXB4 (D) in the inflammatory
exudate at specified intervals is shown here. Data is expressed as individual values with
mean ± SD. n=6 for each time point.
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5.3.2 Lipid mediator analysis of inflammatory exudate at the site of 
UVkEc triggered self-resolving dermal inflammation  
  
LC-MS/MS (Liquid Chromatography tandem mass spectrophotometry) was 
used to quantify levels of arachidonic acid (AA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) derived lipid mediators and was performed 
in collaboration with Dr Charles Serhan Lab (Harvard University, USA).  
 
Levels of COX-derived products including PGE2 (Figure 5.4 A), TXB2 (Figure 
5.4 B) and PGF2a (Figure 5.4 C) peaked at 4h. At this time point, the 
concentration of PGE2 was 2,464 ± 947.8 pg/ml, PGF2a  was 3,237 ± 1511 
pg/ml and TXB2 was 1,051 ± 659.2 pg/ml. From 4h, levels of these lipid 
mediators declined gradually and reached baseline levels by 24h. There was a 
transient and mild second rise in these lipids at 48h that was nonetheless 
lower than that at 4h. At 48h, levels of PGE2 were 1,420 ± 699.6 pg/ml, PGF2a 
were 544.7 ± 362.1 pg/ml and TXB2 were 528.4 ± 361.4 pg/ml. Compared to 
PGE2, PGF2a and TXB2, levels of PGD2 had high variance at all the 
investigated time points, and they also lacked a temporal profile (Figure 5.4 
D).  
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Figure 5.3 Effect of naproxen on cytokine and chemokine profile during onset phase of
UV killed E. coli triggered self resolving dermal inflammation
Healthy volunteers received Naproxen 500mg, twice daily for four days. On morning of fourth
day, acute inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in
100μl of saline. Suction blister was raised over the inflamed site 4hr after UVkEc injection to
acquire inflammatory exudate. Cytokines and chemokines in the cell free exudate were
measured by multiplex ELISA and their concentrations at 4hr time point in control vs
naproxen arm are shown here. Data expressed as individual values with mean ± SD. n= 6 for
4hr Control arm and n=3 for the 4hr Naproxen arm. * p< 0.05.
Figure 5.4 Profile of prostanoids at the site of UV killed E. coli triggered self resolving
dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of PGE2 (A), PGF2a (B), TXB2 (C) and PGD2 (D) in the inflammatory
exudate at specified intervals are shown here. Data is expressed as individual values with
mean ± SD. n=6 for each time point.
Figure 5.5 Profile of lipoxins and aspirin triggered-lipoxins at the site of UV killed E.
coli triggered self resolving dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of LXA4 (A), LXB4 (B), AT-LXA4 (C), AT-LXB4 (D) in the inflammatory
exudate at specified intervals is shown here. Data is expressed as individual values with
mean ± SD. n=6 for each time point.
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The concentration of LXA4 and AT-LXA4 did not change during different 
phases of inflammation, and the mean levels were < 40 pg/ml across all the 
time points (Figure 5.5 A, C). In contrast, LXB4 showed an increasing trend 
from baseline to 4h with levels increasing from 39.02 ± 26.08 pg/ml at baseline 
to 105.5 ± 30.97 pg/ml at 4h. Between 4h and 48h the levels of LXB4 declined 
(Figure 5.5 B). Unlike LXB4, the levels of AT-LXB4 did not differ between the 
any of the time-points and the mean level was < 50pg/ml (Figure 5.5 D).   
Figure 5.3 Effect of naproxen on cytokine and chemokine profile during onset phase of
UV killed E. coli triggered self resolving dermal inflammation
Healthy volunteers received Naproxen 500mg, twice daily for four days. On morning of fourth
day, acute inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in
100μl of saline. Suction blister was raised over the inflamed site 4hr after UVkEc injection to
acquire inflammatory exudate. Cytokines and chemokines in the cell free exudate were
measured by multiplex ELISA and their concentrations at 4hr time point in control vs
naproxen arm are shown here. Data expressed as individual values with mean ± SD. n= 6 for
4hr Control arm and n=3 for the 4hr Naproxen arm. * p< 0.05.
Figure 5.4 Profile of prostanoids at the site of UV killed E. coli triggered self resolving
dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of PGE2 (A), PGF2a (B), TXB2 (C) and PGD2 (D) in the inflammatory
exudate at specified intervals are shown here. Data is expressed as individual values with
mean ± SD. n=6 for each time point.
Figure 5.5 Profile of lipoxins and aspirin triggered-lipoxins at the site of UV killed E.
coli triggered self resolving dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by the
intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of LXA4 (A), LXB4 (B), AT-LXA4 (C), AT-LXB4 (D) in the inflammatory
exudate at specified intervals is shown here. Data is expressed as individual values with
mean ± SD. n=6 for each time point.
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The concentration of RvE1 and RvE2, the EPA derived lipid mediators did not 
increase during any specific phase of the inflammatory response (Figure 5.6 
A, B). However, the levels of RvE3 showed an increasing trend between 
baseline and 8h. At baseline, RvE3 levels were 160.2 ± 112.5 pg/ml, and at 8h 
they were 291.6 ± 50.97 pg/ml. The levels of RvE3 remained high until 14h, at 
which point they were 274.3 ± 29.06 pg/ml. (Figure 5.6 C). From 14h onwards 
the concentration of RvE3 levels declined and reached baseline values at 72h.    
Figure 5.6 Profile of E-series resolvins at the site of UV killed E. coli triggered self
resolving dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of RvE1 (A), RvE2 (B), and RvE3 (C) in the inflammatory exudate at
specified intervals is shown here. Data is expressed as individual values with mean ± SD.
n=6 for each time point.
Figure 5.7 Profile of D-series resolvins and maresin 1 at the site of UV killed E. coli
triggered self resolving dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of RvD1 (A), RvD2 (B), and RvD3 (C), RvD5 (D), RvD6 (E), AT-RvD1 (F),
AT-RvD3 (G) and Maresin 1 (H) in the inflammatory exudate at specified intervals is shown
here. Data is expressed as individual values with mean ± SD. n=6 for each time point.
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The concentration of DHA derived metabolites including D- series resolvins 
and maresin 1 did not differ significantly from baseline during the onset or 
resolution time points. The mean levels of these metabolites were < 20pg/ml at 
all time points apart from RvD2 and AT-RvD1. At 4h, the levels of RvD2 and 
AT-RvD1 were 43.05 ± 62.42 pg/ml and 267.2 ± 449.9 pg/ml respectively 
(Figure 5.7 B, F).   
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Figure 5.6 Profile of E-series resolvins at the site of UV killed E. coli triggered self
resolving dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of RvE1 (A), RvE2 (B), and RvE3 (C) in the inflammatory exudate at
specified intervals is shown here. Data is expressed as individual values with mean ± SD.
n=6 for each time point.
Figure 5.7 Profile of D-series resolvins and maresin 1 at the site of UV killed E. coli
triggered self resolving dermal inflammation
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. A suction blister was raised over the inflamed site at the specified intervals to collect
the inflammatory exudate. Lipid mediators in the cell free exudate were analysed by liquid
chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard
University). Levels of RvD1 (A), RvD2 (B), and RvD3 (C), RvD5 (D), RvD6 (E), AT-RvD1 (F),
AT-RvD3 (G) and Maresin 1 (H) in the inflammatory exudate at specified intervals is shown
here. Data is expressed as individual values with mean ± SD. n=6 for each time point.
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5.3.3 Expression of SPM receptors at the site of UVkEc triggered self-
resolving dermal inflammation 
 
SPM receptors (FPR2/ALX, ChemR23, GPR18 and GPR32) were investigated 
in the skin biopsy by immunohistochemistry and was performed in 
collaboration with histologists at UCL Institute of Neurology. Skin biopsy was 
taken at baseline and at 4h, the time point when neutrophils start to clear from 
the site.  
    
FPR2/ALX, the receptor for lipoxin A4, RvD1 and AT-RvD1 was detected at 4h 
mainly on the inflamed endothelium with no detectable expression on the 
endothelium of naïve skin (Figure 5.8 A, B). The expression of ChemR23, the 
receptor for RvE1 was observed on the epithelium and endothelium in the 
naïve skin and was elevated mainly on the infiltrating leucocytes in the 4h 
inflamed skin (Figure 5.8 C, D). GPR18, the receptor for RvD2 was observed 
on naive endothelium, and at 4h it was expressed on the endothelium and 
infiltrating leucocytes (Figure 5.9 A, B). GPR32, the receptor for RvD1 and 
AT-RvD1 was observed mainly on the leucocytes in the 4h inflamed skin 
(Figure 5.9 C, D). 
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Figure 5.8 SPM receptor (FPR2 and ChemR23) expression on the endothelium and the 
infiltrating leucocytes.- at the baseline and 4hr in the UV killed E. coli triggered self 
resolving dermal inflammation model
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. 4hr after injection a 3mm skin punch biopsy was taken from the inflamed site under
local anaesthesia. Naive skin was treated as baseline. Formalin fixed paraffin embedded
(FFPE) skin sections were probed by immunohistochemistry department at UCL Institute of
Neurology for SPM receptor identification. Low magnification (5x) and high magnification
(40x) images at baseline and at the 4hr time point are shown here for FPR2 (A and B) and
ChemR23 (C and D). Red arrow highlights endothelium and black arrow highlight the
infiltrating leucocytes. Representative images from n=3.
Figure 5.9 SPM receptor (GPR18 and GPR32) expression on the endothelium and the 
infiltrating leucocytes at the baseline and 4hr in the UV killed E. coli triggered self 
resolving dermal inflammation model
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. 4hr after injection a 3mm skin punch biopsy was taken from the inflamed site under
local anaesthesia. Naive skin was treated as baseline. Formalin fixed paraffin embedded
(FFPE) skin sections were probed by immunohistochemistry department at UCL Institute of
Neurology for SPM receptor identification. Low magnification (5x) and high magnification
(40x) images at baseline and at 4hr time point are shown here for GPR18 (A and B) and
GPR32 (C and D). Red arrow highlights endothelium and black arrow highlight the infiltrating
leucocytes. Representative images from n=3
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Figure 5.8 SPM receptor (FPR2 and ChemR23) expression on the endothelium and the 
infiltrating leucocytes.- at the baseline and 4hr in the UV killed E. coli triggered self 
resolving dermal inflammation model
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. 4hr after injection a 3mm skin punch biopsy was taken from the inflamed site under
local anaesthesia. Naive skin was treated as baseline. Formalin fixed paraffin embedded
(FFPE) skin sections were probed by immunohistochemistry department at UCL Institute of
Neurology for SPM receptor identification. Low magnification (5x) and high magnification
(40x) images at baseline and at the 4hr time point are shown here for FPR2 (A and B) and
ChemR23 (C and D). Red arrow highlights endothelium and black arrow highlight the
infiltrating leucocytes. Representative images from n=3.
Figure 5.9 SPM receptor (GPR18 and GPR32) expression on the endothelium and the 
infiltrating leucocytes at the baseline and 4hr in the UV killed E. coli triggered self 
resolving dermal inflammation model
Acute inflammation was triggered in the ventral aspect of forearm of healthy volunteers by
the intradermal injection of 1.5 x 107 UV killed E. coli (UVKEc) suspended in 100μl of sterile
saline. 4hr after injection a 3mm skin punch biopsy was taken from the inflamed site under
local anaesthesia. Naive skin was treated as baseline. Formalin fixed paraffin embedded
(FFPE) skin sections were probed by immunohistochemistry department at UCL Institute of
Neurology for SPM receptor identification. Low magnification (5x) and high magnification
(40x) images at baseline and at 4hr time point are shown here for GPR18 (A and B) and
GPR32 (C and D). Red arrow highlights endothelium and black arrow highlight the infiltrating
leucocytes. Representative images from n=3
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5.3.4 Effect of SPMs on resolution biomarkers 
 
5.3.4.1 Effect of SPMs on vascular hyperaemia during resolution 
 
The injection of cocktail of SPMs into the inflamed site at 4h did not alter 
vascular hyperaemia at the site at 10h, compared to the saline arm. At 10h, 
the vascular hyperaemia at the saline-injected site was 0.93 x 106 ± 0.36 x 106 
perfusion units, while at the SPM injected site it was 0.89 x 106 ± 0.42 x 106 
perfusion units. However, at 48h the SPM arm had a decreasing trend in blood 
flow compared to the saline arm. At 48h, the total flux in saline injected arm 
was 1.08 x 106 ± 1.19 x 106 perfusion units and in SPM injected arm it was 
0.68 x 106 ± 0.52 x 106 perfusion units (Figure 5.10).     
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Figure 5.10 Effect of therapeutic administration of SPMs on vascular hyperemia at
resolution time points in UV killed E. coli triggered self resolving dermal inflammation
model
Acute inflammation was triggered by intradermal injection of UVkEc in both the forearms. 4hr
after bacterial injection, SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-
RvD1 in 100µl saline) was injected into the inflamed site at 4hr in one forearm and 100µl of
saline was injected into the contralateral forearm at same time to serve as a control . Vascular
hyperaemia was assessed using a Laser Doppler Imager. The effects of SPM cocktail vs
saline on vascular hyperaemia at specified intervals is shown here. Data is expressed mean ±
SD. n=6 for each time point.
Figure 5.11 Effect of therapeutic administration of SPMs on neutrophil and
monocyte/macrophage numbers at resolution time point in UV killed E. coli triggered
self resolving dermal inflammation model
Acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVKEc) suspended in 100μl of sterile saline in both the forearms. 4hr after bacterial injection,
SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-RvD1 in 100µl saline)
was injected into the inflamed site at 4hr in one forearm and 100µl of saline was injected into
the contralateral forearm at same time to serve as a control . 10hr after UVkEc injection (i.e.
6hr after SPM cocktail/saline injection) a suction blister was raised over the inflamed site on
both forearm sites to acquire the inflammatory exudate. The immune cells in the exudate were
identified by multi color flow cytometry. Neutrophil count/ml (A), neutrophil CD62L MFI (B)
monocytes/macrophages count/ml (D) and monocytes/macrophages CD163 expression (D) in
saline vs SPM group at 10hr is shown here. Data is expressed as individual values. n=6 for
each time point. * = p< 0.05
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5.3.4.2 Effect of SPMs on neutrophil and monocytes/macrophages 
numbers during resolution.  
 
SPMs significantly decreased the number of neutrophils at 10h. At this time 
point, the neutrophil count in saline injected arm was 22,885 ± 15,320 /ml, 
while in SPM injected arm it decreased to be 13,980 ± 8,424 /ml (Figure 5.11 
A). Compared to saline injected arm, there was no difference in neutrophil 
CD62L expression after SPM injection (Figure 5.11 B).  
 
The numbers of monocytes/macrophages and their expression of CD163 did 
not change significantly between saline and SPM injected arm. In the saline 
arm, the monocyte/macrophage count was 71,000 ± 36,255 and in the SPM 
injected arm it was 54,099 ± 27,516 (Figure 5.11 C). The median fluorescence 
intensity of CD163 in saline injected arm was 5,499 ± 6,402 MFI units and in 
the SPM injected arm it was 6,416 ± 5,774 MFI units (Figure 5.11 D). 
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Figure 5.10 Effect of therapeutic administration of SPMs on vascular hyperemia at
resolution time points in UV killed E. coli triggered self resolving dermal inflammation
model
Acute inflammation was triggered by intradermal injection of UVkEc in both the forearms. 4hr
after bacterial injection, SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-
RvD1 in 100µl saline) was injected into the inflamed site at 4hr in one forearm and 100µl of
saline was injected into the contralateral forearm at same time to serve as a control . Vascular
hyperaemia was assessed using a Laser Doppler Imager. The effects of SPM cocktail vs
saline on vascular hyperaemia at specified intervals is shown here. Data is expressed mean ±
SD. n=6 for each time point.
Figure 5.11 Effect of therapeutic administration of SPMs on neutrophil and
monocyte/macrophage numbers at resolution time point in UV killed E. coli triggered
self resolving dermal inflammation model
Acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVKEc) suspended in 100μl of sterile saline in both the forearms. 4hr after bacterial injection,
SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-RvD1 in 100µl saline)
was injected into the inflamed site at 4hr in one forearm and 100µl of saline was injected into
the contralateral forearm at same time to serve as a control . 10hr after UVkEc injection (i.e.
6hr after SPM cocktail/saline injection) a suction blister was raised over the inflamed site on
both forearm sites to acquire the inflammatory exudate. The immune cells in the exudate were
identified by multi color flow cytometry. Neutrophil count/ml (A), neutrophil CD62L MFI (B)
monocytes/macrophages count/ml (D) and monocytes/macrophages CD163 expression (D) in
saline vs SPM group at 10hr is shown here. Data is expressed as individual values. n=6 for
each time point. * = p< 0.05
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5.3.4.3 Effect of SPMs on pro-inflammatory cytokines/chemokines and 
endotoxin 
 
The effect of SPMs on the reduction of pro-inflammatory cytokines or 
chemokines during resolution was not very evident in this model for any of the 
major pro-inflammatory cytokines including IL-8, TNF-a, IL-1b, IL-6, IL12-p70 
and IFN-g (Figure 5.12 A, B, C, D, E, F). Similarly, the mean levels of anti-
inflammatory cytokines IL-4, IL10 and IL-13 were not significantly different 
between the SPM vs. saline injected arm. (Figure 5.12 G, H, I). 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
 
A B C
D E F
G H I
Sa
lin
e
SP
M 
0
100
200
300
TN
Fα
pg
/m
l
Sa
lin
e
SP
M 
800
1200
1600
2000
IL
-8
pg
/m
l
Sa
lin
e
SP
M 
0
500
1000
1500
IL
-1
β
pg
/m
l
Sa
lin
e
SP
M 
0
5000
10000
15000
20000
25000
IF
N
γ
pg
/m
l
Sa
lin
e
SP
M 
15000
17500
20000
22500
IL
-6
pg
/m
l
Sa
lin
e
SP
M 
0
100
200
300
400
IL
-1
2p
70
pg
/m
l
Sa
lin
e
SP
M 
0
20
40
60
80
100
IL
-4
pg
/m
l
Sa
lin
e
SP
M 
0
50
100
150
200
250
IL
-1
0
pg
/m
l
Sa
lin
e
SP
M 
0
50
100
150
200
IL
-1
3
pg
/m
l
Figure 5.12 Effect of therapeutic administration of SPMs on cytokine and chemokine 
profile at resolution time point in UV killed E. coli triggered self resolving dermal 
inflammation
Acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVKEc) suspended in 100μl of sterile saline in both the forearms. 4hr after bacterial injection,
SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-RvD1 in 100µl saline)
was injected into the inflamed site at 4hr in one forearm and 100µl of saline was injected into
the contralateral forearm at same time to serve as a control. 10hr after UVkEc injection (i.e.
6hr after SPM cocktail/saline injection) a suction blister was raised over the inflamed site on
both forearm sites to acquire the inflammatory exudate. Cytokines/chemokines in the
inflammatory exudate were measured by multiplex ELISA. The effect of SPM cocktail vs saline
on cytokine and chemokine profile in the inflammatory exudate at 10hr is shown here. Data is
expressed as individual values. n=4 for each time point.
Figure 5.13 Effect of therapeutic administration of SPMs on endotoxin levels at 
resolution time point in  UV killed E. coli triggered self resolving dermal inflammation
Acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVKEc) suspended in 100μl of sterile saline in both the forearms. 4hr after bacterial injection,
SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-RvD1 in 100µl saline)
was injected into the inflamed site at 4hr in one forearm and 100µl of saline was injected into
the contralateral forearm at same time to serve as a control . 10hr after UVkEc injection (i.e.
6hr after SPM cocktail/saline injection) a suction blister was raised over the inflamed site on
both forearm sites to acquire the inflammatory exudate. Endotoxin as a surrogate for
inflammatory stimulus (UVkEc) was measured using kinetic turbidimetric limulus ameobocyte
lysate test. The effect of SPM cocktail vs saline on endotoxin content in the inflammatory
exudate at 10hr is shown here. Data is expressed as individual values. n=6 for each time
point.
 150 
In addition, SPMs did not increase the clearance of the inflammatory stimulus 
during resolution as evident from the levels of endotoxin, a component of gram 
negative bacterial wall in the 10h blister exudate. The endotoxin level in the 
saline arm was 2.42 ± 2.11 EU, and in the SPM group, it was 2.21 ± 2.67 EU 
(Figure 5.13). 
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Figure 5.12 Effect of therapeutic administration of SPMs on cytokine and chemokine 
profile at resolution time point in UV killed E. coli triggered self resolving dermal 
inflammation
Acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVKEc) suspended in 100μl of sterile saline in both the forearms. 4hr after bacterial injection,
SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-RvD1 in 100µl saline)
was injected into the inflamed site at 4hr in one forearm and 100µl of saline was injected into
the contralateral forearm at same time to serve as a control. 10hr after UVkEc injection (i.e.
6hr after SPM cocktail/saline injection) a suction blister was raised over the inflamed site on
both forearm sites to acquire the inflammatory exudate. Cytokines/chemokines in the
inflammatory exudate were measured by multiplex ELISA. The effect of SPM cocktail vs saline
on cytokine and chemokine profile in the inflammatory exudate at 10hr is shown here. Data is
expressed as individual values. n=4 for each time point.
Figure 5.13 Effect of therapeutic administration of SPMs on endotoxin levels at 
resolution time point in  UV killed E. coli triggered self resolving dermal inflammation
Acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVKEc) suspended in 100μl of sterile saline in both the forearms. 4hr after bacterial injection,
SPM cocktail (570 pM LXB4, 115 pM RvE1, 450 pM RvD2, 3.2 nM AT-RvD1 in 100µl saline)
was injected into the inflamed site at 4hr in one forearm and 100µl of saline was injected into
the contralateral forearm at same time to serve as a control . 10hr after UVkEc injection (i.e.
6hr after SPM cocktail/saline injection) a suction blister was raised over the inflamed site on
both forearm sites to acquire the inflammatory exudate. Endotoxin as a surrogate for
inflammatory stimulus (UVkEc) was measured using kinetic turbidimetric limulus ameobocyte
lysate test. The effect of SPM cocktail vs saline on endotoxin content in the inflammatory
exudate at 10hr is shown here. Data is expressed as individual values. n=6 for each time
point.
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5.4 DISCUSSION 
 
The beneficial effects of SPMs has been demonstrated in multiple mouse 
models of inflammatory diseases and in human ex vivo assays [117] 
[219][220]. Multiple studies have also validated SPM physiology in humans. 
For example, SPMs have been identified in plasma of healthy volunteers [221]. 
SPMs have also been identified in patient populations from sites of 
inflammation, including in joint effusions of rheumatoid arthritis patients [222] 
and bronchoalveolar lavage of asthma patients [223]. In addition, studies in 
sepsis patients have shown that SPM profiles in plasma can aid in stratification 
of disease severity and help in predicting their survival [224].  
Taking this forward, we have now identified the presence of SPMs in a human 
model of self-resolving acute inflammation triggered by UV-killed E. coli. In 
addition, we determined the expression of the receptors that they work upon, 
and have shown that exogenously adding these local mediators into the 
established site of inflammation hastens the resolution cascade. Specifically, 
SPMs, when added therapeutically at the resolution tipping point, led to 
enhanced neutrophil clearance within the ensuing 6h. Increased expression of 
SPM receptors in the 4h inflamed skin supported the therapeutic 
administration of SPMs which is also consistent with the clinical scenario 
where patients interact with their doctors once inflammation is already 
established, and so it makes sense to attempt to facilitate the resolution of this 
inflammation instead of only preventing the onset of inflammation. Taken 
together, these data show, for the first time, the potential efficacy of SPMs in 
humans.  
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The mechanisms by which SPMs reduce neutrophil numbers in this model are 
not certain at this stage. The lack of increased CD163 on resolution-phase 
macrophages reduces the likelihood of increased efferocytosis. SPMs also 
failed to reduce the levels of classic neutrophil chemoattractants. Another 
possible mechanism could be through increase in production of nitric oxide 
that can lead to reduced adherence of neutrophils to endothelium [225]. This 
hypothesis garners support from two observations. First, the SPM receptors 
including FPR2/ALX and GPR18 are expressed abundantly on the inflamed 
endothelium in this model and second, from results of murine studies which 
show that SPMs such as RvD2 can increase the production of nitric oxide 
[154]. The action of SPMs on endothelium could also lead to reduced 
neutrophil transmigration. This could be through the action of RvD1 on 
FPR2/ALX on endothelial cells that prevents the IL-17 mediated 
downregulation of developmental endothelial locus-1 (del-1), an endothelial 
cell secreted anti-inflammatory protein that limits neutrophil transmigration 
[226]. Other mechanisms such as enhanced reverse transmigration back into 
systemic circulation or enhanced lymphatic drainage cannot be excluded as 
possible mechanisms through which SPMs are promoting neutrophil clearance 
during resolution in this human model [80] [86].  
One of the principle concerns of promoting neutrophil clearance in the context 
of bacterial infection is that the host immune system might not efficiently clear 
the bacteria. This could result in continuous activation of the innate immune 
response leading to chronic inflammation. This is very well exemplified in 
chronic granulomatous disease, which results from a failure of the phagocytic 
NADPH oxidase enzyme system to produce superoxide and kill invading 
infections leading to a predisposition to recurrent bacterial and fungal 
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infections and the development of inflammatory granulomas [227]. According 
to murine studies, a distinctive feature of SPMs is that they not only promote 
neutrophil clearance but also enhance bacterial clearance. This has been 
demonstrated in multiple mouse models of bacterial infection including E. coli 
triggered sepsis [154], aspiration pneumonia [228], P. aeruginosa induced lung 
infection [129]. However, in this model, SPMs did not show a reduction in 
levels of endotoxin, a surrogate marker of gram negative bacterial load. While 
it is not known whether the effect of SPMs on different resolution biomarkers is 
dose dependent, it could be that dose of SPMs used here was low for exerting 
bacterial clearance. The total dose of SPMs added to the inflamed site here 
was around 150pg and the murine studies described above demonstrated the 
effect of SPMs on enhancing bacterial clearance when they were used at 
doses equivalent to 100 ng/mouse. Nonetheless, these data hint that 
supplementation with SPMs does not negatively affect the clearance of 
inflammatory stimulus by impairing the host antimicrobial defence.  
 
In murine dorsal air pouch model of acute resolving inflammation, temporal 
analysis of exudate show appearance of prostaglandins during onset followed 
by SPMs during the resolution phase, a phenomenon referred as lipid mediator 
class switching [229]. However, in this model, we did not see this 
phenomenon, despite observing an expected increase in levels of 
prostaglandins during onset. It might be that these differences are due to site-
specific local degradation of SPMs as similar loss of SPM signal was observed 
by Homman et al in murine model of oxalazone induced dermal inflammation, 
where they also showed that the recovery of SPMs as early as 2h after 
injecting them in healthy mouse skin was < 10 % [230]. Another explanation 
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for the loss of SPM signal could be due to the use of cell-free inflammatory 
exudate for lipid mediator analysis. Preparation of cell-free exudate involves 
centrifugation to separate the cells, and this process perhaps leads to the 
exclusion of membrane-derived microvesicles which have been shown to also 
contain SPMs [231]. Future studies using cell rich exudate or snap frozen skin 
biopsies from the inflamed site for lipidomic analysis can elucidate the extent 
to which SPM compartmentalization in cells contributes to loss of signal. In 
summary, in this model, we did not observe a rise in levels of SPMs 
specifically in the resolution phase as shown previously in murine models.  
 
SPMs transduce their pro-resolving effect through a variety of GPCR receptors 
including FPR2/ALX (receptor for LXA4, RvD1 and AT-RvD1), ChemR23 
(receptor for RvE1), GPR18 (receptor for RvD2) and GPR32 (receptor for AT-
RvD1) [232]. Murine studies have shown that deficiency of these SPM 
receptors heightens the inflammatory response. For instance, FPR2/ALX and 
GPR18 knockout mice showed increased leucocyte infiltration and reduced 
bacterial clearance in the peritoneum compared to wild-type mice in a model of 
caecal ligation and puncture (CLP) induced polymicrobial sepsis [233][234]. 
The expression of these receptors is upregulated during inflammation as 
evident from results of ex vivo studies using primary cells, e.g. stimulation with 
LPS was shown to upregulate the expression of FPR2/ALX on primary mouse 
microvascular endothelium [235]. In another example, expression of ChemR23 
was found to selectively upregulated on pro-inflammatory 
monocytes/macrophages [236]. Extending these observations, we find in our 
model, which represents a dynamic in vivo inflammation setting, that the 
inflamed site at junction between onset and resolution is characterised by 
 155 
increased expression of SPM receptors which could be either due to their 
upregulation on resident immune cells and endothelium or due to migration of 
leucocytes expressing these receptors. Two important implications of this 
observation are that the site is prepared to enhance pro-resolution signalling 
either by endogenously released SPMs and that it is also amenable to 
therapeutic manipulation by exogenous addition of SPMs. Another interesting 
observation made here was that SPM receptors such as ChemR23 and 
GPR18 were expressed on endothelium at baseline skin. Activation of GPR18 
by RvD2 triggers formation of nitric oxide, which in addition to reducing 
leucocyte-endothelial adherence, also plays an important role in maintaining 
endothelial function by preventing platelet aggregation, regulating vasomotor 
tone and by acting as an antioxidant [237]. Constitutive expression of SPM 
receptors on endothelium suggest a possibility where SPMs can be used 
prophylactically to prevent endothelial dysfunction which underlies the 
development of cardiovascular disorders such as atherosclerosis and 
hypertension [238]. In summary, increased expression of SPM receptors at the 
tipping point of resolution in this model highlight that the inflamed site is primed 
to mediate the effects of SPMs. It also lays the foundation for future studies 
which can employ this model to investigate whether pharmacological agonists 
of these receptors can mimic the effect of SPMs on resolution indices in 
humans.  
 
The rationale for using the cocktail of four SPMs (LXB4, RvE1, RvD2 and AT-
RvD1) was based on an ethical argument as it was thought that use of single 
SPM would decrease the likelihood of observing a pro-resolution effect and 
lead to exposing a large number of volunteers to the UVkEc challenge. The 
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choice of SPMs included in the cocktail was guided by receptor expression. A 
representative member of each receptor class was chosen. RvE1 for 
ChemR23 [239], RvD2 for GPR18 [240] and AT-RvD1 for FPR2/ALX and 
GPR32 [220]. LXB4 was also included as it showed a consistent signal at 4h in 
all volunteers. Also for ethical reasons, the concentration of each of the SPMs 
included in the cocktail was at a concentration equivalent to the highest level 
found at the site of inflammation.  
 
In summary, we identified local SPM biosynthesis as well as the receptors that 
transduce their actions at the junction of onset and resolution. In addition, we 
report that therapeutic supplementation of SPMs triggers reduction of 
neutrophils during resolution. Using the UVkEc model of self-resolving 
inflammation, these observations show for the first time in humans that 
harnessing body's own counter-regulatory signals can be used controlling 
inflammation. It also highlights a novel approach to investigate the effect of 
pro-resolving therapies on resolution biomarkers in humans.   
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Chapter 6  
 
Effect of SPM inducing small molecule, JBT-101, 
a cannabinoid receptor 2 agonist, on resolution 
indices in UVkEc triggered self-resolving dermal 
inflammation model 
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6.1 INTRODUCTION  
 
SPM based therapies can be broadly classified into three groups. The first 
group includes supplementation of their substrate, the n-3 fish oils, e.g. 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) [241], the second 
group involves direct administration of the synthetic stable SPM analogues 
which are currently under development, e.g. RvE1 eye drops for dry eye [242] 
and LXA4 mouth rinse for gingivitis [243]. The third group includes orally active 
small molecules that induce SPM generation by modifying the biosynthetic 
machinery, e.g. low dose aspirin (75mg), which acetylates COX-2 to trigger 
formation of family of aspiring triggered lipoxins (also called 15-epi-lipoxins) 
and resolvins [244] and statins, which cause nitrosylation of COX-2 to trigger 
formation of 15-epi-lipoxins [245].  
 
JBT-101 is a cannabinoid receptor-2 (CB2) agonist (chemical name: ajulemic 
acid) and is a novel member of SPM inducing small molecules currently being 
tested in Phase II clinical trials by Corbus Pharmaceuticals (USA) for 
scleroderma, cystic fibrosis, dermatomyositis and systemic lupus 
erythematosus [246]. A murine study has shown that oral administration of 
JBT-101 enhances production of LXA4 and reduces neutrophil migration to the 
peritoneal cavity in zymosan-induced peritonitis model [247]. In another murine 
study, JBT-101 treatment was shown to decrease the burden of P. aeruginosa 
bacteria in the lung [248]. Murine studies have proposed that by inducing SPM 
formation, JBT-101 exerts a positive effect on resolution indices. However, this 
effect of JBT-101 has not been explored in humans yet.  
Using the UVkEc induced self-resolving dermal inflammation model, I 
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conducted an open-label, parallel group, placebo-controlled pilot study to 
investigate whether JBT-101 dose-dependently triggered SPM biosynthesis 
and whether it shows an effect on resolution indices in humans, at doses 
currently being studied in Phase II clinical trials. I also compared the effect of 
JBT-101 on resolution biomarkers with prednisone, a commonly used 
corticosteroid.  
 
6.2 STUDY DESIGN  
 
 
This study involved additional exclusion criteria and clinical monitoring, and 
therefore the design of the study is described here in detail. The study 
procedures for the UVkEc triggered self-resolving dermal inflammation model 
were conducted in a similar manner as described in methods section 2.3.   
  
An open-label, randomised, parallel group, placebo-controlled pilot study was 
conducted in collaboration with Corbus Pharmaceuticals (UCL Ethics Project 
ID: 5051/002). The study was advertised to recruit healthy, young (18-45 
years) male volunteers. Interested volunteers were first invited for a screening 
that was conducted by the study clinician. The following exclusion criteria were 
established for this particular study: 
 
- Smokers (including nicotine, marijuana and other narcotics). 
- Currently ill or were ill in last one week.   
- History of any chronic medical condition (including skin and food allergies 
or diagnosed mental health disorder). 
- Taking regularly prescribed or over-the-counter medication.  
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- Taken any oral corticosteroids or other immunosuppressive agents within 
the last 3 months. 
- Recent vaccination (within 3 months) or take recreational drugs.  
- Enrolled in another research study. 
- Abnormal blood tests during screening  
• Full Blood Count: Haemoglobin, platelet count, total white count 
and differential. 
• Urea and Electrolytes: Urea, Creatinine, Potassium, Sodium, 
Chloride, Calcium. 
• Liver Function Tests: Total Protein, Albumin, Bilirubin, Alkaline 
Phosphatase, Alanine Aminotransferase. 
- Abnormal findings on physical examination during screening. 
- Screening blood pressure >160/100 mmHg or <90/60 mmHg. 
- Screening heart rate >100 beats per minute (bpm) or <45 bpm. 
- Body mass index (BMI) >30 kg/m2 
- Any other condition that, in the opinion of the study clinician or investigator, 
were clinically significant and may put the subject at greater safety risk, 
influence response to study product, or interfere with study assessments. 
 
Volunteers who were eligible after the screening meeting were invited to take 
part in the study within one week of the meeting. The study was conducted in 
clinical procedures room, Rayne Institute, UCL.  
 
The total study duration was seven days. The first day comprised two visits. 
During the first visit, the study clinician obtained the written informed consent 
from the volunteer after ensuring that volunteer's history or health has not 
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changed since screening. After the consent procedure, a blood sample was 
taken, and the volunteer was randomised to one of the four study groups: 
 
 
Group A: Placebo, twice daily for four days, oral.  
 
Group B: 5mg JBT-101, twice daily for four days, oral. 
Group C: 20mg JBT-101, twice daily for four days, oral. 
Group D: 15mg Prednisone, single morning dose for four days, oral.  
 
GMP standard placebo, JBT-101 5mg and 20mg tablets were provided by 
Corbus Pharmaceuticals, USA. Prednisone 15mg was procured from UCL 
pharmacy by Dr Frances Bennett.      
 
After taking the first dose of the investigational drug (depending on the group 
assigned), the volunteer was observed for any side effects in the clinical 
procedures room, Rayne Institute, UCL for 3h. At the end of this period, the 
volunteer was examined for vital signs by the study clinician. The second visit 
was in the evening, 8h after the first visit, during which the volunteer took the 
second dose of the drug. After taking the second dose, the volunteer was 
monitored for 30 min by the study clinician. 
 
On day 2 and day 3 the volunteer was asked to come to clinical procedures 
room in the morning and in the evening to take the investigational drug under 
our observation. A 10ml blood sample was also drawn from the volunteer 
before the morning dose on both these days.  
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On day 4, immediately after volunteer took the morning dose of the 
investigational drug, acute inflammation was triggered in the forearm using 
UVkEc at two sites, one on each forearm. Inflammatory exudate was collected 
in a suction blister raised at 4h (onset time point) on one forearm and at 10h 
(resolution time point) on the contralateral forearm, after UVkEc injection. On 
this day, the forearm was also scanned by a laser Doppler imager to assess 
local vascular hyperaemia at baseline and then at 2h, 4h, 10h after UVkEc 
injection. A 10ml blood sample was also collected at the above time points to 
assess systemic immune response.   
 
On day 5, 6 and 7, the volunteer was asked to visit once in the morning to 
assess the vascular hyperaemia over the inflamed site using laser Doppler 
measurement and to provide a 10ml blood sample to monitor the systemic 
immune response. This was to investigate the effects of JBT-101 on later time 
points of resolution and to ensure that volunteer is recovering without any 
complications.   
 
The study protocol detailing drug administration and procedures conducted on 
each day is summarised in Figure 6.1 
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Study	groups
A : Placebo, BD
B : JBT-101 5mg, BD
C : JBT-101 20mg, BD
D : Prednisone 15mg, OD
• Doppler
• Blood 
• i.d. UVkEc
• Doppler
• Blood 
• Blister
• Doppler
• Blood 
• Blister
• Doppler
• Blood 
• Doppler
• Blood 
• Doppler
• Blood 
Figure 6.1 Protocol of the study investigating effect of 5mg JBT-101, 20mg JBT-101
and prednisone on resolution biomarkers in UVkEc triggered self resolving dermal
inflammation model.
Figure 6.2 Consort diagram of the open label, randomised, parallel group, placebo 
controlled pilot study to test effect of 5mg JBT-101, 20mg JBT-101 and prednisone 
on resolution biomarkers in UVkEc triggered self resolving dermal inflammation 
model. 
Volunteers interested to participate in the study were screened by the study clinician (Dr
Alexander Maini, Dr Marc George and Dr Fran Bennett). If they were eligible as per the
study criteria, they were randomized to one of the four study groups: placebo, 5mg JBT-
101 , 20mg JBT-101, twice daily or 15mg Prednisone once daily for four days. In total, data
was collected from 20 volunteers and each group had 5 volunteers
Figure 6.3 The effect of JBT-101 and prednisone on vascular hyperaemia at the site
of UVkEc triggered self-resolving dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc)
suspended in 100µl of saline in both the forearms. Vascular hyperaemia at the injection
site was assessed at specified intervals by a laser Doppler imager. The comparison of
vascular hyperaemia (mean ± SD) between the four treatment groups (A) and the vascular
hyperaemia for each volunteer in placebo (B), 5mg JBT-101 (B), 20mg JBT-101 (C) and
15mg prednisone (D) group are shown here. Data expressed as individual values with
mean ± SD. n=5/group.
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6.3 RESULTS   
 
 
6.3.1 Volunteer recruitment 
 
 
Twenty-eight volunteers were screened, and five volunteers were excluded. 
The reasons for exclusion were following: out of reference range blood counts 
(n=2), high BMI (n=1), needle phobia (n=1) and loss to follow-up (n=1). The 
remaining 23 volunteers were randomised into the four study groups. In the 
placebo group, two volunteers were excluded. The first volunteer was 
excluded on day 3 because his serum creatinine levels went above the 
reference range. Follow up investigation by study clinician revealed that it was 
due to dehydration. The other volunteer was excluded during analysis as he 
arrived an hour late for the scheduled 4h blister time point. In the 5mg JBT-101 
group, one volunteer was excluded on day 3 as his platelet count was found to 
be below the reference range. Follow up investigation by study clinician 
indicated the low platelet count was not related to the drug. In total, data was 
collected from 20 volunteers, and each group had 5 volunteers (Figure 6.2).               
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Figure 6.1 Protocol of the study investigating effect of 5mg JBT-101, 20mg JBT-101
and prednisone on resolution biomarkers in UVkEc triggered self resolving dermal
inflammation model.
Figure 6.2 Consort diagram of the open label, randomised, parallel group, placebo 
controlled pilot study to test effect of 5mg JBT-101, 20mg JBT-101 and prednisone 
on resolution biomarkers in UVkEc triggered self resolving dermal inflammation 
model. 
Volunteers interested to participate in the study were screened by the study clinician (Dr
Alexander Maini, Dr Marc George and Dr Fran Bennett). If they were eligible as per the
study criteria, they were randomized to one of the four study groups: placebo, 5mg JBT-
101 , 20mg JBT-101, twice daily or 15mg Prednisone once daily for four days. In total, data
was collected from 20 volunteers and each group had 5 volunteers
Figure 6.3 The effect of JBT-101 and prednisone on vascular hyperaemia at the site
of UVkEc triggered self-resolving dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc)
suspended in 100µl of saline in both the forearms. Vascular hyperaemia at the injection
site was assessed at specified intervals by a laser Doppler imager. The comparison of
vascular hyperaemia (mean ± SD) between the four treatment groups (A) and the vascular
hyperaemia for each volunteer in placebo (B), 5mg JBT-101 (B), 20mg JBT-101 (C) and
15mg prednisone (D) group are shown here. Data expressed as individual values with
mean ± SD. n=5/group.
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6.3.2 Effect of JBT-101 on vascular hyperaemia at the site of UVkEc 
triggered acute inflammation  
 
Compared to placebo, JBT-101 dose-dependently increased vascular 
hyperaemia at the site of inflammation. The trend was established as early as 
2h after UVkEc injection and became apparent at 24h. At 24h, the total flux in 
placebo arm was 1.73 x 106 ± 0.7 x 106 perfusion units, which was increased 
by 5mg and 20mg JBT-101 to 2.58 x 106 ± 1.19 x 106 and 5.88 x 106 ± 0.92 x 
106 perfusion units respectively. The kinetics of vascular hyperaemia in 
prednisone group closely followed the placebo group. Between 24h and 48h, 
the vascular hyperaemia decreased in all the treatment groups but the average 
reduction in JBT-101 5mg and prednisone group was higher than the placebo 
group. The reduction from 24h to 48h in placebo group was 610,694 ± 640,780 
perfusion units and in 5mg JBT-101 and prednisone group it was 1.75 x 106 ± 
0.7 x 106 perfusion units and 1.68 x 106 ± 0.7 x 106 perfusion units. The 
vascular hyperaemia also declined in the 20mg JBT-101 group from 24h-48h 
however at 48h it remained higher in the placebo group. At 72h, the blood flow 
returned to baseline levels in all groups apart from 20mg (Figure 6.3 A). 
 
Vascular hyperaemia for each volunteer in the placebo group is shown in 
Figure 6.3 B, 5mg JBT-101 group in Figure 6.3 C, 20mg JBT-101 group in 
Figure 6.3 D and the prednisone group in Figure 6.3 E. The representative 
camera and laser Doppler images at 24h and 48h, from the above four groups 
is shown in Figure 6.4.  
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Figure 6.1 Protocol of the study investigating effect of 5mg JBT-101, 20mg JBT-101
and prednisone on resolution biomarkers in UVkEc triggered self resolving dermal
inflammation model.
Figure 6.2 Consort diagram of the open label, randomised, parallel group, placebo 
controlled pilot study to test effect of 5mg JBT-101, 20mg JBT-101 and prednisone 
on resolution biomarkers in UVkEc triggered self resolving dermal inflammation 
model. 
Volunteers interested to participate in the study were screened by the study clinician (Dr
Alexander Maini, Dr Marc George and Dr Fran Bennett). If they were eligible as per the
study criteria, they were randomized to one of the four study groups: placebo, 5mg JBT-
101 , 20mg JBT-101, twice daily or 15mg Prednisone once daily for four days. In total, data
was collected from 20 volunteers and each group had 5 volunteers
Figure 6.3 The effect of JBT-101 and prednisone on vascular hyperaemia at the site
of UVkEc triggered self-resolving dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc)
suspended in 100µl of saline in both the forearms. Vascular hyperaemia at the injection
site was assessed at specified intervals by a laser Doppler imager. The comparison of
vascular hyperaemia (mean ± SD) between the four treatment groups (A) and the vascular
hyperaemia for each volunteer in placebo (B), 5mg JBT-101 (B), 20mg JBT-101 (C) and
15mg prednisone (D) group are shown here. Data expressed as individual values with
mean ± SD. n=5/group.
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Figure 6.5 The effect of JBT-101 and prednisone on neutrophil numbers and
neutrophil CD62L expression in the inflammatory exudate at the site of UVkEc
triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc)
suspended in100µl of saline in both the forearms. Inflammatory exudate at the injection
site was acquired into a suction blister raised after 4hr (onset phase) on one forearm and
after 10hr (resolution phase) on the contralateral forearm. Cells in the exudate were
phenoytped by multi colour flow cytometry. The neutrophil count/ml (A), proportion of
neutrophils (B) and surface expression of CD62L on neutrophils (C) at 4hr and 10hr is
shown here. Data expressed as individual values with mean± SD. n=5/group. p values are
denoted as < 0.05 = ' * ', <0.01 = ' ** '
Figure 6.4 Representative camera images and laser Doppler images of the site of 
UVkEc triggered dermal inflammation at the 24hr and 48hr time point after JBT-101 
and prednisone administration. 
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc)
suspended in 100µl of saline in both the forearms. Vascular hyperaemia at the injection
site was assessed by a laser Doppler imager. The representative laser Doppler images
and camera images at 24hr and 48hr for each treatment group are shown here.
Representative images from n=5/group.
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6.3.3 Effect of JBT-101 on numbers and phenotype of neutrophils at the 
site of UVkEc triggered acute inflammation 
 
 
In contrast to vascular hyperaemia, 5mg and 20mg of JBT-101 significantly 
reduced numbers of neutrophil, compared to the placebo at 4h. However, the 
reduction in neutrophils by JBT-101 was not dose-dependent. At 4h, in the 
placebo group, number of neutrophils were 261,820 ± 157,068 /ml decreasing 
to 55,067 ± 37,358 /ml in 5mg JBT-101 group and 65,580 ± 36,203 /ml in 
20mg JBT-101 group. Prednisone also caused a significant reduction in 
neutrophils at 4h, equivalent to that of JBT-101. At 4h, the neutrophil count in 
prednisone group was 72,382 ± 54,805 /ml. At 10h, JBT-101 at both the doses 
maintained this reduction in neutrophil numbers, but the differences were not 
significant when compared to placebo. At 10h, in placebo group, the neutrophil 
count was 243,531 ± 225,022 /ml and it was reduced to 119,898 ± 117,045/ml 
in 5mg JBT-101 and to 72,066 ± 45,975/ml in 20mg JBT-101. (Figure 6.5 A). 
The change in the proportion of neutrophils at 4h and 10h after JBT-101 and 
prednisone administration is detailed in Figure 6.5 B.    
 
Previously in this model, I have identified that during resolution phase 
neutrophils express CD62L, which could indicate they acquire a regulatory 
phenotype. I therefore investigated whether JBT-101 promoted expression of 
CD62L on neutrophils during resolution in this study. The CD62L expression 
on neutrophils in the placebo group at 10h was 673 ± 289 MFI units, and it was 
reduced by 5mg and 20mg JBT-101 to 343 ± 717 MFI units and 340 ± 448 MFI 
units, respectively. At 10h, the CD62L expression on neutrophils in prednisone 
group was 1547 ± 827 MFI units (Figure 6.5 C).    
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Figure 6.5 The effect of JBT-101 and prednisone on neutrophil numbers and
neutrophil CD62L expression in the inflammatory exudate at the site of UVkEc
triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc)
suspended in100µl of saline in both the forearms. Inflammatory exudate at the injection
site was acquired into a suction blister raised after 4hr (onset phase) on one forearm and
after 10hr (resolution phase) on the contralateral forearm. Cells in the exudate were
phenoytped by multi colour flow cytometry. The neutrophil count/ml (A), proportion of
neutrophils (B) and surface expression of CD62L on neutrophils (C) at 4hr and 10hr is
shown here. Data expressed as individual values with mean± SD. n=5/group. p values are
denoted as < 0.05 = ' * ', <0.01 = ' ** '
Figure 6.4 Representative camera images and laser Doppler images of the site of 
UVkEc triggered dermal inflammation at the 24hr and 48hr time point after JBT-101 
and prednisone administration. 
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli (UVkEc)
suspended in 100µl of saline in both the forearms. Vascular hyperaemia at the injection
site was assessed by a laser Doppler imager. The representative laser Doppl r images
and camera images at 24hr and 48hr for each treatment group are shown here.
Representative images from n=5/group.
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6.3.4 Effect of JBT-101 on numbers and phenotype of 
monocytes/macrophages at the site of UVkEc triggered acute 
inflammation 
 
The effect of JBT-101 on monocytes/macrophages numbers was not evident 
either at 4h or 10h time point. However, in the prednisone group 
monocytes/macrophages numbers showed a decreasing trend at 4h, which 
reached significance at 10h, when compared to placebo (Figure 6.6 A). At 
10h, the number of monocytes/macrophages in the placebo group were 
71,711 ± 31,263/ml, and prednisone decreased it to 9,678 ± 4,940/ml. The 
change in the proportion of monocytes/macrophages at 4h and 10h after JBT-
101 and prednisone administration is detailed in Figure 6.6 B. 
 
CD163, a cell surface marker acquired my monocytes/macrophages when 
they phagocytose apoptotic neutrophils was assessed to investigate whether 
JBT-101 differentiated them to a pro-resolution phenotype. While CD163 
expression on monocytes/macrophages was increased in all treatment groups 
from 4h to 10h, there was no difference between placebo and any of the two 
doses of JBT. Prednisone increased expression of monocyte/macrophage 
CD163 at both the time points. At 4h, CD163 expression in the placebo group 
was 704 ± 243 MFI units and it increased to 5,233 ± 2,144 MFI units in 
prednisone group. At 10h, CD163 expression in the placebo group was 2383 ± 
477 MFI units and it increased to 5,233 ± 2,144 MFI units in prednisone group 
(Figure 6.6 C).   
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CD86 provides a co-stimulatory signal for T cell proliferation and is a marker 
for pro-inflammatory macrophages [249]. Here, CD86 expression was 
measured on monocytes/macrophages to assess whether JBT-101 influenced 
their phenotype [250]. At 4h, the differences in monocytes/macrophages CD86 
expression between the investigation groups were insignificant. However, at 
10h, compared to placebo there was a decreasing trend in CD86 expression in 
5mg JBT-101, 20mg JBT-101 and prednisone group. In placebo, the 
monocytes/macrophages CD86 expression was 1856 ± 275 MFI units, and it 
decreased to 1514 ± 487 MFI units in 5mg JBT-101, 1758 ± 276 MFI units in 
20mg JBT-101 and 1285 ± 202 MFI units in prednisone group (Figure 6.6 D).   
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Figure 6.6 The effect of JBT-101 and prednisone on monocyte/macrophage
numbers and monocyte/macrophage CD163 and CD86 expression in the
inflammatory exudate at the site of UVkEc triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day,
acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory exudate at the
injection site was acquired into a suction blister raised after 4hr (onset phase) on one
forearm and after 10hr (resolution phase) on the contralateral forearm. Cells in the
exudate were phenoytped by multi colour flow cytometry. The monocyte/macrophage
count/ml (A), proportion of monocytes/macrophages (B) and surface expression of
CD163 (C) and CD86 (D) on monocytes/macrophages at 4hr and 10hr is shown here.
Data expressed as individual values with mean± SD. n=5/group. p values are denoted as
< 0.05 = ' * ', <0.01 = ' ** '
Figure 6.7 The effect of JBT-101 and prednisone on cytokines and chemokines in
the inflammatory exudate at the site of UVkEc triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily once daily for four days. On
fourth day, acute inflammation was triggered by intradermal injection of 1.5 x 107 UV
killed E. coli (UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory
exudate at the injection site was acquired into a suction blister raised after 4h (onset
phase) on one forearm and after 10h (resolution phase) on the contralateral forearm.
Cytokines and chemokines in the inflammatory exudate were measured by multiplex
ELISA. The concentrations of cytokines and chemokines in the inflammatory exudate at
4hr and 10hr are shown here. Data expressed as individual values with mean± SD.
n=5/group. n=4 for CD86 MFI. p values are denoted as < 0.05 = ' * ', <0.01 = ' ** '
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6.3.5 Effect of JBT-101 on cytokines and chemokines at the site of UVkEc 
triggered acute inflammation 
 
Despite inhibiting neutrophil numbers at 4h, JBT-101 increased the levels of 
pro-inflammatory cytokines TNFa  and IL-1b  (Figure 6.7 A, B) with the 
exception of a trend towards a reduction in IL-8. JBT-101 dose-dependently 
decreased the levels of IL-8. At 4h, IL-8 levels in placebo group were 5,930 ± 
2,062 pg/ml and 5mg JBT-101 and 20mg JBT-101 decreased it to 3,298 pg/ml 
± 1,728 and 3,023 ± 2,762 pg/ml respectively. Prednisone also showed a 
decreasing trend for IL-8, but it was less apparent than either of the doses of 
JBT-101. At 4h IL-8 levels in prednisone group were 4,288 ±3,073 pg/ml 
(Figure 6.7 C). At 10h, both doses of JBT-101 maintained the reduction in 
levels of IL-8, but the differences were less apparent compared to placebo. 
 
Interestingly, only 5mg JBT-101 and prednisone decreased levels of IFN- g at 
4h. IFN- g was 3,249 ± 3,164 pg/ml in the placebo group and 5mg JBT-101 
decreased it to 894 ± 331 pg/ml, and prednisone decreased it to 327 ± 157 
pg/ml (Figure 6.7 D). The levels of IL-4, IL-10 and IL-13, were not different 
between placebo, JBT-101 and prednisone groups (Figure 6.7 E, F, H). 
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Figure 6.6 The effect of JBT-101 and prednisone on monocyte/macrophage
numbers and monocyte/macrophage CD163 and CD86 expression in the
inflammatory exudate at the site of UVkEc triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day,
acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory exudate at the
injection site was acquired into a suction blister raised after 4hr (onset phase) on one
forearm and after 10hr (resolution phase) on the contralateral forearm. Cells in the
exudate were phenoytped by multi colour flow cytometry. The monocyte/macrophage
count/ml (A), proportion of monocytes/macrophages (B) and surface expression of
CD163 (C) and CD86 (D) on monocytes/macrophages at 4hr and 10hr is shown here.
Data expressed as individual values with mean± SD. n=5/group. p values are denoted as
< 0.05 = ' * ', <0.01 = ' ** '
Figure 6.7 The effect of JBT-101 and prednisone on cytokines and chemokines in
the inflammatory exudate at the site of UVkEc triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily once daily for four days. On
fourth day, acute inflammation was triggered by intradermal injection of 1.5 x 107 UV
killed E. coli (UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory
exudate at the injection site was acquired into a suction blister raised after 4h (onset
phase) on one forearm and after 10h (resolution phase) on the contralateral forearm.
Cytokines and chemokines in the inflammatory exudate were measured by multiplex
ELISA. The concentrations of cytokines and chemokines in the inflammatory exudate at
4hr and 10hr are shown here. Data expressed as individual values with mean± SD.
n=5/group. p values are denoted as < 0.05 = ' * ', <0.01 = ' ** '
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6.3.6 Effect of JBT-101 on the endotoxin levels at the site of UVkEc 
triggered acute inflammation 
  
Removal of inflammatory stimulus from the site of inflammation is one of the 
hallmarks of resolution. Endotoxin is the component of gram-negative bacterial 
cell wall and has been used as a surrogate marker of bacterial load [251]. To 
assess whether JBT-101 promotes the removal of inflammatory stimulus, I 
measured endotoxin in the blister exudate. At 4h, compared to placebo, both 
doses of JBT-101 showed a dose-dependent decreasing trend in endotoxin. 
The relative endotoxin levels in the placebo group were 14.60 ± 4.22 EU and 
5mg JBT-101 and 20mg JBT-101 decreased it to 5.26 ± 2.00 EU and to 6.78 ± 
4.27 EU respectively. Prednisone did not alter endotoxin levels compared to 
placebo. At 4h, the endotoxin levels in prednisone group were 17.18 ± 5.25 
EU. At 10h, the levels of endotoxin declined in the placebo group. However, at 
this time point, the decreasing trend in endotoxin levels between placebo and 
JBT group was less obvious (Figure 6.8).    
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Figure 6.8 The effect of JBT-101 and prednisone on endotoxin content in the
inflammatory exudate at the site of UVkEc triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day,
acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory exudate at the
injection site was acquired into a suction blister raised after 4hr (onset phase) on one
forearm and after 10hr (resolution phase) on the contralateral forearm. Endotoxin as a
surrogate for inflammatory stimulus (UVkEc) was measured using kinetic turbidimetric
limulus ameobocyte lysate test. The relative concentration of endotoxin in the
inflammatory exudate at 4hr and 10hr is shown here. Data expressed as individual
values with mean± SD. n=5/group.
Figure 6.9 The effect of JBT-101 and prednisone on prostanoids in the
inflammatory exudate at the site of UVkEc triggered dermal inflammation
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day,
acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory exudate at the
injection site was acquired into a suction blister raised after 4hr (onset phase) on one
forearm and after 10hr (resolution phase) on the contralateral forearm. Lipid mediators in
the inflammatory exudate were analysed by liquid chromatography mass
spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard University). The
concentrations of prostanoids in the inflammatory exudate at 4hr and 10hr are shown
here. Data expressed as individual values with mean ± SD. n=5/group. p values are
denoted as < 0.05 = ' * ', <0.01 = ' ** ’, <0.001 = ' *** '. <0.0001 = ‘****’
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6.3.7 Effect of JBT-101 on lipid mediators at the site of UVkEc triggered 
acute inflammation 
 
JBT-101 decreased the levels of leukotriene LTB4 and prostanoids including 
PGE2, TXB2, PGF2a in a dose-dependent manner during onset and resolution 
phases. 20mg JBT-101 inhibited LTB4 to a greater extent than prednisone at 
4h and 10h. At 4h, the LTB4 level in placebo was 126.17 ± 85.25 pg/ml and it 
decreased to 58.37 ± 23.86 pg/ml in 5mg JBT-101 group and further to 12.11 ± 
2.32 pg/ml in 20mg JBT-101 group. At 4h, the levels of LTB4 in prednisone 
group were 41.98 ± 28.24 pg/ml (Figure 6.9 A). The levels of PGE2, 
PGF2a  and TXB2,  are shown in Figure 6.9 B, C, D. The levels of PGD2 were 
decreased only by the 20mg JBT-101 (Figure 6.9 E).      
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Figure 6.8 The effect of JBT-101 and prednisone on endotoxin content in the
inflammatory exudate at the site of UVkEc triggered dermal inflammation.
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day,
acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory exudate at the
injection site was acquired into a suction blister raised after 4hr (onset phase) on one
forearm and after 10hr (resolution phase) on the contralateral forearm. Endotoxin as a
surrogate for inflammatory stimulus (UVkEc) was measured using kinetic turbidimetric
limulus ameobocyte lysate test. The relative concentration of endotoxin in the
inflammatory exudate at 4hr and 10hr is shown here. Data expressed as individual
values with mean± SD. n=5/group.
Figure 6.9 The effect of JBT-101 and prednisone on LTB4 and prostanoids in the
inflammatory exudate at the site of UVkEc triggered dermal inflammation
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 ,
20mg JBT-101, twice daily or 15mg prednisone once daily for four days. On fourth day,
acute inflammation was triggered by intradermal injection of 1.5 x 107 UV killed E. coli
(UVkEc) suspended in 100µl of saline in both the forearms. Inflammatory exudate at the
injection site was acquired into a suction blister raised after 4hr (onset phase) on one
forearm and after 10hr (resolution phase) on the contralateral forearm. Lipid mediators in
the inflammatory exudate were analysed by liquid chromatography mass
spectrophotometry (LC-MS) by Prof. Serhan laboratory (Harvard University). The
concentrations of prostanoids in the inflammatory exudate at 4hr and 10hr are shown
here. Data expressed as individual values with mean ± SD. n=5/group. p values are
denoted as < 0.05 = ' * ', <0.01 = ' ** ’, <0.001 = ' *** '. <0.0001 = ‘****’
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In general terms, levels of SPMs were substantially lower than conventional 
prostaglandins. JBT-101 dose-dependently increased LXA4 and more potently 
at the 10h time-point. At 10h, the levels of LXA4 in the placebo group were 
4.44 ± 0.2 pg/ml and 5mg JBT-101 raised it to 6.29 ± 2.45 pg/ml and 20mg 
JBT-101 increased it to 12.26 ± 2.23 pg/ml (Figure 6.10 A). The levels LXB4 
levels showed a decreasing trend in the 5mg JBT- 101 group at 4h and 10h, 
while the 20mg JBT-101 showed an increasing trend (Figure 6.10 B).  
 
Of the DHA derived metabolites, the precursor of D-series resolvins 17-HDHA 
was dose-dependently reduced in the JBT and also by prednisone at onset 
and resolution phase (Figure 6.10 C). The levels of D-series resolvins, RvD1 
increased dose dependently by JBT-101 and the also by prednisone at both 
the time points. At 4h, RvD1 was undetectable in the placebo group while in 
the 5mg JBT-101 and 20mg JBT-101 it increased to 0.916 ± 2.048 pg/ml and 
7.55 ± 2.178 pg/ml respectively. At 10h, the levels of RvD1 in the placebo 
group was 1.72 ± 2.37 pg/ml, and it was increased by 5mg JBT-101 to 2.72 ± 
2.49 pg/ml and by 20mg JBT-101 to 6.04 ± 2.15 pg/ml (Figure 6.10 D). The 
levels of RvD3 were detected only in the 20mg JBT-101 group, and it 
increased from 4h to 10h. At 4h, it was 8.48 ± 2.31 pg/ml, and at 10h it was 
16.48 ± 5.47 pg/ml (Figure 6.10 E). The levels of 14-HDHA, PD-1 and 18-
HEPE, were not different between placebo, JBT-101 and prednisone groups 
and are shown in Figure 6.10 F, G, H.  
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Figure 6.10 The effect of JBT-101 and prednisone on specialised pro-resolving
mediators (SPMs) in the inflammatory exudate at the site of UVkEc triggered acute
inflammation
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in 100µl of
saline in both the forearms. Inflammatory exudate at the injection site was acquired into a
suction blister raised after 4h (onset phase) on one forearm and after 10h (resolution phase)
on the contralateral forearm. Lipid mediators in the inflammatory exudate were analysed by
liquid chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory
(Harvard University). The concentrations of SPMs in the inflammatory exudate at 4hr and
10hr are shown here. Data expressed as individual values with mean± SD. n=5/group. p
values are denoted as < 0.05 = ' * ', <0.01 = ' ** ’, <0.001 = ' *** '. <0.0001 = ‘****’
Figure 6.11 The effect of JBT-101 and prednisone on peripheral blood neutrophil
count in the UVkEc triggered self-resolving acute inflammation model
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in both the
forearms. Peripheral blood was taken at specified intervals after inflammation and full blood
analysis was performed by an external pathology lab (The Doctor’s laboratory, London, UK).
The peripheral blood neutrophil count in placebo (A), 5mg JBT-101 (B), 20mg JBT-101 (C)
and 15mg prednisone (D) and the comparison of peripheral blood neutrophil count (mean ±
SD) between the four treatment groups (E) is shown here. Data expressed as individual
values with mean± SD. n=5/group.
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Correlation between the neutrophil numbers at the site with the soluble 
mediators measured in this study revealed a significant positive correlation 
only with LTB4 in the 20mg group at 4h (Table 6.1).  
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6.3.8 Effect of JBT-101 on the systemic immune response at the site of 
UVkEc triggered acute inflammation 
  
The systemic immune response was assessed by measuring peripheral blood 
neutrophil and monocyte count and the CRP levels. 
 
At 4h, circulating neutrophil numbers showed an increasing trend in 5mg JBT-
101 and prednisone group when compared to placebo (Figure 6.11 A). At 4h, 
the neutrophil numbers per ml of blood in placebo group was 8.59 x 106 ± 2.78 
/ml, while in 5mg JBT-101, 20mg JBT-101 and prednisone group it was 10.4 x 
106 ± 3.22 /ml, 8.52 x 106 ± 2.02 /ml, 11.29 x 106 ± 4.05 /ml respectively. From 
4h onwards, the neutrophil count started to decline, and the differences 
between groups were less apparent. Peripheral blood neutrophil count for 
each volunteer in the placebo group is shown in Figure 6.11 B, the 5mg JBT-
101 group in Figure 6.11 C, the 20mg JBT-101 group in Figure 6.11 D and 
the prednisone group in Figure 6.11 E.  
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Figure 6.10 The effect of JBT-101 and prednisone on specialised pro-resolving
mediators (SPMs) in the inflammatory exudate at the site of UVkEc triggered acute
inflammation
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in 100µl of
saline in both the forearms. Inflammatory exudate at the injection site was acquired into a
suction blister raised after 4h (onset phase) on one forearm and after 10h (resolution phase)
on the contralateral forearm. Lipid mediators in the inflammatory exudate were analysed by
liquid chromatography mass spectrophotometry (LC-MS) by Prof. Serhan laboratory
(Harvard University). The concentrations of SPMs in the inflammatory exudate at 4hr and
10hr are shown here. Data expressed as individual values with mean± SD. n=5/group. p
values are denoted as < 0.05 = ' * ', <0.01 = ' ** ’, <0.001 = ' *** '. <0.0001 = ‘****’
Figure 6.11 The effect of JBT-101 and prednisone on peripheral blood neutrophil
count in the UVkEc triggered self-resolving acute inflammation model
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in both the
forearms. Peripheral blood was taken at specified intervals after inflammation and full blood
analysis was performed by an external pathology lab (The Doctor’s laboratory, London, UK).
The peripheral blood neutrophil count in placebo (A), 5mg JBT-101 (B), 20mg JBT-101 (C)
and 15mg prednisone (D) and the comparison of peripheral blood neutrophil count (mean ±
SD) between the four treatment groups (E) is shown here. Data expressed as individual
values with mean± SD. n=5/group.
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The numbers of peripheral monocyte per ml of blood were not different 
between any of the groups during the onset of inflammation. However, 20mg 
JBT-101 showed a trend towards during later time points of resolution, e.g. At 
48h, monocyte count in the placebo group was 0.47 x 106 ± 0.19 /ml, and 
20mg JBT-101 increased it to 0.81 x 106 ± 0.45 /ml (Figure 6.12 A). Peripheral 
blood monocyte count for each volunteer in the placebo group is shown in 
Figure 6.12 B, the 5mg JBT-101 group in Figure 6.12 C, the 20mg JBT-101 
group in Figure 6.12 D and prednisone group in Figure 6.12 E respectively. 
By 72h, the peripheral blood neutrophil and monocyte count returned to 
baseline levels.  
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Figure 6.12 The effect of JBT-101 and prednisone on peripheral blood monocyte
count in the UVkEc triggered self-resolving acute inflammation model
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in both the
forearms. Peripheral blood was taken specified intervals after inflammation and full blood
analysis was performed by an external pathology lab (The Doctor’s laboratory, London, UK).
The peripheral blood monocyte count in placebo (A), 5mg JBT-101 (B), 20mg JBT-101 (C)
and 15mg prednisone (D) and the comparison of peripheral blood monocyte count (mean ±
SD) between the four treatment groups (E) is shown here Data expressed as individual
values with mean± SD. n=5/group.
Figure 6.13 The effect of JBT-101 and prednisone on serum C- reactive protein levels
in the UVkEc triggered self-resolving acute inflammation model
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in both the
forearms. Peripheral blood was taken at specified intervals after inflammation, serum was
separated and analysed for C- reactive protein (The Doctor’s laboratory, London, UK). The
serum CRP in placebo (A), 5mg JBT-101 (B), 20mg JBT-101 (C) and 15mg prednisone (D)
and the comparison of peripheral blood neutrophil (mean ± SD) between the four treatment
groups (E) is shown here. Data expressed as individual values with mean± SD. n=5/group.
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C-reactive protein (CRP) is an acute-phase protein produced from the liver in 
response to acute inflammation [252]. In placebo and both the JBT-101 dose 
groups, CRP levels began to rise from 10h and showed an increasing trend 
between 10h to 24h. However, between 24h and 48h, the 5mg JBT-101 
showed a decreasing trend. At 48h, the CRP level in the placebo group was 
10.98 ± 11.01 mg/L, and in the 5mg JBT-101 and 20mg JBT-101 group, it was 
6.6 ± 3.43 mg/L and 13.44 ± 10.18 mg/L respectively. Volunteers in 
prednisone group inhibited the rise of CRP at all the time points (Figure 6.13 
A). Serum CRP levels for each volunteer in the placebo group is shown in 
Figure 6.13 B, the 5mg JBT-101 group in Figure 6.13 C, the 20mg JBT-101 
group in Figure 6.13 D and the prednisone group in Figure 6.13 E. 
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Figure 6.12 The effect of JBT-101 and prednisone on peripheral blood monocyte
count in the UVkEc triggered self-resolving acute inflammation model
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in both the
forearms. Peripheral blood was taken specified intervals after inflammation and full blood
analysis was performed by an external pathology lab (The Doctor’s laboratory, London, UK).
The peripheral blood monocyte count in placebo (A), 5mg JBT-101 (B), 20mg JBT-101 (C)
and 15mg prednisone (D) and the comparison of peripheral blood monocyte count (mean ±
SD) between the four treatment groups (E) is shown here Data expressed as individual
values with mean± SD. n=5/group.
Figure 6.13 The effect of JBT-101 and prednisone on serum C- reactive protein levels
in the UVkEc triggered self-resolving acute inflammation model
Healthy male volunteers were randomized to receive either placebo, 5mg JBT-101 , 20mg
JBT-101, twice daily or 15mg Prednisone once daily for four days. On fourth day, acute
inflammation was triggered by intradermal injection of UV killed E. coli (UVkEc) in both the
forearms. Peripheral blood was taken at specified intervals after inflammation, serum was
separated and analysed for C- reactive protein (The Doctor’s laboratory, London, UK). The
serum CRP in placebo (A), 5mg JBT-101 (B), 20mg JBT-101 (C) and 15mg prednisone (D)
and the comparison of peripheral blood neutrophil (mean ± SD) between the four treatment
groups (E) is shown here. Data expressed as individual values with mean± SD. n=5/group.
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6.4 DISCUSSION 
 
In this pilot study, we found that JBT-101 at both 5mg and 20mg doses was as 
effective as prednisone in decreasing neutrophil numbers during onset. This 
effect was co-incident with its dose-dependent reduction of IL-8 and endotoxin. 
In addition, JBT-101 dose-dependently decreased the levels of LTB4 and 
prostanoids including PGE2, PGF2a and TXB2 during onset and resolution. 
Furthermore, it was observed that JBT-101 increased the concentration of 
SPMs including LXA4, RvD1 and RvD3 at the resolution time point but only at 
the higher 20mg dose.    
 
Studies in mice using zymosan-induced peritonitis model have shown that 
JBT-101 increases the formation of LXA4 and have further proposed that the 
mechanism through which JBT-101 exerts an effect on neutrophil reduction is 
via LXA4 [247]. While our study validates the observation that JBT-101 induces 
the formation of LXA4, it warrants a discussion as to whether this is the main 
mechanism through which JBT-101 mediates neutrophil reduction. Three 
observations made here discourage me from linking the rise in SPMs by JBT-
101 with its effect on neutrophil reduction in this model. Firstly, the levels of 
LXA4 were increased significantly only in the 20mg group and that too at the 
10h time point. This suggests a lack of dose-dependent effect of JBT-101 on 
increasing SPMs. Secondly, JBT-101 reduced neutrophil numbers at both the 
lower 5mg and the higher 20mg dose and mainly at the 4h time point. This 
highlights the absence of concurrence as the effect of JBT-101 on inducing 
SPMs was at 10h while its effect on reducing neutrophil numbers was obvious 
at 4h. Thirdly, there was no inverse correlation observed between neutrophil 
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count and levels of any of the SPMs at either time points. It could be argued 
that these correlation studies include only five volunteers per group, 
nevertheless they provide a hint to question whether the rise in SPMs is 
associated with a reduction in neutrophil numbers. Also, JBT-101 
counterintuitively decreased the levels of 17-HDHA, a DHA metabolite which 
has been shown to directly inhibit the production of pro-inflammatory cytokine 
TNFa [254]. Taken together, these observations suggest the need for further 
investigations in both mice and humans before SPMs could be associated as 
the main mechanism through which JBT-101 is mediating neutrophil reduction. 
One approach to investigate this would be to test the effect of JBT-101 using 
specific FPR2/ALX (LXA4 receptor) knockout mice, which have been shown to 
abrogate the inhibitory effect of LXA4 on neutrophil migration [151]. Another 
approach to test whether the levels of LXA4 in the 10h blister fluid in this model 
can inhibit neutrophil migration could be accomplished by using the 10h blister 
fluid in an in vitro neutrophil migration assay with or without FPR2/ALX 
receptor antagonist such as BOC-2 [255]. It would be important to elucidate 
the main mechanism of JBT-101, so that correct disease indications are 
considered for future clinical trials using this potent anti-inflammatory drug.   
 
The effect of JBT-101 on neutrophil reduction in this model may also be due to 
its inhibitory effect on other neutrophil chemoattractants measured in this 
model. For instance, JBT-101 dose-dependently and at both the 4h and the 
10h time point reduced the levels of LTB4, a potent neutrophil chemoattractant 
which acts via BLT1 receptor on neutrophils and mediates their extravasation 
to tissues [24], [256]. The likelihood of this mechanism is also supported by the 
observation that LTB4 significantly correlated with the neutrophil count at 4h 
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albeit only in the 20mg group. Another mechanism could be through the effect 
of JBT-101 on inhibition of prostaglandins PGE2 and PGF2a, both of which can 
induce the production of neutrophil chemoattractants such as IL-17 and IL-8 
[257] [258]. The possible role of this mechanism is also supported by the 
observation in this model that JBT-101 caused a dose-dependent reduction in 
IL-8 levels at 4h. The reduction in IL-8 observed in this model could also be 
due to the effect of JBT-101 on reducing IL-8 transcription activity by its direct 
effect on activating PPARg [259]. This could be another mechanism through 
which JBT-101 is reducing neutrophil numbers at 4h. Taken together, the 
observations in this model suggest that JBT-101 is inhibiting neutrophil 
migration possibly via its effect on inhibition of pro-inflammatory mediators.   
 
JBT-101 at both low dose (5mg) and the high dose (20mg) showed equally 
potent inhibition of neutrophil count at 4h. This suggests that 5mg JBT-101 
might be engaging additional mechanisms to reduce neutrophil numbers at 4h. 
One of them could be through inhibition of IFN-g, which has been shown to 
directly induce neutrophil migration after intraperitoneal administration in rat 
peritoneal cavity [260] and was reduced only in the 5mg JBT-101 group in this 
model. Another mechanism could be via PGD2 and/or its metabolite 15d-PGJ2, 
both of which have been shown to reduce neutrophil trafficking in multiple 
murine models of acute inflammation [138,261–263]. The possibility of this 
mechanism operating in the 5mg JBT-101 group is suggested by the 
observation that the 5mg JBT-101 prevented the inhibition of PGD2, which was 
alternatively decreased by 20mg JBT-101. Additionally, it has been shown that 
JBT-101 can induce the formation of 15d-PGJ2 from healthy human fibroblasts 
and it could be that at 5mg, JBT-101 specifically increases 15d-PGJ2 in this 
 192 
model [264][253]. A definitive way to confirm this would be to compare the 
levels of 15d-PGJ2 in the blister fluid of volunteers in the 5mg and 20mg JBT-
101 group at 4h. In summary, the observation that 5mg JBT-101 exerts a 
potent effect on neutrophil migration in combination with the knowledge 
obtained from Phase 1 safety and toxicology studies (reference: JBT-101 
investigator brochure) that the 5mg has lower incidence of side effects 
compared to 20mg, suggest that the use of lower dose of JBT-101, depending 
on the clinical condition, could offer a better risk-benefit profile.  
 
The effect of JBT-101 on some of the pro-inflammatory cytokines measured in 
this model are in the opposite direction to the results observed in in vitro 
studies. For instance, 5mg JBT-101 and 20mg JBT-101 showed an increasing 
trend for pro-inflammatory cytokines IL1-b and TNFa at 4h in this model. 
However, in vitro cytokine release assays using LPS stimulated synovial fluid 
monocytes show that pre-treatment with JBT-101 decreases both IL1-b and 
TNFa [265]. One reason for these divergent results could be due to the 
absence of endothelial cells in the in vitro systems described above. Selective 
activation of CB2 receptor on human umbilical venous endothelial cells 
(HUVECs) by 2-arachidonoylglycerol, an endogenous cannabinoid, has been 
shown that to increase the production of TNF-a in in vitro assays [266]. From 
this, it could be speculated that the activation of the CB2 receptor by JBT-101 
on the endothelium at the inflamed is overriding the effect of JBT-101 on 
immune cells and thus leading to increase in levels of TNF-a and IL-1b. This 
hypothesis could be tested using an in vitro assay incorporating PBMC- 
endothelial cell co-culture [267], and could be further confirmed by in vivo 
murine studies. Taken together, this observation highlights the importance and 
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representativeness of in vivo models to predict the effect of novel drugs on 
inflammation biomarkers in humans.    
 
In this model, JBT-101 dose-dependently increased vascular hyperaemia 
despite inhibiting COX activity as evident from the reduction of prostanoids. 
This is counterintuitive as previously it was shown in this model that naproxen, 
a conventional COX-1/2 inhibitor reduces blood flow at the site (Chapter 5, 
Figure 5.1 A). One likely explanation for increased vascular hyperaemia by 
JBT-101 could be due to its direct activation of PPARg in endothelial cells 
which can lead to increased formation nitric oxide, a potent vasodilator [253] 
[268]. Notably, the vascular hyperaemia increased at 24h and 48h in the 20mg 
group, and this raised the question whether the 20mg dose of JBT-101 is 
causing a rebound inflammation. While the volunteers in the 20mg group did 
not report of increased pain over the forearm site at these later time points, to 
definitively answer this question a separate study was conducted (by Dr 
Frances Bennett and Ms Alice Henderson) to ask this question. Briefly, they 
recruited five volunteers in the placebo group and the JBT-20mg group and put 
them on the same dosing regimen as for the original study (described in Figure 
6.1). However, blisters were raised at 24h and 48h after UVkEC injection, and 
the level of inflammation was assessed by neutrophil numbers in the blister. 
The results of this study showed that the neutrophil count was not different 
between the placebo and JBT-101 group at 24h or 48h (Appendix Figure 8.5), 
suggesting that the vasodilation at 24h and 48h in JBT-101 arm might not be 
associated with rebound inflammation. To confirm this, measurement of 
inflammatory cytokines in the 24h and 48h blister fluid are ongoing in our 
laboratory. An interesting observation made during this follow up study was 
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that vascular hyperaemia in the JBT-101 20 mg group was lower at 10hr and 
24hr compared to the original study, where blisters were raised at 4hr and 
10hr. It could be that JBT-101 induces formation of endogenous factors, not 
currently known, between 4h and 10h and removal of these factors by the 
process of suction blister, leads to increased vascular hyperaemia. In 
summary, JBT-101 induced vasodilation seen in this model at the later time 
points is unlikely to be associated with increased inflammation.  
  
In addition to exerting a potent inhibitory effect on neutrophil trafficking at 4h, 
JBT-101 also showed a dose-dependent decreasing trend in levels of 
endotoxin. This observation is consistent with the results in murine studies 
which showed that JBT-101 decreases bacterial load while also reducing 
neutrophilic inflammation in a model of P. aeruginosa induced lung 
inflammation [248]. One of the mechanisms that could underlie this effect of 
JBT-101 may be through increased production of nitric oxide via PPARg (as 
described above), which in addition to being a potent vasodilator can also 
enhance bacterial clearance as shown previously in a murine model of E. coli 
triggered peritonitis [269]. Measurement of NO levels in the blister fluid could 
provide further evidence into the role of this mechanism in reducing endotoxin. 
On a related note, another observation made in this model was that JBT-101 
did not decrease the circulating CRP levels. CRP is produced by the liver in 
response to inflammatory stress and has been shown to directly participate in 
bacterial clearance by activating complement, opsonisation and promoting 
neutrophil phagocytosis [252][270]. This could imply that the JBT-101 might 
not have systemic immunosuppressive effects. Also, compared to JBT-101, 
prednisone showed an increasing trend for endotoxin levels at both the time 
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points and strongly inhibited the rise of circulating CRP. Bearing in mind that 
corticosteroids increase risk of local and systemic infections [271], together 
these observations provide a clue that JBT might be acting as a local anti-
inflammatory without compromising the host's antimicrobial defence at local 
and systemic levels. 
 
In this model, the anti-inflammatory effect of JBT-101, evidenced by its effect 
on inhibition of neutrophil migration was to the same extent as naproxen and 
prednisone. In addition, studies in mice have shown that JBT-101 lacks the 
potential for gastrointestinal ulceration, a common side effect of NSAIDs. [272]. 
Moreover, the effect of JBT-101 on enhancing endotoxin clearance in this 
model provide the preliminary evidence that JBT-101 does not interfere with 
antimicrobial defence systems like corticosteroids. Taken together, these 
observations suggest that JBT-101 could be a novel anti-inflammatory agent 
for treatment of chronic inflammatory drugs with a better risk-benefit ratio. The 
promise of JBT-101 in this regard is further supported by results from the 
recently concluded Phase II clinical trials. In cystic fibrosis patients, JBT-101 
reduced the number of neutrophils and levels of IL-8 in the patient's sputum 
and lowered the frequency of acute pulmonary exacerbations [273]. In another 
phase II trial in scleroderma patients, JBT-101 offered a clinical benefit as 
evidenced by significantly lowering scleroderma clinical disease scores called 
CRISS, Combined Response Index in diffuse cutaneous Systemic Sclerosis 
(CRISS) [274]. In summary, these results support future clinical development 
for JBT-101 and also the expansion of its indications to other chronic 
inflammatory disorders, e.g. rheumatoid arthritis, where disease management 
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is difficult due to side effects associated with long-term use of NSAIDs and 
corticosteroids. 
 
In conclusion, this study shows that JBT-101, at doses currently being 
investigated in Phase II clinical trials, exerts a profound anti-inflammatory in 
UVkEc triggered self-resolving dermal inflammation model. This effect is most 
likely due to its effect on inhibition of pro-inflammatory lipids than the rise in 
levels of SPMs. Further investigations are required to understand the 
contribution of SPMs in explaining the effect of JBT-101 on resolution indices.   
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Chapter 7  
 
Summary of findings and future directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 198 
7.1 Summary of findings  
 
My PhD aim was to develop a human model of acute resolving inflammation 
and use it as a tool to investigate the local generation of SPMs and also test 
their effect on resolution indices. In chapter 3, I performed a detailed 
characterisation of the cantharidin skin blister to validate its use for 
investigating resolution biomarkers. However, I found that the cantharidin 
blister model was associated with incomplete clearance of apoptotic 
neutrophils during the resolution, an important hallmark of resolution. In 
chapter 4, I describe a novel model where inflammation was triggered by 
injecting UVkEc in the dermis, and the inflammatory exudate was collected in a 
suction blister raised at different time points of the inflammatory spectrum. The 
UVkEc triggered dermal inflammation model allowed me to appreciate a clear 
temporal profile of inflammatory cells, pro-inflammatory cytokines and vascular 
hyperaemia during onset and resolution. In Chapter 5, using the UVkEc 
triggered self-resolving dermal inflammation model, I identified the presence of 
SPMs at the inflamed site and the key receptors through which they act. I then 
utilised this model as the first in human proof of concept platform to investigate 
the effect of two different types of SPM based therapies. Using a local route of 
administration, I demonstrated that therapeutic supplementation of SPMs 
(LXB4, RvE1, RvD2, AT-RvD1) reduced neutrophil numbers during the 
resolution phase, but had an insignificant effect on other indices of resolution 
including clearance of inflammatory stimulus, decrease in levels of pro-
inflammatory cytokines or switching pro-resolving macrophage phenotype. In 
chapter 6, I tested the pro-resolution effect of orally active SPM inducing small 
molecule JBT-101, CB2 receptor agonist (Corbus Pharmaceuticals) using this 
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novel model. Indeed, in this model JBT-101 inhibited neutrophil infiltration at 
onset coincident with the reduction of inflammatory mediators including LTB4, 
PGE2, PGF2a, IL-8 and also enhanced endotoxin clearance. It is also triggered 
the biosynthesis of SPMs including LXB4, RvD1 and RvD3 during the 
resolution phase but the neither the levels of these SPMs nor the time point 
when their synthesis increased correlated with the response of JBT-101 on 
resolution biomarkers. In totality, this thesis demonstrates a novel human 
model of self-resolving dermal inflammation that allows determination of 
quantifiable indices of resolution. Using this model as a tool to investigate 
resolution in humans, I found SPMs and expression of their receptors at the 
inflamed site, but the therapeutic addition of SPMs at endogenous levels 
resulted only in the reduction of neutrophils and modest effects on other 
resolution indices. And while JBT-101 exhibited anti-inflammatory effects 
comparable to prednisone, convincing evidence is lacking to place SPMs as a 
key mechanism of action of JBT-101.    
 
7.2 Implications of the detailed characterisation of cantharidin skin 
blister  
 
Detailed investigation of cantharidin skin blister revealed incomplete clearance 
of neutrophils during resolution. This observation discouraged me to use it 
further for investigation of SPMs, as one of the main effects of SPMs is on 
neutrophil clearance. However, the same observation provided the clue that 
stromal scaffold around the inflammatory cells could be important for their 
clearance, and this led me to develop the UVkEc triggered dermal 
inflammation model. Another important insight I derived from this observation 
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was that cantharidin blister can be used as a model to study neutrophil 
apoptosis in humans. This additional use of cantharidin model has now been 
exploited in our laboratory to show that neutrophil apoptosis is defective in 
aged volunteers (> 65 years) compared to young volunteers (< 45 years) (Roel 
De Maeyer, personal communication). In addition to allowing investigation of 
defects in neutrophil apoptosis, the cantharidin blister model can also serve as 
a proof of concept platform in humans to study the drugs modulating neutrophil 
apoptosis, e.g. cyclin dependent kinase inhibitors [275]. 
 
7.3 The potential use of UVkEc triggered self-resolving dermal 
inflammation model to solve the controversy around role of fish oils in 
inducing SPM formation in humans    
 
The beneficial effects of supplementation of n-3 fish oils, e.g. EPA and DHA in 
inflammatory disorders including arthritis and asthma triggered the research to 
identify the molecular mechanisms of their anti-inflammatory effect [276]. This 
led to the identification and characterisation of SPMs including resolvins, 
maresins and protectins [219]. Supplementation of n-3 fish oils is becoming a 
conventional approach to increase the SPM levels. However, this approach 
has yielded conflicting results in clinical studies conducted by different groups. 
On one hand, a study by Barden et al. in healthy volunteers observed a 
significant increase in plasma levels of RvE1 [277]. The same group has also 
observed increased plasma levels of SPMs including RvD1, AT-RvD1, RvD2 in 
clinical populations, e.g. arthritis [278] and chronic kidney disease [279]. 
Contrastingly, studies by Skarke et al. showed that fish oil supplements failed 
to increase SPM levels in healthy volunteer plasma either in a steady state or 
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after systemic endotoxin challenge [280]. Fischer et al. also failed to detect D- 
or E- series resolvins in healthy volunteers after fish oil supplementation 
despite seeing a rise in the levels of its precursor 17-HDHA and 18-HEPE 
respectively [281]. While the exact reasons for this discrepancy are unclear at 
this stage, it has been speculated that they could be due to differences in 
analytical techniques including the use of deuterated internal standards and 
other inherent challenges, e.g. low levels of these mediators, sample 
extraction from a complex biological matrix such as plasma [282]. In summary, 
the consensus is lacking on whether fish oils can increase SPM levels in 
humans. 
 
I speculate whether the choice of tissue can influence the detection of SPMs. 
SPMs are a product of transcellular metabolism, a process which involves 
coordinated action between multiple cell types, each contributing the enzymes 
necessary for the specific steps in SPM biosynthesis, e.g. neutrophil 5-LO and 
platelet 12-LO interaction in LXA4 formation [283], neutrophil 5-LO and 
endothelial acetylated COX-2 interaction in formation of RvE1/E2 [284]. It is 
likely that the site of local tissue inflammation facilitates interaction between 
these cell types which could increase SPM generation unlike in plasma where 
immune cells are in circulation. The validity of this argument gains some 
support from a recent study investigating the effect of fish oil supplementation 
on SPM levels in arthritis patients. Here it was shown that the conversion of 
SPM precursors 18-HEPE and 17-HDHA into the corresponding E-series and 
D-series resolvins was greater in synovial fluid compartment compared to 
plasma [278].  
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I propose to test the effect of fish oil supplementation using UVkEc triggered 
dermal inflammation model to address whether the use of local tissue instead 
of plasma can enhance SPM detection. This model would allow temporal 
analysis and comparison of local tissue inflammatory exudate and plasma in 
the same person. Importantly, this study could be conducted in healthy 
volunteers, and thus it would preclude the interactions of fish oils with other 
medications and co-morbidities that are observed in clinical populations.     
 
7.4 Potential applicability of UVkEc triggered self-resolving dermal 
inflammation model to guide the clinical development of stable synthetic 
SPM analogues 
 
Although research demonstrating the effect of fish oils on inducing SPM 
formation in humans is still controversial, the discovery of SPMs as 
endogenous mediators of resolution of inflammation has led to the 
development of an alternative approach that involves direct supplementation 
with SPMs. Synthetic stable SPM analogues which resist metabolic 
inactivation by eicosanoid reductase, the main enzyme involved in SPM 
degradation, and those that can be delivered orally or intravenously have been 
developed to advance this approach, e.g. 3-oxo-15-epi-LXA4 analogues which 
can be delivered orally or intravenously and have been shown to retain 
biological activity similar to native LXA4 as evidenced by their effect on 
reducing leucocyte infiltration in multiple murine models of inflammation such 
as zymosan-induced peritonitis and ischaemia reperfusion injury in lung [285]. 
Another example is of benzo-diacetylenic-17R-RvD1-methyl ester (BDA-RvD1) 
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which like the native RvD1 has been shown to reduce neutrophil infiltration and 
hasten bacteria clearance in E. coli induced peritonitis model [286]. 
 
Clinical development of these stable SPM analogues will be a very promising 
and reliable approach to test the direct effect of SPMs in humans on resolution 
biomarkers. It can also help us understand whether effects of SPMs on 
different resolution indices is dose dependent in humans. After establishing the 
safety of these analogues in Phase I clinical trials, I propose that the use of 
UVkEc induced self-resolving dermal inflammation model would be helpful to 
obtain information about their pharmacokinetics and preliminary evidence of its 
pharmacodynamic activity in humans. For instance, after oral or intravenous 
delivery, the tissue bioavailability and stability of these synthetic SPMs at 
steady state and during inflammation can be obtained by measuring their 
levels in the inflammatory exudate obtained at different time points. In addition, 
the model can allow to investigate the effect of SPMs at different doses on the 
resolution biomarkers. Such proof of concept studies would not only guide 
dose optimization of these SPMs for use in future studies in patients but would 
also help in choosing an appropriate biomarker for future clinical trials for 
different types of inflammatory conditions, e.g. neutrophil clearance for 
autoimmune conditions, endotoxin clearance for infectious diseases or 
assessment of local pain for their analgesic use.  
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7.5 Conclusion 
 
In this thesis, I developed a novel human model of resolution of acute 
inflammation triggered by intradermal injection of UV-killed E. coli. Using this 
model, I demonstrated that supplementation with SPMs, at physiological 
doses, hastened resolution as noticeable from increased neutrophil clearance. 
I also showed that JBT-101, a CB2 receptor agonist, had a potent anti-
inflammatory effect which is likely due to its effect on inhibition of pro-
inflammatory lipid mediators than enhancing SPM biosynthesis. Clinical 
development of synthetic SPM analogues can confirm and extend these 
observations to accomplish the objective of harnessing SPMs for therapeutic 
gain.     
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Figure 8.1: Additional lipid mediators in cantharidin skin blister at 24hr and 
72hr 
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Figure 8.2 : Additional cytokines and chemokines measured at the site of 
UVkEc triggereed acute resolving inflammation. 
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Figure 8.3: Additional cytokines and chemokines measured at the site of 
UVkEc triggereed acute resolving inflammation. 
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Figure 8.4: Demonstration of measurement of pain threshold using algometer (A) and temperature 
using infrared thermometer (B) at the site of UVkEc triggered acute inflammation 
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Figure 8.5 : The effect of 20mg JBT-101 vs. placebo on neutrophil numbers and vascular
hyperaemia when blister was raised at 24hr and 48hr time point at the site of UVkEc triggered self
resolving dermal inflammation
Healthy male volunteers were randomized to receive either Placebo, or JBT-10120mg, twice daily for four
days. On fourth day, acute inflammation was triggered by intradermal injection of UV killed E. coli on both
the forearms. Inflammatory exudate at the injection site was acquired into a suction blister raised at 24hr
on one forearm and at 48hr on the contralateral forearm. Vascular hyperaemia at the injection site was
assessed by a laser Doppler imager (moorLDI-HIR).
Figure 8.4 A shows the neutrophil count at 24hr and 48hr vs the neutrophil count at 4hr and 10hr blister.
Figure 8.4 B shows vascular hyperaemia over the inflammation site when blister was raised at 24hr and
48hr (dotted line) vs the vascular hyperaemia over the inflammation site when blister was raised at 4hr
and 10hr (solid line). Figure 8.4 C shows the representative laser Doppler and camera images at 24hr
and 48hr. Data expressed as mean ± SD. n=5.
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